Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mutant p53 and Cellular Stress Pathways: A Criminal Alliance That Promotes Cancer Progression</title><author><name sortKey="D Razi, Gabriella" sort="D Razi, Gabriella" uniqKey="D Razi G" first="Gabriella" last="D Razi">Gabriella D Razi</name><affiliation><nlm:aff id="af1-cancers-11-00614">Department of Medical Sciences, University ‘G. d’Annunzio’, 66013 Chieti, Italy</nlm:aff></affiliation><affiliation><nlm:aff id="af2-cancers-11-00614">Department of Research, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy</nlm:aff></affiliation></author><author><name sortKey="Cirone, Mara" sort="Cirone, Mara" uniqKey="Cirone M" first="Mara" last="Cirone">Mara Cirone</name><affiliation><nlm:aff id="af3-cancers-11-00614">Department of Experimental Medicine, “Sapienza” University of Rome, 00185 Rome, Italy</nlm:aff></affiliation><affiliation><nlm:aff id="af4-cancers-11-00614">Laboratory Affiliated to Pasteur Institute, Italy-Foundation Cenci Bolognetti, 00161 Rome, Italy</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">31052524</idno><idno type="pmc">6563084</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563084</idno><idno type="RBID">PMC:6563084</idno><idno type="doi">10.3390/cancers11050614</idno><date when="2019">2019</date><idno type="wicri:Area/Pmc/Corpus">000886</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000886</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Mutant p53 and Cellular Stress Pathways: A Criminal Alliance That Promotes Cancer Progression</title><author><name sortKey="D Razi, Gabriella" sort="D Razi, Gabriella" uniqKey="D Razi G" first="Gabriella" last="D Razi">Gabriella D Razi</name><affiliation><nlm:aff id="af1-cancers-11-00614">Department of Medical Sciences, University ‘G. d’Annunzio’, 66013 Chieti, Italy</nlm:aff></affiliation><affiliation><nlm:aff id="af2-cancers-11-00614">Department of Research, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy</nlm:aff></affiliation></author><author><name sortKey="Cirone, Mara" sort="Cirone, Mara" uniqKey="Cirone M" first="Mara" last="Cirone">Mara Cirone</name><affiliation><nlm:aff id="af3-cancers-11-00614">Department of Experimental Medicine, “Sapienza” University of Rome, 00185 Rome, Italy</nlm:aff></affiliation><affiliation><nlm:aff id="af4-cancers-11-00614">Laboratory Affiliated to Pasteur Institute, Italy-Foundation Cenci Bolognetti, 00161 Rome, Italy</nlm:aff></affiliation></author></analytic><series><title level="j">Cancers</title><idno type="eISSN">2072-6694</idno><imprint><date when="2019">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>The capability of cancer cells to manage stress induced by hypoxia, nutrient shortage, acidosis, redox imbalance, loss of calcium homeostasis and exposure to drugs is a key factor to ensure cancer survival and chemoresistance. Among the protective mechanisms utilized by cancer cells to cope with stress a pivotal role is played by the activation of heat shock proteins (HSP) response, anti-oxidant response induced by nuclear factor erythroid 2-related factor 2 (NRF2), the hypoxia-inducible factor-1 (HIF-1), the unfolded protein response (UPR) and autophagy, cellular processes strictly interconnected. However, depending on the type, intensity or duration of cellular stress, the balance between pro-survival and pro-death pathways may change, and cell survival may be shifted into cell death. Mutations of p53 (mutp53), occurring in more than 50% of human cancers, may confer oncogenic gain-of-function (GOF) to the protein, mainly due to its stabilization and interaction with the above reported cellular pathways that help cancer cells to adapt to stress. This review will focus on the interplay of mutp53 with HSPs, NRF2, UPR, and autophagy and discuss how the manipulation of these interconnected processes may tip the balance towards cell death or survival, particularly in response to therapies.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Vousden, K H" uniqKey="Vousden K">K.H. Vousden</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Reinhardt, H C" uniqKey="Reinhardt H">H.C. Reinhardt</name></author><author><name sortKey="Schumacher, B" uniqKey="Schumacher B">B. Schumacher</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bykov, V J N" uniqKey="Bykov V">V.J.N. Bykov</name></author><author><name sortKey="Eriksson, S E" uniqKey="Eriksson S">S.E. Eriksson</name></author><author><name sortKey="Bianchi, J" uniqKey="Bianchi J">J. Bianchi</name></author><author><name sortKey="Wiman, K G" uniqKey="Wiman K">K.G. Wiman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Housman, G" uniqKey="Housman G">G. Housman</name></author><author><name sortKey="Byler, S" uniqKey="Byler S">S. Byler</name></author><author><name sortKey="Heerboth, S" uniqKey="Heerboth S">S. Heerboth</name></author><author><name sortKey="Lapinska, K" uniqKey="Lapinska K">K. Lapinska</name></author><author><name sortKey="Longacre, M" uniqKey="Longacre M">M. Longacre</name></author><author><name sortKey="Snyder, N" uniqKey="Snyder N">N. Snyder</name></author><author><name sortKey="Sarkar, S" uniqKey="Sarkar S">S. Sarkar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zahreddine, H" uniqKey="Zahreddine H">H. Zahreddine</name></author><author><name sortKey="Borden, K L" uniqKey="Borden K">K.L. Borden</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kandoth, C" uniqKey="Kandoth C">C. Kandoth</name></author><author><name sortKey="Mclellan, M D" uniqKey="Mclellan M">M.D. McLellan</name></author><author><name sortKey="Vandin, F" uniqKey="Vandin F">F. Vandin</name></author><author><name sortKey="Ye, K" uniqKey="Ye K">K. Ye</name></author><author><name sortKey="Niu, B" uniqKey="Niu B">B. Niu</name></author><author><name sortKey="Lu, C" uniqKey="Lu C">C. Lu</name></author><author><name sortKey="Xie, M" uniqKey="Xie M">M. Xie</name></author><author><name sortKey="Zhang, Q" uniqKey="Zhang Q">Q. Zhang</name></author><author><name sortKey="Mcmichael, J F" uniqKey="Mcmichael J">J.F. McMichael</name></author><author><name sortKey="Wyczalkowski, M A" uniqKey="Wyczalkowski M">M.A. Wyczalkowski</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kim, M P" uniqKey="Kim M">M.P. Kim</name></author><author><name sortKey="Zhang, Y" uniqKey="Zhang Y">Y. Zhang</name></author><author><name sortKey="Lozano, G" uniqKey="Lozano G">G. Lozano</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Muller, P A" uniqKey="Muller P">P.A. Muller</name></author><author><name sortKey="Vousden, K H" uniqKey="Vousden K">K.H. Vousden</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Xu, J" uniqKey="Xu J">J. Xu</name></author><author><name sortKey="Reumers, J" uniqKey="Reumers J">J. Reumers</name></author><author><name sortKey="Couceiro, J R" uniqKey="Couceiro J">J.R. Couceiro</name></author><author><name sortKey="De Smet, F" uniqKey="De Smet F">F. De Smet</name></author><author><name sortKey="Gallardo, R" uniqKey="Gallardo R">R. Gallardo</name></author><author><name sortKey="Rudyak, S" uniqKey="Rudyak S">S. Rudyak</name></author><author><name sortKey="Cornelis, A" uniqKey="Cornelis A">A. Cornelis</name></author><author><name sortKey="Rozenski, J" uniqKey="Rozenski J">J. Rozenski</name></author><author><name sortKey="Zwolinska, A" uniqKey="Zwolinska A">A. Zwolinska</name></author><author><name sortKey="Marine, J C" uniqKey="Marine J">J.C. Marine</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Garcia, P B" uniqKey="Garcia P">P.B. Garcia</name></author><author><name sortKey="Attardi, L D" uniqKey="Attardi L">L.D. Attardi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schulz Heddergott, R" uniqKey="Schulz Heddergott R">R. Schulz-Heddergott</name></author><author><name sortKey="Moll, U M" uniqKey="Moll U">U.M. Moll</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kim, M P" uniqKey="Kim M">M.P. Kim</name></author><author><name sortKey="Lozano, G" uniqKey="Lozano G">G. Lozano</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cordani, M" uniqKey="Cordani M">M. Cordani</name></author><author><name sortKey="Pacchiana, R" uniqKey="Pacchiana R">R. Pacchiana</name></author><author><name sortKey="Butera, G" uniqKey="Butera G">G. Butera</name></author><author><name sortKey="D Razi, G" uniqKey="D Razi G">G. D’Orazi</name></author><author><name sortKey="Scarpa, A" uniqKey="Scarpa A">A. Scarpa</name></author><author><name sortKey="Donadelli, M" uniqKey="Donadelli M">M. Donadelli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gurtner, A" uniqKey="Gurtner A">A. Gurtner</name></author><author><name sortKey="Falcone, E" uniqKey="Falcone E">E. Falcone</name></author><author><name sortKey="Garibaldi, F" uniqKey="Garibaldi F">F. Garibaldi</name></author><author><name sortKey="Piaggio, G" uniqKey="Piaggio G">G. Piaggio</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mantovani, F" uniqKey="Mantovani F">F. Mantovani</name></author><author><name sortKey="Collavin, L" uniqKey="Collavin L">L. Collavin</name></author><author><name sortKey="Del Sal, G" uniqKey="Del Sal G">G. Del Sal</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Riha, R" uniqKey="Riha R">R. Riha</name></author><author><name sortKey="Gupta Saraf, P" uniqKey="Gupta Saraf P">P. Gupta-Saraf</name></author><author><name sortKey="Bhanja, P" uniqKey="Bhanja P">P. Bhanja</name></author><author><name sortKey="Badkul, S" uniqKey="Badkul S">S. Badkul</name></author><author><name sortKey="Saha, S" uniqKey="Saha S">S. Saha</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sane, S" uniqKey="Sane S">S. Sane</name></author><author><name sortKey="Rezvani, K" uniqKey="Rezvani K">K. Rezvani</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Muller, P A J" uniqKey="Muller P">P.A.J. Muller</name></author><author><name sortKey="Vousden, K H" uniqKey="Vousden K">K.H. Vousden</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Joerger, A C" uniqKey="Joerger A">A.C. Joerger</name></author><author><name sortKey="Fersht, A R" uniqKey="Fersht A">A.R. Fersht</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lukashchuk, N" uniqKey="Lukashchuk N">N. Lukashchuk</name></author><author><name sortKey="Vousden, K H" uniqKey="Vousden K">K.H. Vousden</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, D" uniqKey="Li D">D. Li</name></author><author><name sortKey="Marchencko, N D" uniqKey="Marchencko N">N.D. Marchencko</name></author><author><name sortKey="Moll, U M" uniqKey="Moll U">U.M. Moll</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Alexandrova, E M" uniqKey="Alexandrova E">E.M. Alexandrova</name></author><author><name sortKey="Moll, U M" uniqKey="Moll U">U.M. Moll</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Peng, Y" uniqKey="Peng Y">Y. Peng</name></author><author><name sortKey="Chen, L" uniqKey="Chen L">L. Chen</name></author><author><name sortKey="Li, C" uniqKey="Li C">C. Li</name></author><author><name sortKey="Lu, W" uniqKey="Lu W">W. Lu</name></author><author><name sortKey="Chen, J" uniqKey="Chen J">J. Chen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, D" uniqKey="Li D">D. Li</name></author><author><name sortKey="Marchenko, N D" uniqKey="Marchenko N">N.D. Marchenko</name></author><author><name sortKey="Schultz, R" uniqKey="Schultz R">R. Schultz</name></author><author><name sortKey="Fischer, V" uniqKey="Fischer V">V. Fischer</name></author><author><name sortKey="Velasco Hernandez, T" uniqKey="Velasco Hernandez T">T. Velasco-Hernandez</name></author><author><name sortKey="Talos, F" uniqKey="Talos F">F. Talos</name></author><author><name sortKey="Moll, U M" uniqKey="Moll U">U.M. Moll</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Trepel, J" uniqKey="Trepel J">J. Trepel</name></author><author><name sortKey="Mollapour, M" uniqKey="Mollapour M">M. Mollapour</name></author><author><name sortKey="Gaccone, G" uniqKey="Gaccone G">G. Gaccone</name></author><author><name sortKey="Neckers, L" uniqKey="Neckers L">L. Neckers</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Whitesell, L" uniqKey="Whitesell L">L. Whitesell</name></author><author><name sortKey="Sutphin, P D" uniqKey="Sutphin P">P.D. Sutphin</name></author><author><name sortKey="Pulcini, E J" uniqKey="Pulcini E">E.J. Pulcini</name></author><author><name sortKey="Martinez, J D" uniqKey="Martinez J">J.D. Martinez</name></author><author><name sortKey="Cook, P H" uniqKey="Cook P">P.H. Cook</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Proia, D A" uniqKey="Proia D">D.A. Proia</name></author><author><name sortKey="Bates, R C" uniqKey="Bates R">R.C. Bates</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Solarova, Z" uniqKey="Solarova Z">Z. Solárová</name></author><author><name sortKey="Mojzis, J" uniqKey="Mojzis J">J. Mojžiš</name></author><author><name sortKey="Solar, P" uniqKey="Solar P">P. Solár</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kr Mer, O H" uniqKey="Kr Mer O">O.H. Krämer</name></author><author><name sortKey="Mahboobi, S" uniqKey="Mahboobi S">S. Mahboobi</name></author><author><name sortKey="Sellmer, A" uniqKey="Sellmer A">A. Sellmer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, D" uniqKey="Li D">D. Li</name></author><author><name sortKey="Ozog, L" uniqKey="Ozog L">L. Ozog</name></author><author><name sortKey="Marchenko, N" uniqKey="Marchenko N">N. Marchenko</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gomez Pastor, R" uniqKey="Gomez Pastor R">R. Gomez-Pastor</name></author><author><name sortKey="Burchfiel, E T" uniqKey="Burchfiel E">E.T. Burchfiel</name></author><author><name sortKey="Thiele, D J" uniqKey="Thiele D">D.J. Thiele</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Home, T" uniqKey="Home T">T. Home</name></author><author><name sortKey="Jensen, R A" uniqKey="Jensen R">R.A. Jensen</name></author><author><name sortKey="Rap, R" uniqKey="Rap R">R. Rap</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sharma, C" uniqKey="Sharma C">C. Sharma</name></author><author><name sortKey="Seo, Y H" uniqKey="Seo Y">Y.H. Seo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dai, C" uniqKey="Dai C">C. Dai</name></author><author><name sortKey="Santagata, S" uniqKey="Santagata S">S. Santagata</name></author><author><name sortKey="Tang, Z" uniqKey="Tang Z">Z. Tang</name></author><author><name sortKey="Shi, J" uniqKey="Shi J">J. Shi</name></author><author><name sortKey="Cao, J" uniqKey="Cao J">J. Cao</name></author><author><name sortKey="Kwon, H" uniqKey="Kwon H">H. Kwon</name></author><author><name sortKey="Bronson, R T" uniqKey="Bronson R">R.T. Bronson</name></author><author><name sortKey="Whitesell, L" uniqKey="Whitesell L">L. Whitesell</name></author><author><name sortKey="Lindquist, S" uniqKey="Lindquist S">S. Lindquist</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Muller, P A" uniqKey="Muller P">P.A. Muller</name></author><author><name sortKey="Caswell, P T" uniqKey="Caswell P">P.T. Caswell</name></author><author><name sortKey="Doyle, B" uniqKey="Doyle B">B. Doyle</name></author><author><name sortKey="Iwanicki, M P" uniqKey="Iwanicki M">M.P. Iwanicki</name></author><author><name sortKey="Tan, E H" uniqKey="Tan E">E.H. Tan</name></author><author><name sortKey="Karim, S" uniqKey="Karim S">S. Karim</name></author><author><name sortKey="Lukashchuk, N" uniqKey="Lukashchuk N">N. Lukashchuk</name></author><author><name sortKey="Gillespie, D A" uniqKey="Gillespie D">D.A. Gillespie</name></author><author><name sortKey="Ludwig, R L" uniqKey="Ludwig R">R.L. Ludwig</name></author><author><name sortKey="Gosselin, P" uniqKey="Gosselin P">P. Gosselin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yarden, Y" uniqKey="Yarden Y">Y. Yarden</name></author><author><name sortKey="Pines, G" uniqKey="Pines G">G. Pines</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dai, C" uniqKey="Dai C">C. Dai</name></author><author><name sortKey="Whitesell, L" uniqKey="Whitesell L">L. Whitesell</name></author><author><name sortKey="Rogers, A B" uniqKey="Rogers A">A.B. Rogers</name></author><author><name sortKey="Lindquist, S" uniqKey="Lindquist S">S. Lindquist</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Parrales, A" uniqKey="Parrales A">A. Parrales</name></author><author><name sortKey="Ranjan, A" uniqKey="Ranjan A">A. Ranjan</name></author><author><name sortKey="Iyer, S V" uniqKey="Iyer S">S.V. Iyer</name></author><author><name sortKey="Padhye, S" uniqKey="Padhye S">S. Padhye</name></author><author><name sortKey="Weir, S J" uniqKey="Weir S">S.J. Weir</name></author><author><name sortKey="Roy, A" uniqKey="Roy A">A. Roy</name></author><author><name sortKey="Iwakuma, T" uniqKey="Iwakuma T">T. Iwakuma</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wiech, M" uniqKey="Wiech M">M. Wiech</name></author><author><name sortKey="Olszewski, M B" uniqKey="Olszewski M">M.B. Olszewski</name></author><author><name sortKey="Tracz Gaszewska, Z" uniqKey="Tracz Gaszewska Z">Z. Tracz-Gaszewska</name></author><author><name sortKey="Wawrzynow, B" uniqKey="Wawrzynow B">B. Wawrzynow</name></author><author><name sortKey="Zylicz, M" uniqKey="Zylicz M">M. Zylicz</name></author><author><name sortKey="Zylicz, A" uniqKey="Zylicz A">A. Zylicz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Freed Pastor, W A" uniqKey="Freed Pastor W">W.A. Freed-Pastor</name></author><author><name sortKey="Mizuno, H" uniqKey="Mizuno H">H. Mizuno</name></author><author><name sortKey="Zhao, X" uniqKey="Zhao X">X. Zhao</name></author><author><name sortKey="Langer D, A" uniqKey="Langer D A">A. Langerød</name></author><author><name sortKey="Moon, S H" uniqKey="Moon S">S.H. Moon</name></author><author><name sortKey="Rodriguez Barrueco, R" uniqKey="Rodriguez Barrueco R">R. Rodriguez-Barrueco</name></author><author><name sortKey="Barsotti, A" uniqKey="Barsotti A">A. Barsotti</name></author><author><name sortKey="Chicas, A" uniqKey="Chicas A">A. Chicas</name></author><author><name sortKey="Li, W" uniqKey="Li W">W. Li</name></author><author><name sortKey="Polotskaia, A" uniqKey="Polotskaia A">A. Polotskaia</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mullen, P J" uniqKey="Mullen P">P.J. Mullen</name></author><author><name sortKey="Yu, R" uniqKey="Yu R">R. Yu</name></author><author><name sortKey="Longo, J" uniqKey="Longo J">J. Longo</name></author><author><name sortKey="Archer, M C" uniqKey="Archer M">M.C. Archer</name></author><author><name sortKey="Penn, L Z" uniqKey="Penn L">L.Z. Penn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sorrentino, G" uniqKey="Sorrentino G">G. Sorrentino</name></author><author><name sortKey="Ruggeri, N" uniqKey="Ruggeri N">N. Ruggeri</name></author><author><name sortKey="Specchia, V" uniqKey="Specchia V">V. Specchia</name></author><author><name sortKey="Cordenonsi, M" uniqKey="Cordenonsi M">M. Cordenonsi</name></author><author><name sortKey="Mano, M" uniqKey="Mano M">M. Mano</name></author><author><name sortKey="Dupont, S" uniqKey="Dupont S">S. Dupont</name></author><author><name sortKey="Manfrin, A" uniqKey="Manfrin A">A. Manfrin</name></author><author><name sortKey="Ingallina, E" uniqKey="Ingallina E">E. Ingallina</name></author><author><name sortKey="Sommaggio, R" uniqKey="Sommaggio R">R. Sommaggio</name></author><author><name sortKey="Piazza, S" uniqKey="Piazza S">S. Piazza</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ingallina, E" uniqKey="Ingallina E">E. Ingallina</name></author><author><name sortKey="Sorrentino, G" uniqKey="Sorrentino G">G. Sorrentino</name></author><author><name sortKey="Bertolio, R" uniqKey="Bertolio R">R. Bertolio</name></author><author><name sortKey="Lisek, K" uniqKey="Lisek K">K. Lisek</name></author><author><name sortKey="Zannini, A" uniqKey="Zannini A">A. Zannini</name></author><author><name sortKey="Azzolin, L" uniqKey="Azzolin L">L. Azzolin</name></author><author><name sortKey="Severino, L U" uniqKey="Severino L">L.U. Severino</name></author><author><name sortKey="Scaini, D" uniqKey="Scaini D">D. Scaini</name></author><author><name sortKey="Mano, M" uniqKey="Mano M">M. Mano</name></author><author><name sortKey="Mantovani, F" uniqKey="Mantovani F">F. Mantovani</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Moon, S H" uniqKey="Moon S">S.H. Moon</name></author><author><name sortKey="Huang, C H" uniqKey="Huang C">C.H. Huang</name></author><author><name sortKey="Houlihan, S L" uniqKey="Houlihan S">S.L. Houlihan</name></author><author><name sortKey="Regunath, K" uniqKey="Regunath K">K. Regunath</name></author><author><name sortKey="Freed Pastor, W A" uniqKey="Freed Pastor W">W.A. Freed-Pastor</name></author><author><name sortKey="Morris, J P" uniqKey="Morris J">J.P. Morris</name></author><author><name sortKey="Tschaharganeh, D F" uniqKey="Tschaharganeh D">D.F. Tschaharganeh</name></author><author><name sortKey="Kastenhuber, E R" uniqKey="Kastenhuber E">E.R. Kastenhuber</name></author><author><name sortKey="Barsotti, A M" uniqKey="Barsotti A">A.M. Barsotti</name></author><author><name sortKey="Culp Hill, R" uniqKey="Culp Hill R">R. Culp-Hill</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Alexandrova, E M" uniqKey="Alexandrova E">E.M. Alexandrova</name></author><author><name sortKey="Marchenko, N D" uniqKey="Marchenko N">N.D. Marchenko</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Walter, P" uniqKey="Walter P">P. Walter</name></author><author><name sortKey="Gilmore, R" uniqKey="Gilmore R">R. Gilmore</name></author><author><name sortKey="Blobel, G" uniqKey="Blobel G">G. Blobel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hetz, C" uniqKey="Hetz C">C. Hetz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Walter, P" uniqKey="Walter P">P. Walter</name></author><author><name sortKey="Ron, D" uniqKey="Ron D">D. Ron</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Donnelly, N" uniqKey="Donnelly N">N. Donnelly</name></author><author><name sortKey="Storchov, Z" uniqKey="Storchov Z">Z. Storchov</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Deegan, S" uniqKey="Deegan S">S. Deegan</name></author><author><name sortKey="Saveljeva, S" uniqKey="Saveljeva S">S. Saveljeva</name></author><author><name sortKey="Gorman, A M" uniqKey="Gorman A">A.M. Gorman</name></author><author><name sortKey="Samali, A" uniqKey="Samali A">A. Samali</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Huang, Z" uniqKey="Huang Z">Z. Huang</name></author><author><name sortKey="Zhou, L" uniqKey="Zhou L">L. Zhou</name></author><author><name sortKey="Chen, Z" uniqKey="Chen Z">Z. Chen</name></author><author><name sortKey="Nice, E C" uniqKey="Nice E">E.C. Nice</name></author><author><name sortKey="Huang, C" uniqKey="Huang C">C. Huang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Avril, T" uniqKey="Avril T">T. Avril</name></author><author><name sortKey="Vauleon, E" uniqKey="Vauleon E">E. Vauleon</name></author><author><name sortKey="Chevet, E" uniqKey="Chevet E">E. Chevet</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chevet, E" uniqKey="Chevet E">E. Chevet</name></author><author><name sortKey="Hetz, C" uniqKey="Hetz C">C. Hetz</name></author><author><name sortKey="Samali, A" uniqKey="Samali A">A. Samali</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yadav, R K" uniqKey="Yadav R">R.K. Yadav</name></author><author><name sortKey="Chae, S W" uniqKey="Chae S">S.W. Chae</name></author><author><name sortKey="Kim, H R" uniqKey="Kim H">H.R. Kim</name></author><author><name sortKey="Char, J" uniqKey="Char J">J. Char</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bertolotti, A" uniqKey="Bertolotti A">A. Bertolotti</name></author><author><name sortKey="Zhang, Y" uniqKey="Zhang Y">Y. Zhang</name></author><author><name sortKey="Hendershot, L M" uniqKey="Hendershot L">L.M. Hendershot</name></author><author><name sortKey="Harding, H P" uniqKey="Harding H">H.P. Harding</name></author><author><name sortKey="Ron, D" uniqKey="Ron D">D. Ron</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shen, J" uniqKey="Shen J">J. Shen</name></author><author><name sortKey="Chen, X" uniqKey="Chen X">X. Chen</name></author><author><name sortKey="Hendershot, L" uniqKey="Hendershot L">L. Hendershot</name></author><author><name sortKey="Prywes, R" uniqKey="Prywes R">R. Prywes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yoshida, H" uniqKey="Yoshida H">H. Yoshida</name></author><author><name sortKey="Matsui, T" uniqKey="Matsui T">T. Matsui</name></author><author><name sortKey="Yamamoto, A" uniqKey="Yamamoto A">A. Yamamoto</name></author><author><name sortKey="Okada, T" uniqKey="Okada T">T. Okada</name></author><author><name sortKey="Mori, K" uniqKey="Mori K">K. Mori</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Acosta Alvear, D" uniqKey="Acosta Alvear D">D. Acosta-Alvear</name></author><author><name sortKey="Zhou, Y" uniqKey="Zhou Y">Y. Zhou</name></author><author><name sortKey="Blais, A" uniqKey="Blais A">A. Blais</name></author><author><name sortKey="Tsikitis, M" uniqKey="Tsikitis M">M. Tsikitis</name></author><author><name sortKey="Lents, N H" uniqKey="Lents N">N.H. Lents</name></author><author><name sortKey="Arias, C" uniqKey="Arias C">C. Arias</name></author><author><name sortKey="Lennon, C J" uniqKey="Lennon C">C.J. Lennon</name></author><author><name sortKey="Kluger, Y" uniqKey="Kluger Y">Y. Kluger</name></author><author><name sortKey="Dynlacht, B D" uniqKey="Dynlacht B">B.D. Dynlacht</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Senft, D" uniqKey="Senft D">D. Senft</name></author><author><name sortKey="Ronai, Z A" uniqKey="Ronai Z">Z.A. Ronai</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Urra, H" uniqKey="Urra H">H. Urra</name></author><author><name sortKey="Dufey, E" uniqKey="Dufey E">E. Dufey</name></author><author><name sortKey="Avril, T" uniqKey="Avril T">T. Avril</name></author><author><name sortKey="Chevet, E" uniqKey="Chevet E">E. Chevet</name></author><author><name sortKey="Hetx, C" uniqKey="Hetx C">C. Hetx</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shajahan, A N" uniqKey="Shajahan A">A.N. Shajahan</name></author><author><name sortKey="Riggings, R B" uniqKey="Riggings R">R.B. Riggings</name></author><author><name sortKey="Clarke, R" uniqKey="Clarke R">R. Clarke</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Namba, T" uniqKey="Namba T">T. Namba</name></author><author><name sortKey="Chu, K" uniqKey="Chu K">K. Chu</name></author><author><name sortKey="Kodama, R" uniqKey="Kodama R">R. Kodama</name></author><author><name sortKey="Byun, S" uniqKey="Byun S">S. Byun</name></author><author><name sortKey="Wan Yoon, K" uniqKey="Wan Yoon K">K. Wan Yoon</name></author><author><name sortKey="Hiraki, M" uniqKey="Hiraki M">M. Hiraki</name></author><author><name sortKey="Mandinova, A" uniqKey="Mandinova A">A. Mandinova</name></author><author><name sortKey="Lee, S W" uniqKey="Lee S">S.W. Lee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Luo, B" uniqKey="Luo B">B. Luo</name></author><author><name sortKey="Lee, A S" uniqKey="Lee A">A.S. Lee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dai, C" uniqKey="Dai C">C. Dai</name></author><author><name sortKey="Dai, S" uniqKey="Dai S">S. Dai</name></author><author><name sortKey="Cao, J" uniqKey="Cao J">J. Cao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Marcu, M G" uniqKey="Marcu M">M.G. Marcu</name></author><author><name sortKey="Doyle, M" uniqKey="Doyle M">M. Doyle</name></author><author><name sortKey="Bertolotti, A" uniqKey="Bertolotti A">A. Bertolotti</name></author><author><name sortKey="Ron, D" uniqKey="Ron D">D. Ron</name></author><author><name sortKey="Hendershot, L" uniqKey="Hendershot L">L. Hendershot</name></author><author><name sortKey="Neckers, L" uniqKey="Neckers L">L. Neckers</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schultze, T W" uniqKey="Schultze T">T.W. Schultze</name></author><author><name sortKey="Blagosklonny, M V" uniqKey="Blagosklonny M">M.V. Blagosklonny</name></author><author><name sortKey="Ingui, C" uniqKey="Ingui C">C. Ingui</name></author><author><name sortKey="Neckers, L" uniqKey="Neckers L">L. Neckers</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sato, S" uniqKey="Sato S">S. Sato</name></author><author><name sortKey="Fujita, N" uniqKey="Fujita N">N. Fujita</name></author><author><name sortKey="Tsuruo, T" uniqKey="Tsuruo T">T. Tsuruo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Donze, O" uniqKey="Donze O">O. Donze</name></author><author><name sortKey="Abbas Terki, T" uniqKey="Abbas Terki T">T. Abbas-Terki</name></author><author><name sortKey="Picard, D" uniqKey="Picard D">D. Picard</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Xu, W" uniqKey="Xu W">W. Xu</name></author><author><name sortKey="Mimmaugh, E" uniqKey="Mimmaugh E">E. Mimmaugh</name></author><author><name sortKey="Rosser, M F" uniqKey="Rosser M">M.F. Rosser</name></author><author><name sortKey="Nicchitta, C" uniqKey="Nicchitta C">C. Nicchitta</name></author><author><name sortKey="Marcu, M" uniqKey="Marcu M">M. Marcu</name></author><author><name sortKey="Yarden, Y" uniqKey="Yarden Y">Y. Yarden</name></author><author><name sortKey="Neckers, L" uniqKey="Neckers L">L. Neckers</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vogiatzi, F" uniqKey="Vogiatzi F">F. Vogiatzi</name></author><author><name sortKey="Brandt, D T" uniqKey="Brandt D">D.T. Brandt</name></author><author><name sortKey="Schneikert, J" uniqKey="Schneikert J">J. Schneikert</name></author><author><name sortKey="Fuchs, J" uniqKey="Fuchs J">J. Fuchs</name></author><author><name sortKey="Grikscheit, K" uniqKey="Grikscheit K">K. Grikscheit</name></author><author><name sortKey="Wanzel, M" uniqKey="Wanzel M">M. Wanzel</name></author><author><name sortKey="Pavlakis, E" uniqKey="Pavlakis E">E. Pavlakis</name></author><author><name sortKey="Charles, J P" uniqKey="Charles J">J.P. Charles</name></author><author><name sortKey="Timofeev, O" uniqKey="Timofeev O">O. Timofeev</name></author><author><name sortKey="Nist, A" uniqKey="Nist A">A. Nist</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rojo De La Vega, M" uniqKey="Rojo De La Vega M">M. Rojo de la Vega</name></author><author><name sortKey="Chapman, E" uniqKey="Chapman E">E. Chapman</name></author><author><name sortKey="Zhang, D D" uniqKey="Zhang D">D.D. Zhang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dayalan Naidu, S" uniqKey="Dayalan Naidu S">S. Dayalan Naidu</name></author><author><name sortKey="Kostov, R V" uniqKey="Kostov R">R.V. Kostov</name></author><author><name sortKey="Dinkova Kostova, A T" uniqKey="Dinkova Kostova A">A.T. Dinkova-Kostova</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wu, S" uniqKey="Wu S">S. Wu</name></author><author><name sortKey="Lu, H" uniqKey="Lu H">H. Lu</name></author><author><name sortKey="Bai, Y" uniqKey="Bai Y">Y. Bai</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, X J" uniqKey="Wang X">X.J. Wang</name></author><author><name sortKey="Sun, Z" uniqKey="Sun Z">Z. Sun</name></author><author><name sortKey="Villeneuve, N F" uniqKey="Villeneuve N">N.F. Villeneuve</name></author><author><name sortKey="Zhang, S" uniqKey="Zhang S">S. Zhang</name></author><author><name sortKey="Zhao, F" uniqKey="Zhao F">F. Zhao</name></author><author><name sortKey="Li, Y" uniqKey="Li Y">Y. Li</name></author><author><name sortKey="Chen, W" uniqKey="Chen W">W. Chen</name></author><author><name sortKey="Yi, X" uniqKey="Yi X">X. Yi</name></author><author><name sortKey="Zheng, W" uniqKey="Zheng W">W. Zheng</name></author><author><name sortKey="Wondrak, G T" uniqKey="Wondrak G">G.T. Wondrak</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lau, A" uniqKey="Lau A">A. Lau</name></author><author><name sortKey="Villeneuve, N F" uniqKey="Villeneuve N">N.F. Villeneuve</name></author><author><name sortKey="Sun, Z" uniqKey="Sun Z">Z. Sun</name></author><author><name sortKey="Wong, P K" uniqKey="Wong P">P.K. Wong</name></author><author><name sortKey="Zhang, D D" uniqKey="Zhang D">D.D. Zhang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Menegon, S" uniqKey="Menegon S">S. Menegon</name></author><author><name sortKey="Columbano, A" uniqKey="Columbano A">A. Columbano</name></author><author><name sortKey="Giordano, S" uniqKey="Giordano S">S. Giordano</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yang, H" uniqKey="Yang H">H. Yang</name></author><author><name sortKey="Villani, R M" uniqKey="Villani R">R.M. Villani</name></author><author><name sortKey="Wang, H" uniqKey="Wang H">H. Wang</name></author><author><name sortKey="Simpson, M J" uniqKey="Simpson M">M.J. Simpson</name></author><author><name sortKey="Roberts, M S" uniqKey="Roberts M">M.S. Roberts</name></author><author><name sortKey="Tang, M" uniqKey="Tang M">M. Tang</name></author><author><name sortKey="Liang, X" uniqKey="Liang X">X. Liang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="No, J H" uniqKey="No J">J.H. No</name></author><author><name sortKey="Kim, Y B" uniqKey="Kim Y">Y.B. Kim</name></author><author><name sortKey="Song, Y S" uniqKey="Song Y">Y.S. Song</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Glorieux, V" uniqKey="Glorieux V">V. Glorieux</name></author><author><name sortKey="Calderon, P B" uniqKey="Calderon P">P.B. Calderon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Glorieux, C" uniqKey="Glorieux C">C. Glorieux</name></author><author><name sortKey="Calderon, P B" uniqKey="Calderon P">P.B. Calderon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zeekpudsa, P" uniqKey="Zeekpudsa P">P. Zeekpudsa</name></author><author><name sortKey="Kukongviriyapan, V" uniqKey="Kukongviriyapan V">V. Kukongviriyapan</name></author><author><name sortKey="Senggunprai, L" uniqKey="Senggunprai L">L. Senggunprai</name></author><author><name sortKey="Sripa, B" uniqKey="Sripa B">B. Sripa</name></author><author><name sortKey="Prawan, A" uniqKey="Prawan A">A. Prawan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yang, Y" uniqKey="Yang Y">Y. Yang</name></author><author><name sortKey="Zhang, Y" uniqKey="Zhang Y">Y. Zhang</name></author><author><name sortKey="Wu, Q" uniqKey="Wu Q">Q. Wu</name></author><author><name sortKey="Cui, X" uniqKey="Cui X">X. Cui</name></author><author><name sortKey="Lin, Z" uniqKey="Lin Z">Z. Lin</name></author><author><name sortKey="Liu, S" uniqKey="Liu S">S. Liu</name></author><author><name sortKey="Chen, L" uniqKey="Chen L">L. Chen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Doherty, J" uniqKey="Doherty J">J. Doherty</name></author><author><name sortKey="Baehrcke, E H" uniqKey="Baehrcke E">E.H. Baehrcke</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pankiv, S" uniqKey="Pankiv S">S. Pankiv</name></author><author><name sortKey="Clausen, T H" uniqKey="Clausen T">T.H. Clausen</name></author><author><name sortKey="Lamark, T" uniqKey="Lamark T">T. Lamark</name></author><author><name sortKey="Brech, A" uniqKey="Brech A">A. Brech</name></author><author><name sortKey="Bruun, J A" uniqKey="Bruun J">J.A. Bruun</name></author><author><name sortKey="Outzen, H" uniqKey="Outzen H">H. Outzen</name></author><author><name sortKey="Overvatn, A" uniqKey="Overvatn A">A. Overvatn</name></author><author><name sortKey="Bjorkoy, G" uniqKey="Bjorkoy G">G. Bjorkoy</name></author><author><name sortKey="Johansen, T" uniqKey="Johansen T">T. Johansen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Klionsky, D J" uniqKey="Klionsky D">D.J. Klionsky</name></author><author><name sortKey="Abdelmohsen, K" uniqKey="Abdelmohsen K">K. Abdelmohsen</name></author><author><name sortKey="Abe, A" uniqKey="Abe A">A. Abe</name></author><author><name sortKey="Abedin, M J" uniqKey="Abedin M">M.J. Abedin</name></author><author><name sortKey="Abeliovich, H" uniqKey="Abeliovich H">H. Abeliovich</name></author><author><name sortKey="Acevedo Arozena, A" uniqKey="Acevedo Arozena A">A. Acevedo Arozena</name></author><author><name sortKey="Adachi, H" uniqKey="Adachi H">H. Adachi</name></author><author><name sortKey="Adams, C M" uniqKey="Adams C">C.M. Adams</name></author><author><name sortKey="Adams, P D" uniqKey="Adams P">P.D. Adams</name></author><author><name sortKey="Adeli, K" uniqKey="Adeli K">K. Adeli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jiang, T" uniqKey="Jiang T">T. Jiang</name></author><author><name sortKey="Harder, B" uniqKey="Harder B">B. Harder</name></author><author><name sortKey="Rojo De La Vega, M" uniqKey="Rojo De La Vega M">M. Rojo de la Vega</name></author><author><name sortKey="Wong, P K" uniqKey="Wong P">P.K. Wong</name></author><author><name sortKey="Chapman, E" uniqKey="Chapman E">E. Chapman</name></author><author><name sortKey="Zhand, D D" uniqKey="Zhand D">D.D. Zhand</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, W" uniqKey="Chen W">W. Chen</name></author><author><name sortKey="Sun, Z" uniqKey="Sun Z">Z. Sun</name></author><author><name sortKey="Wang, X J" uniqKey="Wang X">X.J. Wang</name></author><author><name sortKey="Jiang, T" uniqKey="Jiang T">T. Jiang</name></author><author><name sortKey="Huang, Z" uniqKey="Huang Z">Z. Huang</name></author><author><name sortKey="Fang, D" uniqKey="Fang D">D. Fang</name></author><author><name sortKey="Zhang, D D" uniqKey="Zhang D">D.D. Zhang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cullinan, S B" uniqKey="Cullinan S">S.B. Cullinan</name></author><author><name sortKey="Zhang, D" uniqKey="Zhang D">D. Zhang</name></author><author><name sortKey="Hannink, M" uniqKey="Hannink M">M. Hannink</name></author><author><name sortKey="Arvisais, E" uniqKey="Arvisais E">E. Arvisais</name></author><author><name sortKey="Kaufman, R J" uniqKey="Kaufman R">R.J. Kaufman</name></author><author><name sortKey="Diehl, J A" uniqKey="Diehl J">J.A. Diehl</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Harding, H P" uniqKey="Harding H">H.P. Harding</name></author><author><name sortKey="Zhangm, Y" uniqKey="Zhangm Y">Y. Zhangm</name></author><author><name sortKey="Bertolottim, A" uniqKey="Bertolottim A">A. Bertolottim</name></author><author><name sortKey="Zeng, H" uniqKey="Zeng H">H. Zeng</name></author><author><name sortKey="Ron, D" uniqKey="Ron D">D. Ron</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kalo, E" uniqKey="Kalo E">E. Kalo</name></author><author><name sortKey="Kogan Sakin, I" uniqKey="Kogan Sakin I">I. Kogan-Sakin</name></author><author><name sortKey="Solomon, H" uniqKey="Solomon H">H. Solomon</name></author><author><name sortKey="Bar Nathan, E" uniqKey="Bar Nathan E">E. Bar-Nathan</name></author><author><name sortKey="Shay, M" uniqKey="Shay M">M. Shay</name></author><author><name sortKey="Shetzer, Y" uniqKey="Shetzer Y">Y. Shetzer</name></author><author><name sortKey="Dekel, E" uniqKey="Dekel E">E. Dekel</name></author><author><name sortKey="Goldfinger, N" uniqKey="Goldfinger N">N. Goldfinger</name></author><author><name sortKey="Buganim, Y" uniqKey="Buganim Y">Y. Buganim</name></author><author><name sortKey="Stambolsky, P" uniqKey="Stambolsky P">P. Stambolsky</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lisek, K" uniqKey="Lisek K">K. Lisek</name></author><author><name sortKey="Campaner, E" uniqKey="Campaner E">E. Campaner</name></author><author><name sortKey="Ciani, Y" uniqKey="Ciani Y">Y. Ciani</name></author><author><name sortKey="Walerych, D" uniqKey="Walerych D">D. Walerych</name></author><author><name sortKey="Del Sal, G" uniqKey="Del Sal G">G. Del Sal</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hamada, S" uniqKey="Hamada S">S. Hamada</name></author><author><name sortKey="Taguchi, K" uniqKey="Taguchi K">K. Taguchi</name></author><author><name sortKey="Masamume, A" uniqKey="Masamume A">A. Masamume</name></author><author><name sortKey="Yamamoto, M" uniqKey="Yamamoto M">M. Yamamoto</name></author><author><name sortKey="Shimosegawa, T" uniqKey="Shimosegawa T">T. Shimosegawa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Walerych, D" uniqKey="Walerych D">D. Walerych</name></author><author><name sortKey="Lisek, K" uniqKey="Lisek K">K. Lisek</name></author><author><name sortKey="Sommaggio, R" uniqKey="Sommaggio R">R. Sommaggio</name></author><author><name sortKey="Piazza, S" uniqKey="Piazza S">S. Piazza</name></author><author><name sortKey="Ciani, Y" uniqKey="Ciani Y">Y. Ciani</name></author><author><name sortKey="Dalla, E" uniqKey="Dalla E">E. Dalla</name></author><author><name sortKey="Rajkowska, K" uniqKey="Rajkowska K">K. Rajkowska</name></author><author><name sortKey="Gaweda Walerych, K" uniqKey="Gaweda Walerych K">K. Gaweda-Walerych</name></author><author><name sortKey="Ingallina, E" uniqKey="Ingallina E">E. Ingallina</name></author><author><name sortKey="Tonelli, C" uniqKey="Tonelli C">C. Tonelli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, G L" uniqKey="Wang G">G.L. Wang</name></author><author><name sortKey="Jiang, H" uniqKey="Jiang H">H. Jiang</name></author><author><name sortKey="Rue, E A" uniqKey="Rue E">E.A. Rue</name></author><author><name sortKey="Semenza, G L" uniqKey="Semenza G">G.L. Semenza</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Soni, S" uniqKey="Soni S">S. Soni</name></author><author><name sortKey="Padwad, Y S" uniqKey="Padwad Y">Y.S. Padwad</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yu, T" uniqKey="Yu T">T. Yu</name></author><author><name sortKey="Tang, B" uniqKey="Tang B">B. Tang</name></author><author><name sortKey="Sun, X" uniqKey="Sun X">X. Sun</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Amelio, I" uniqKey="Amelio I">I. Amelio</name></author><author><name sortKey="Mancini, M" uniqKey="Mancini M">M. Mancini</name></author><author><name sortKey="Petrova, V" uniqKey="Petrova V">V. Petrova</name></author><author><name sortKey="Cairns, R A" uniqKey="Cairns R">R.A. Cairns</name></author><author><name sortKey="Vikhreva, P" uniqKey="Vikhreva P">P. Vikhreva</name></author><author><name sortKey="Nicolai, S" uniqKey="Nicolai S">S. Nicolai</name></author><author><name sortKey="Marini, A" uniqKey="Marini A">A. Marini</name></author><author><name sortKey="Antonov, A A" uniqKey="Antonov A">A.A. Antonov</name></author><author><name sortKey="Le Quesne, J" uniqKey="Le Quesne J">J. Le Quesne</name></author><author><name sortKey="Baena Acevedo, J D" uniqKey="Baena Acevedo J">J.D. Baena Acevedo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Toth, R K" uniqKey="Toth R">R.K. Toth</name></author><author><name sortKey="Warfel, N A" uniqKey="Warfel N">N.A. Warfel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ren, D" uniqKey="Ren D">D. Ren</name></author><author><name sortKey="Villeneuve, N F" uniqKey="Villeneuve N">N.F. Villeneuve</name></author><author><name sortKey="Jiang, T" uniqKey="Jiang T">T. Jiang</name></author><author><name sortKey="Wu, T" uniqKey="Wu T">T. Wu</name></author><author><name sortKey="Lau, A" uniqKey="Lau A">A. Lau</name></author><author><name sortKey="Toppin, H A" uniqKey="Toppin H">H.A. Toppin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Xiang, Y" uniqKey="Xiang Y">Y. Xiang</name></author><author><name sortKey="Ye, W" uniqKey="Ye W">W. Ye</name></author><author><name sortKey="Huang, C" uniqKey="Huang C">C. Huang</name></author><author><name sortKey="Lou, B" uniqKey="Lou B">B. Lou</name></author><author><name sortKey="Zhang, J" uniqKey="Zhang J">J. Zhang</name></author><author><name sortKey="Yu, D" uniqKey="Yu D">D. Yu</name></author><author><name sortKey="Huang, X" uniqKey="Huang X">X. Huang</name></author><author><name sortKey="Chen, B" uniqKey="Chen B">B. Chen</name></author><author><name sortKey="Zhou, M" uniqKey="Zhou M">M. Zhou</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Xiang, Y" uniqKey="Xiang Y">Y. Xiang</name></author><author><name sortKey="Ye, W" uniqKey="Ye W">W. Ye</name></author><author><name sortKey="Huang, C" uniqKey="Huang C">C. Huang</name></author><author><name sortKey="Yu, D" uniqKey="Yu D">D. Yu</name></author><author><name sortKey="Chen, H" uniqKey="Chen H">H. Chen</name></author><author><name sortKey="Deng, T" uniqKey="Deng T">T. Deng</name></author><author><name sortKey="Zhang, F" uniqKey="Zhang F">F. Zhang</name></author><author><name sortKey="Lou, B" uniqKey="Lou B">B. Lou</name></author><author><name sortKey="Zhang, J" uniqKey="Zhang J">J. Zhang</name></author><author><name sortKey="Shi, K" uniqKey="Shi K">K. Shi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, F" uniqKey="Chen F">F. Chen</name></author><author><name sortKey="Liu, Y" uniqKey="Liu Y">Y. Liu</name></author><author><name sortKey="Wang, S" uniqKey="Wang S">S. Wang</name></author><author><name sortKey="Guo, X" uniqKey="Guo X">X. Guo</name></author><author><name sortKey="Shi, P" uniqKey="Shi P">P. Shi</name></author><author><name sortKey="Wang, W" uniqKey="Wang W">W. Wang</name></author><author><name sortKey="Xu, B" uniqKey="Xu B">B. Xu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mitsuishi, Y" uniqKey="Mitsuishi Y">Y. Mitsuishi</name></author><author><name sortKey="Taguchi, K" uniqKey="Taguchi K">K. Taguchi</name></author><author><name sortKey="Kawatani, Y" uniqKey="Kawatani Y">Y. Kawatani</name></author><author><name sortKey="Shibata, T" uniqKey="Shibata T">T. Shibata</name></author><author><name sortKey="Nukiwa, T" uniqKey="Nukiwa T">T. Nukiwa</name></author><author><name sortKey="Aburatani, H" uniqKey="Aburatani H">H. Aburatani</name></author><author><name sortKey="Yamamoto, M" uniqKey="Yamamoto M">M. Yamamoto</name></author><author><name sortKey="Motohash, H" uniqKey="Motohash H">H. Motohash</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Denicola, G M" uniqKey="Denicola G">G.M. DeNicola</name></author><author><name sortKey="Chen, P H" uniqKey="Chen P">P.H. Chen</name></author><author><name sortKey="Mullarky, E" uniqKey="Mullarky E">E. Mullarky</name></author><author><name sortKey="Sudderth, J A" uniqKey="Sudderth J">J.A. Sudderth</name></author><author><name sortKey="Hu, Z" uniqKey="Hu Z">Z. Hu</name></author><author><name sortKey="Wu, D" uniqKey="Wu D">D. Wu</name></author><author><name sortKey="Tang, H" uniqKey="Tang H">H. Tang</name></author><author><name sortKey="Xie, Y" uniqKey="Xie Y">Y. Xie</name></author><author><name sortKey="Asara, J M" uniqKey="Asara J">J.M. Asara</name></author><author><name sortKey="Huffman, K E" uniqKey="Huffman K">K.E. Huffman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wolpaw, A J" uniqKey="Wolpaw A">A.J. Wolpaw</name></author><author><name sortKey="Dang, C V" uniqKey="Dang C">C.V. Dang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liu, J" uniqKey="Liu J">J. Liu</name></author><author><name sortKey="Zhang, C" uniqKey="Zhang C">C. Zhang</name></author><author><name sortKey="Hu, W" uniqKey="Hu W">W. Hu</name></author><author><name sortKey="Feng, Z" uniqKey="Feng Z">Z. Feng</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yang, J" uniqKey="Yang J">J. Yang</name></author><author><name sortKey="Altahan, A" uniqKey="Altahan A">A. AlTahan</name></author><author><name sortKey="Jones, D T" uniqKey="Jones D">D.T. Jones</name></author><author><name sortKey="Buffa, F M" uniqKey="Buffa F">F.M. Buffa</name></author><author><name sortKey="Bridges, E" uniqKey="Bridges E">E. Bridges</name></author><author><name sortKey="Interiano, R B" uniqKey="Interiano R">R.B. Interiano</name></author><author><name sortKey="Quc, C" uniqKey="Quc C">C. Quc</name></author><author><name sortKey="Vogt, N" uniqKey="Vogt N">N. Vogt</name></author><author><name sortKey="Lia, J L" uniqKey="Lia J">J.-L. Lia</name></author><author><name sortKey="Baban, D" uniqKey="Baban D">D. Baban</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shanle, E K" uniqKey="Shanle E">E.K. Shanle</name></author><author><name sortKey="Xu, W" uniqKey="Xu W">W. Xu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, X" uniqKey="Chen X">X. Chen</name></author><author><name sortKey="Iliopoulos, D" uniqKey="Iliopoulos D">D. Iliopoulos</name></author><author><name sortKey="Zhang, Q" uniqKey="Zhang Q">Q. Zhang</name></author><author><name sortKey="Tang, Q" uniqKey="Tang Q">Q. Tang</name></author><author><name sortKey="Greenblatt, M B" uniqKey="Greenblatt M">M.B. Greenblatt</name></author><author><name sortKey="Hatziapostolou, M" uniqKey="Hatziapostolou M">M. Hatziapostolou</name></author><author><name sortKey="Lim, E" uniqKey="Lim E">E. Lim</name></author><author><name sortKey="Tam, W L" uniqKey="Tam W">W.L. Tam</name></author><author><name sortKey="Ni, M" uniqKey="Ni M">M. Ni</name></author><author><name sortKey="Chen, Y" uniqKey="Chen Y">Y. Chen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Menendez, D" uniqKey="Menendez D">D. Menendez</name></author><author><name sortKey="Inga, A" uniqKey="Inga A">A. Inga</name></author><author><name sortKey="Resnick, M A" uniqKey="Resnick M">M.A. Resnick</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cook, K L" uniqKey="Cook K">K.L. Cook</name></author><author><name sortKey="Clarke, P A G" uniqKey="Clarke P">P.A.G. Clarke</name></author><author><name sortKey="Parmar, J" uniqKey="Parmar J">J. Parmar</name></author><author><name sortKey="Hu, R" uniqKey="Hu R">R. Hu</name></author><author><name sortKey="Schwartz Roberts, J L" uniqKey="Schwartz Roberts J">J.L. Schwartz-Roberts</name></author><author><name sortKey="Abu Asab, M" uniqKey="Abu Asab M">M. Abu-Asab</name></author><author><name sortKey="Warri, A" uniqKey="Warri A">A. Warri</name></author><author><name sortKey="Baumann, W T" uniqKey="Baumann W">W.T. Baumann</name></author><author><name sortKey="Clarke, R" uniqKey="Clarke R">R. Clarke</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Garufi, A" uniqKey="Garufi A">A. Garufi</name></author><author><name sortKey="Trisciuoglio, D" uniqKey="Trisciuoglio D">D. Trisciuoglio</name></author><author><name sortKey="Porru, M" uniqKey="Porru M">M. Porru</name></author><author><name sortKey="Leonetti, C" uniqKey="Leonetti C">C. Leonetti</name></author><author><name sortKey="Stoppacciaro, A" uniqKey="Stoppacciaro A">A. Stoppacciaro</name></author><author><name sortKey="D Razi, V" uniqKey="D Razi V">V. D’Orazi</name></author><author><name sortKey="Avantaggiati, M" uniqKey="Avantaggiati M">M. Avantaggiati</name></author><author><name sortKey="Crispini, A" uniqKey="Crispini A">A. Crispini</name></author><author><name sortKey="Pucci, D" uniqKey="Pucci D">D. Pucci</name></author><author><name sortKey="D Razi, G" uniqKey="D Razi G">G. D’Orazi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Garufi, A" uniqKey="Garufi A">A. Garufi</name></author><author><name sortKey="Pucci, D" uniqKey="Pucci D">D. Pucci</name></author><author><name sortKey="D Razi, V" uniqKey="D Razi V">V. D’Orazi</name></author><author><name sortKey="Cirone, M" uniqKey="Cirone M">M. Cirone</name></author><author><name sortKey="Bossi, G" uniqKey="Bossi G">G. Bossi</name></author><author><name sortKey="Avantaggiati, M L" uniqKey="Avantaggiati M">M.L. Avantaggiati</name></author><author><name sortKey="D Razi, G" uniqKey="D Razi G">G. D’Orazi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Garufi, A" uniqKey="Garufi A">A. Garufi</name></author><author><name sortKey="D Razi, V" uniqKey="D Razi V">V. D’Orazi</name></author><author><name sortKey="Crispini, A" uniqKey="Crispini A">A. Crispini</name></author><author><name sortKey="D Razi, G" uniqKey="D Razi G">G. D’Orazi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Garufi, A" uniqKey="Garufi A">A. Garufi</name></author><author><name sortKey="Pistritto, G" uniqKey="Pistritto G">G. Pistritto</name></author><author><name sortKey="Cirone, M" uniqKey="Cirone M">M. Cirone</name></author><author><name sortKey="D Razi, G" uniqKey="D Razi G">G. D’Orazi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Garufi, A" uniqKey="Garufi A">A. Garufi</name></author><author><name sortKey="Pistritto, G" uniqKey="Pistritto G">G. Pistritto</name></author><author><name sortKey="Baldari, S" uniqKey="Baldari S">S. Baldari</name></author><author><name sortKey="Toietta, G" uniqKey="Toietta G">G. Toietta</name></author><author><name sortKey="Cirone, M" uniqKey="Cirone M">M. Cirone</name></author><author><name sortKey="D Razi, G" uniqKey="D Razi G">G. D’Orazi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="D Razi, G" uniqKey="D Razi G">G. D’Orazi</name></author><author><name sortKey="Cirone, M" uniqKey="Cirone M">M. Cirone</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Thongrakard, V" uniqKey="Thongrakard V">V. Thongrakard</name></author><author><name sortKey="Titone, R" uniqKey="Titone R">R. Titone</name></author><author><name sortKey="Follo, C" uniqKey="Follo C">C. Follo</name></author><author><name sortKey="Morani, F" uniqKey="Morani F">F. Morani</name></author><author><name sortKey="Suksamrarn, A" uniqKey="Suksamrarn A">A. Suksamrarn</name></author><author><name sortKey="Tencomanao, T" uniqKey="Tencomanao T">T. Tencomanao</name></author><author><name sortKey="Isidoro, C" uniqKey="Isidoro C">C. Isidoro</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Foggetti, G" uniqKey="Foggetti G">G. Foggetti</name></author><author><name sortKey="Ottaggio, L" uniqKey="Ottaggio L">L. Ottaggio</name></author><author><name sortKey="Russo, D" uniqKey="Russo D">D. Russo</name></author><author><name sortKey="Monti, P" uniqKey="Monti P">P. Monti</name></author><author><name sortKey="Degan, P" uniqKey="Degan P">P. Degan</name></author><author><name sortKey="Fronza, G" uniqKey="Fronza G">G. Fronza</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, J" uniqKey="Wang J">J. Wang</name></author><author><name sortKey="Zhao, Q" uniqKey="Zhao Q">Q. Zhao</name></author><author><name sortKey="Qi, Q" uniqKey="Qi Q">Q. Qi</name></author><author><name sortKey="Gu, H Y" uniqKey="Gu H">H.Y. Gu</name></author><author><name sortKey="Rong, J J" uniqKey="Rong J">J.J. Rong</name></author><author><name sortKey="Mu, R" uniqKey="Mu R">R. Mu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Aggarwal, M" uniqKey="Aggarwal M">M. Aggarwal</name></author><author><name sortKey="Saxena, R" uniqKey="Saxena R">R. Saxena</name></author><author><name sortKey="Sinclair, E" uniqKey="Sinclair E">E. Sinclair</name></author><author><name sortKey="Fu, Y" uniqKey="Fu Y">Y. Fu</name></author><author><name sortKey="Jacobs, A" uniqKey="Jacobs A">A. Jacobs</name></author><author><name sortKey="Dyba, M" uniqKey="Dyba M">M. Dyba</name></author><author><name sortKey="Wang, X" uniqKey="Wang X">X. Wang</name></author><author><name sortKey="Berry, D" uniqKey="Berry D">D. Berry</name></author><author><name sortKey="Kallakury, B" uniqKey="Kallakury B">B. Kallakury</name></author><author><name sortKey="Mueller, S C" uniqKey="Mueller S">S.C. Mueller</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Granato, M" uniqKey="Granato M">M. Granato</name></author><author><name sortKey="Gilardini Montani, M S" uniqKey="Gilardini Montani M">M.S. Gilardini Montani</name></author><author><name sortKey="D Razi, G" uniqKey="D Razi G">G. D’Orazi</name></author><author><name sortKey="Faggioni, A" uniqKey="Faggioni A">A. Faggioni</name></author><author><name sortKey="Cirone, M" uniqKey="Cirone M">M. Cirone</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rodriguez, O C" uniqKey="Rodriguez O">O.C. Rodriguez</name></author><author><name sortKey="Choudhury, S" uniqKey="Choudhury S">S. Choudhury</name></author><author><name sortKey="Kolukula, V" uniqKey="Kolukula V">V. Kolukula</name></author><author><name sortKey="Vietsch, E E" uniqKey="Vietsch E">E.E. Vietsch</name></author><author><name sortKey="Catania, J" uniqKey="Catania J">J. Catania</name></author><author><name sortKey="Preet, A" uniqKey="Preet A">A. Preet</name></author><author><name sortKey="Reynoso, K" uniqKey="Reynoso K">K. Reynoso</name></author><author><name sortKey="Bargonetti, J" uniqKey="Bargonetti J">J. Bargonetti</name></author><author><name sortKey="Wellstein, A" uniqKey="Wellstein A">A. Wellstein</name></author><author><name sortKey="Albanese, C" uniqKey="Albanese C">C. Albanese</name></author><author><name sortKey="Avantaggiati, M L" uniqKey="Avantaggiati M">M.L. Avantaggiati</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vakifahmetoglu Norberg, H" uniqKey="Vakifahmetoglu Norberg H">H. Vakifahmetoglu-Norberg</name></author><author><name sortKey="Kim, M" uniqKey="Kim M">M. Kim</name></author><author><name sortKey="Xia, H G" uniqKey="Xia H">H.G. Xia</name></author><author><name sortKey="Iwanicki, M P" uniqKey="Iwanicki M">M.P. Iwanicki</name></author><author><name sortKey="Ofengeim, D" uniqKey="Ofengeim D">D. Ofengeim</name></author><author><name sortKey="Coloff, J L" uniqKey="Coloff J">J.L. Coloff</name></author><author><name sortKey="Pan, L" uniqKey="Pan L">L. Pan</name></author><author><name sortKey="Ince, T A" uniqKey="Ince T">T.A. Ince</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G. Kroemer</name></author><author><name sortKey="Brugge, J S" uniqKey="Brugge J">J.S. Brugge</name></author><author><name sortKey="Yuan, J" uniqKey="Yuan J">J. Yuan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Baldari, S" uniqKey="Baldari S">S. Baldari</name></author><author><name sortKey="Ubertini, V" uniqKey="Ubertini V">V. Ubertini</name></author><author><name sortKey="Garufi, A" uniqKey="Garufi A">A. Garufi</name></author><author><name sortKey="D Razi, G" uniqKey="D Razi G">G. D’Orazi</name></author><author><name sortKey="Bossi, G" uniqKey="Bossi G">G. Bossi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cordani, M" uniqKey="Cordani M">M. Cordani</name></author><author><name sortKey="Butera, G" uniqKey="Butera G">G. Butera</name></author><author><name sortKey="Pacchiana, R" uniqKey="Pacchiana R">R. Pacchiana</name></author><author><name sortKey="Donadelli, M" uniqKey="Donadelli M">M. Donadelli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cordani, M" uniqKey="Cordani M">M. Cordani</name></author><author><name sortKey="Oppici, E" uniqKey="Oppici E">E. Oppici</name></author><author><name sortKey="Dando, I" uniqKey="Dando I">I. Dando</name></author><author><name sortKey="Buttirini, E" uniqKey="Buttirini E">E. Buttirini</name></author><author><name sortKey="Dalla Pozza, E" uniqKey="Dalla Pozza E">E. Dalla Pozza</name></author><author><name sortKey="Nadal Serrano, M" uniqKey="Nadal Serrano M">M. Nadal-Serrano</name></author><author><name sortKey="Oliver, J" uniqKey="Oliver J">J. Oliver</name></author><author><name sortKey="Roca, P" uniqKey="Roca P">P. Roca</name></author><author><name sortKey="Mariotto, S" uniqKey="Mariotto S">S. Mariotto</name></author><author><name sortKey="Cellini, B" uniqKey="Cellini B">B. Cellini</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dando, I" uniqKey="Dando I">I. Dando</name></author><author><name sortKey="Cordani, M" uniqKey="Cordani M">M. Cordani</name></author><author><name sortKey="Donadelli, M" uniqKey="Donadelli M">M. Donadelli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wullschleger, S" uniqKey="Wullschleger S">S. Wullschleger</name></author><author><name sortKey="Loewith, R" uniqKey="Loewith R">R. Loewith</name></author><author><name sortKey="Hall, M N" uniqKey="Hall M">M.N. Hall</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Paquette, M" uniqKey="Paquette M">M. Paquette</name></author><author><name sortKey="El Houjeiri, L" uniqKey="El Houjeiri L">L. El-Houjeiri</name></author><author><name sortKey="Pause, A" uniqKey="Pause A">A. Pause</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kim, G G" uniqKey="Kim G">G.G. Kim</name></author><author><name sortKey="Buel, G R" uniqKey="Buel G">G.R. Buel</name></author><author><name sortKey="Blenis, J" uniqKey="Blenis J">J. Blenis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jewell, J L" uniqKey="Jewell J">J.L. Jewell</name></author><author><name sortKey="Guan, K L" uniqKey="Guan K">K.L. Guan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Catena, V" uniqKey="Catena V">V. Catena</name></author><author><name sortKey="Fanciulli, M" uniqKey="Fanciulli M">M. Fanciulli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pietrocola, F" uniqKey="Pietrocola F">F. Pietrocola</name></author><author><name sortKey="Bravo San Pedro, J M" uniqKey="Bravo San Pedro J">J.M. Bravo-San Pedro</name></author><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L. Galluzzi</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G. Kroemer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Granato, M" uniqKey="Granato M">M. Granato</name></author><author><name sortKey="Rizzello, C" uniqKey="Rizzello C">C. Rizzello</name></author><author><name sortKey="Romeo, M A" uniqKey="Romeo M">M.A. Romeo</name></author><author><name sortKey="Yadav, S" uniqKey="Yadav S">S. Yadav</name></author><author><name sortKey="Santarelli, R" uniqKey="Santarelli R">R. Santarelli</name></author><author><name sortKey="D Razi, G" uniqKey="D Razi G">G. D’Orazi</name></author><author><name sortKey="Faggioni, A" uniqKey="Faggioni A">A. Faggioni</name></author><author><name sortKey="Cirone, M" uniqKey="Cirone M">M. Cirone</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Masuelli, L" uniqKey="Masuelli L">L. Masuelli</name></author><author><name sortKey="Granato, M" uniqKey="Granato M">M. Granato</name></author><author><name sortKey="Benvenuto, M" uniqKey="Benvenuto M">M. Benvenuto</name></author><author><name sortKey="Mattera, R" uniqKey="Mattera R">R. Mattera</name></author><author><name sortKey="Bernardini, R" uniqKey="Bernardini R">R. Bernardini</name></author><author><name sortKey="Mattei, M" uniqKey="Mattei M">M. Mattei</name></author><author><name sortKey="D Mati, G" uniqKey="D Mati G">G. d’Amati</name></author><author><name sortKey="D Razi, G" uniqKey="D Razi G">G. D’Orazi</name></author><author><name sortKey="Faggioni, A" uniqKey="Faggioni A">A. Faggioni</name></author><author><name sortKey="Bei, R" uniqKey="Bei R">R. Bei</name></author><author><name sortKey="Cirone, M" uniqKey="Cirone M">M. Cirone</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="White, E" uniqKey="White E">E. White</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gurpinar, E" uniqKey="Gurpinar E">E. Gurpinar</name></author><author><name sortKey="Vousden, K H" uniqKey="Vousden K">K.H. Vousden</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Blandino, G" uniqKey="Blandino G">G. Blandino</name></author><author><name sortKey="Di Agostino, S" uniqKey="Di Agostino S">S. Di Agostino</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="review-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Cancers (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Cancers (Basel)</journal-id><journal-id journal-id-type="publisher-id">cancers</journal-id><journal-title-group><journal-title>Cancers</journal-title></journal-title-group><issn pub-type="epub">2072-6694</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31052524</article-id><article-id pub-id-type="pmc">6563084</article-id><article-id pub-id-type="doi">10.3390/cancers11050614</article-id><article-id pub-id-type="publisher-id">cancers-11-00614</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Mutant p53 and Cellular Stress Pathways: A Criminal Alliance That Promotes Cancer Progression</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6876-9105</contrib-id><name><surname>D’Orazi</surname><given-names>Gabriella</given-names></name><xref ref-type="aff" rid="af1-cancers-11-00614">1</xref><xref ref-type="aff" rid="af2-cancers-11-00614">2</xref><xref rid="c1-cancers-11-00614" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2207-9624</contrib-id><name><surname>Cirone</surname><given-names>Mara</given-names></name><xref ref-type="aff" rid="af3-cancers-11-00614">3</xref><xref ref-type="aff" rid="af4-cancers-11-00614">4</xref><xref rid="c1-cancers-11-00614" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-cancers-11-00614"><label>1</label>Department of Medical Sciences, University ‘G. d’Annunzio’, 66013 Chieti, Italy</aff><aff id="af2-cancers-11-00614"><label>2</label>Department of Research, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy</aff><aff id="af3-cancers-11-00614"><label>3</label>Department of Experimental Medicine, “Sapienza” University of Rome, 00185 Rome, Italy</aff><aff id="af4-cancers-11-00614"><label>4</label>Laboratory Affiliated to Pasteur Institute, Italy-Foundation Cenci Bolognetti, 00161 Rome, Italy</aff><author-notes><corresp id="c1-cancers-11-00614"><label>*</label>Correspondence: <email>gdorazi@unich.it</email> (G.D.); <email>mara.cirone@uniroma1.it</email> (M.C.)</corresp></author-notes><pub-date pub-type="epub"><day>02</day><month>5</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2019</year></pub-date><volume>11</volume><issue>5</issue><elocation-id>614</elocation-id><history><date date-type="received"><day>16</day><month>4</month><year>2019</year></date><date date-type="accepted"><day>01</day><month>5</month><year>2019</year></date></history><permissions><copyright-statement>© 2019 by the authors.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The capability of cancer cells to manage stress induced by hypoxia, nutrient shortage, acidosis, redox imbalance, loss of calcium homeostasis and exposure to drugs is a key factor to ensure cancer survival and chemoresistance. Among the protective mechanisms utilized by cancer cells to cope with stress a pivotal role is played by the activation of heat shock proteins (HSP) response, anti-oxidant response induced by nuclear factor erythroid 2-related factor 2 (NRF2), the hypoxia-inducible factor-1 (HIF-1), the unfolded protein response (UPR) and autophagy, cellular processes strictly interconnected. However, depending on the type, intensity or duration of cellular stress, the balance between pro-survival and pro-death pathways may change, and cell survival may be shifted into cell death. Mutations of p53 (mutp53), occurring in more than 50% of human cancers, may confer oncogenic gain-of-function (GOF) to the protein, mainly due to its stabilization and interaction with the above reported cellular pathways that help cancer cells to adapt to stress. This review will focus on the interplay of mutp53 with HSPs, NRF2, UPR, and autophagy and discuss how the manipulation of these interconnected processes may tip the balance towards cell death or survival, particularly in response to therapies.</p></abstract><kwd-group><kwd>mutant p53 (mutp53)</kwd><kwd>gain-of-function (GOF)</kwd><kwd>autophagy</kwd><kwd>endoplasmic reticulum (ER) stress</kwd><kwd>unfolded protein response (UPR)</kwd><kwd>antioxidant response</kwd><kwd>heat shock protein (HSP)</kwd><kwd>nuclear factor erythroid 2-related factor 2 (NRF2)</kwd><kwd>hypoxia-inducible factor 1 (HIF-1)</kwd><kwd>anticancer therapy</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-cancers-11-00614"><title>1. Introduction</title><p>An important protagonist in cellular network preventing human cancer development by protecting the cells from DNA damage and oncogenic signals is p53 tumor suppressor, a DNA sequence-specific transcription factor. Following stress stimuli, such as hypoxia or DNA damage, p53 accumulates in the nucleus and becomes activated inducing target genes involved in several different cellular responses, such as growth arrest, senescence, apoptosis, and DNA repair. These activities prevent the establishment of mutations in the future generation of cells, highlighting the role of oncosuppressor p53 as “guardian of the genome” [<xref rid="B1-cancers-11-00614" ref-type="bibr">1</xref>,<xref rid="B2-cancers-11-00614" ref-type="bibr">2</xref>]. For these reasons, cancer cells try to get rid of a functional wild-type (wt) p53 pathway that is indeed incompatible with neoplastic growth. An intact wtp53 pathway is also functionally at the base of the tumor cell response to anticancer therapies [<xref rid="B3-cancers-11-00614" ref-type="bibr">3</xref>]. Thus, wtp53 loss of function may lead to the development of chemoresistance. This is an important factor in anticancer therapeutic failure [<xref rid="B4-cancers-11-00614" ref-type="bibr">4</xref>] that urgently needs to be solved to improve the clinical outcome of anticancer treatments. Mechanistically, a variety of different cellular systems contribute to chemoresistance including tumor heterogeneity, drug-inactivation, evasion of apoptosis, enhanced DNA repair and increased drug efflux [<xref rid="B5-cancers-11-00614" ref-type="bibr">5</xref>]. <italic>TP53</italic> is the most frequently inactivated tumor suppressor gene in tumors, being mutated in over 50% of human cancer types and indirectly inactivated in many others [<xref rid="B6-cancers-11-00614" ref-type="bibr">6</xref>,<xref rid="B7-cancers-11-00614" ref-type="bibr">7</xref>]. Majority of p53 mutations are missense mutations (i.e., R175H, R248Q, R273H, R280K) (hereafter referred to as “mutp53”), classified as structural/conformational and DNA-contact mutations that lead to the synthesis of p53 proteins unable to bind the target gene promoters of wtp53 [<xref rid="B8-cancers-11-00614" ref-type="bibr">8</xref>]. In addition, mutp53 can sequester various tumor suppressors including p53 itself (dominant-negative function) and the family members p63 and p73 inhibiting their pro-apoptotic function [<xref rid="B9-cancers-11-00614" ref-type="bibr">9</xref>]. Mouse models of different hotspot mutp53 and clinical data from germline and sporadic cancers have clearly established that p53 missense mutations not only abolish the tumor suppressive function but may also acquire new tumorigenic driver activities, namely, gain-of-function (GOF) [<xref rid="B10-cancers-11-00614" ref-type="bibr">10</xref>,<xref rid="B11-cancers-11-00614" ref-type="bibr">11</xref>]. The best described mechanism of mutp53 GOF is its ability to interact with other transcription factors including NF-Y, Sp1, ETS1/2, NF-kB and SMADs [<xref rid="B12-cancers-11-00614" ref-type="bibr">12</xref>], and this interaction profoundly changes the cancer cell transcriptome and proteome, supporting cancer cell survival, tumor progression, invasion, metastasis and chemoresistance [<xref rid="B13-cancers-11-00614" ref-type="bibr">13</xref>,<xref rid="B14-cancers-11-00614" ref-type="bibr">14</xref>,<xref rid="B15-cancers-11-00614" ref-type="bibr">15</xref>]. As a result, cancer cells develop an addiction to these mutp53 oncogenic functions to survive and proliferate. Given their proliferative nature due to oncogene activation, cancer cells undergo various forms of intrinsic stress and adverse environmental challenges, such as oxidative, electrophilic, proteotoxic, inflammatory stress, and nutrient deprivation, that try to manage by activating molecular/cellular pathways, such as autophagy, heat shock protein (HSP), antioxidant response by nuclear factor erythroid 2-related factor 2 (NRF2), endoplasmic reticulum (ER) stress, and unfolded protein response (UPR), pathways often interconnected. For their survival in a hostile environment, cancer cells are uniquely reliant on the UPR in a way that normal cells are not. Cancer cells adapt to gain advantage from the UPR to prevent apoptosis, favoring tumor progression and resistance to drug treatments [<xref rid="B16-cancers-11-00614" ref-type="bibr">16</xref>]. Components of the heat shock protein response as well as of the UPR, often overexpressed in cancer cells to promote resistance to anticancer therapies, could be targeted to tip the balance towards apoptosis. The response to stress is triggered by oncogenic transcription factors such as heat shock factor 1 (HSF1), the UPR transcription program, NRF2 and hypoxia-inducible factor-1 (HIF-1) that may interact with mutp53 enhancing its GOF. Therefore, mutp53 GOF functional activity may vary according to changes within tumor cells or in the tumor microenvironment [<xref rid="B12-cancers-11-00614" ref-type="bibr">12</xref>]. In this review, the interplay between mutp53 and the molecular pathways activated in response to stress is discussed, unveiling how their strict interconnection sustains mutp53 oncogenic potential and synergizes with other oncogenic transcription factors and highlighting how their manipulation could improve the clinical outcome of the anticancer therapies of mutp53-carrying cancers.</p></sec><sec id="sec2-cancers-11-00614"><title>2. Mutant p53 and Heat Shock Factor 1 (HSF1)/Heat Shock Proteins (HSP) Oncogenic Signaling</title><p>Under normal conditions, wtp53 is targeted by the E3-ubiquitin ligases MDM2, COP1, Pih2, CHIP for ubiquitination and rapid degradation via proteasome. After DNA damage wtp53 undergoes posttranslational modifications-induced stabilization and nuclear translocation for transcriptional activity [<xref rid="B17-cancers-11-00614" ref-type="bibr">17</xref>]. Differently from wtp53, mutp53 proteins attain hyperstability because they may acquire a misfolded and partially denatured conformation with high tendency to form micro- and macro-aggregates [<xref rid="B18-cancers-11-00614" ref-type="bibr">18</xref>,<xref rid="B19-cancers-11-00614" ref-type="bibr">19</xref>] that cannot undergo proteasomal degradation [<xref rid="B20-cancers-11-00614" ref-type="bibr">20</xref>,<xref rid="B21-cancers-11-00614" ref-type="bibr">21</xref>]. This hyperstability is involved in mutp53 oncogenic function. Mutp53 proteins bind the cellular chaperones heat shock proteins (HSP), such as HSP90, an ATP-dependent molecular chaperone that protects several proteins, including mutp53, from proteolytic degradation [<xref rid="B22-cancers-11-00614" ref-type="bibr">22</xref>]. The interaction of mutp53 with HSP90 inhibits MDM2 ubiquitin-protein isopeptidase ligase function by concealing the ARF-binding site on MDM2, resulting in the stabilization of both mutp53 and MDM2 [<xref rid="B23-cancers-11-00614" ref-type="bibr">23</xref>]. Moreover, HSP90 inactivates CHIP, severely impairing the degradation of mutp53 [<xref rid="B24-cancers-11-00614" ref-type="bibr">24</xref>]. HSP90 is aberrantly activated or upregulated in cancer cells, compared to the normal ones, therefore is considered an important target for anticancer therapy [<xref rid="B25-cancers-11-00614" ref-type="bibr">25</xref>]. The inhibition of HSP90 by geldanamycin derivative 17-allylamino-demethoxy geldanamicyn (17-AAG) [<xref rid="B26-cancers-11-00614" ref-type="bibr">26</xref>] or by new generation inhibitor ganetespib [<xref rid="B27-cancers-11-00614" ref-type="bibr">27</xref>] has been shown to release mutp53 from the complex, enabling efficient p53 degradation [<xref rid="B24-cancers-11-00614" ref-type="bibr">24</xref>]. Of note, HSP90 inhibition may sensitize cancer cells to different therapies [<xref rid="B28-cancers-11-00614" ref-type="bibr">28</xref>]. HSP90 functional activation includes deacetylation by HDAC6 and its inactivation by HADC inhibitor vorinostat (SAHA) or by HDAC6 knockdown leads to HSP90 hyper-acetylation with loss of HSP90 chaperone activity and release of mutp53 which can undergo degradation [<xref rid="B21-cancers-11-00614" ref-type="bibr">21</xref>,<xref rid="B29-cancers-11-00614" ref-type="bibr">29</xref>] (<xref ref-type="fig" rid="cancers-11-00614-f001">Figure 1</xref>a). HSP90 transcription is mediated by heat shock factor 1 (HSF1), the master regulator of the heat shock response, basally activated in cancer cells to cope with proteotoxic stress due to aneuploidy, oxidative stress and reactive oxygen species (ROS), hypoxia and acidosis [<xref rid="B30-cancers-11-00614" ref-type="bibr">30</xref>,<xref rid="B31-cancers-11-00614" ref-type="bibr">31</xref>]. HSF1, other than maintaining cellular homeostasis by stress-mediated induction of HSP, coordinates cellular processes critical for malignancy, such as metastasis, cell cycle control, and inhibition of apoptosis [<xref rid="B31-cancers-11-00614" ref-type="bibr">31</xref>,<xref rid="B32-cancers-11-00614" ref-type="bibr">32</xref>]. Not surprisingly, HFS1 is upregulated in many types of cancers that hijack HSF1-dependent pathways to promote their own survival and its targeting is a promising strategy to combat cancer [<xref rid="B32-cancers-11-00614" ref-type="bibr">32</xref>,<xref rid="B33-cancers-11-00614" ref-type="bibr">33</xref>]. Intriguingly, several mutp53 proteins (i.e., R273H, R175H, R280K) induce HSF1 upregulation, and mutp53R280K has been shown to interact with activated p-Ser326 HSF1 stimulating its transcriptional activity toward HSP90 and HSP70, in breast cancer cells [<xref rid="B30-cancers-11-00614" ref-type="bibr">30</xref>]. Then, HSP90 stabilizes mutp53 itself in a positive feed-forward loop that reinforces the mutp53/HSF/HSP oncogenic signaling [<xref rid="B30-cancers-11-00614" ref-type="bibr">30</xref>]. The HSF1 activation by mutp53 can be stimulated by deregulated MAPK signaling [<xref rid="B34-cancers-11-00614" ref-type="bibr">34</xref>]. Thus, mutp53 drives enhanced recycling of EGFR to the cancer cell surface [<xref rid="B35-cancers-11-00614" ref-type="bibr">35</xref>] activating the MAPK and PI3K signaling cascade leading to HSF1 phosphoactivation [<xref rid="B36-cancers-11-00614" ref-type="bibr">36</xref>] (<xref ref-type="fig" rid="cancers-11-00614-f001">Figure 1</xref>b). These findings may have clinical implications because the chemoresistance induced by mutp53-carrying cancer cells [<xref rid="B11-cancers-11-00614" ref-type="bibr">11</xref>] may be, at least in part, counteracted by targeting the mutp53/HSF1 regulatory loop. The proof-of-concept of the nature of mutp53 pro-oncogenic function modifiers comes from in vivo studies in transgenic <italic>Hsf1</italic>-knockout, <italic>Trp53R172H</italic> (equal to R175H in human) mice that do not develop cancer [<xref rid="B37-cancers-11-00614" ref-type="bibr">37</xref>]. Inhibition of EGFR, Her2 or of their downstream effectors can interrupt the mutp53-HSF1- Her2/EGFR circuitry in cancers bearing Her2/mutp53 double positive mutation (i.e., breast cancer, pancreatic cancer, and non-small cell lung cancers) [<xref rid="B11-cancers-11-00614" ref-type="bibr">11</xref>].</p><p>Mutp53 stabilization is also achieved by the interaction with chaperone DNAJA1, an Hsp40 family member that protects mutp53 from CHIP-mediated degradation [<xref rid="B38-cancers-11-00614" ref-type="bibr">38</xref>]. Both Hsp40 and CHIP interact with Hsp70 that cooperates with HSP90 in stabilizing mutp53 [<xref rid="B39-cancers-11-00614" ref-type="bibr">39</xref>] (<xref ref-type="fig" rid="cancers-11-00614-f001">Figure 1</xref>a). The latter regulatory mechanism can be disrupted by statins, cholesterol-lowering drugs, that, by reducing the level of mevalonate-5-phosphate in the mevalonate pathway (MVP), induce CHIP-mediated degradation of mutp53 [<xref rid="B38-cancers-11-00614" ref-type="bibr">38</xref>]. MVP is required for mutp53-Hsp40 interaction, and its upregulation is one of the mutp53 GOF by activating the sterol biosynthesis master transcription factor SREBP [<xref rid="B40-cancers-11-00614" ref-type="bibr">40</xref>]. The MVP produces sterols and isoprenoids required for the synthesis of membranes and lipid rafts, signal transduction and protein prenylation that are integral to tumor growth and progression [<xref rid="B41-cancers-11-00614" ref-type="bibr">41</xref>]. The interplay between mutp53 and MVP also promotes tumor cells’ aberrant mechano-responsiveness and tumor invasion through activation of YAP/TAZ and geranylgeranylation pyrophosphate (GGPP)-dependent RhoA activation [<xref rid="B42-cancers-11-00614" ref-type="bibr">42</xref>,<xref rid="B43-cancers-11-00614" ref-type="bibr">43</xref>]. On the contrary, wtp53 downregulates the MVP to induce tumor suppression [<xref rid="B44-cancers-11-00614" ref-type="bibr">44</xref>]. Thus, p53 blocks activation of SREBP-2, the master transcriptional regulator of the MVP, by transcriptionally inducing the <italic>ABCA1</italic> cholesterol transporter gene [<xref rid="B44-cancers-11-00614" ref-type="bibr">44</xref>]. These findings demonstrate that the oncogenic cooperation of mutp53 with the HSP machinery by HSF1 interaction renders cancer cells more resistant to proteotoxic stress providing a strong survival advantage to cancer cells that acquire chemoresistance and invasion ability [<xref rid="B45-cancers-11-00614" ref-type="bibr">45</xref>]. Therefore, pharmacological blockade of mutp53-stabilizing mechanisms by eliciting mutp53 degradation may restrain tumor growth in mutp53-carrying tumors and increase tumor-free survival of mutp53 knock-in mice [<xref rid="B21-cancers-11-00614" ref-type="bibr">21</xref>,<xref rid="B22-cancers-11-00614" ref-type="bibr">22</xref>,<xref rid="B24-cancers-11-00614" ref-type="bibr">24</xref>,<xref rid="B45-cancers-11-00614" ref-type="bibr">45</xref>].</p></sec><sec id="sec3-cancers-11-00614"><title>3. Mutant p53 and the Endoplasmic Reticulum (ER) Stress/Unfolded Protein Response (UPR)</title><p>The endoplasmic reticulum (ER) is the principal intracellular organelle responsible for protein folding, localization and post-translational modifications [<xref rid="B46-cancers-11-00614" ref-type="bibr">46</xref>]. Under normal growth condition, the unfolded protein response (UPR) ensures the maintenance of cellular homeostasis thereby controlling the cell-fate decision under ER stress [<xref rid="B47-cancers-11-00614" ref-type="bibr">47</xref>]. ER stress is activated by a variety of factors in the intracellular or extracellular compartment, i.e., glucose deprivation, hypoxia, acidosis, inhibition of protein glycosylation, disturbance of intracellular Ca2+ stores, promoting the accumulation of unfolded or misfolded proteins in the ER [<xref rid="B48-cancers-11-00614" ref-type="bibr">48</xref>,<xref rid="B49-cancers-11-00614" ref-type="bibr">49</xref>]. To cope with ER stress, cells activate the HSP machinery and the UPR to reduce the amount of misfolded proteins through ubiquitin-proteasome-dependent ERAD (ER-associated degeneration) and autophagy systems [<xref rid="B50-cancers-11-00614" ref-type="bibr">50</xref>,<xref rid="B51-cancers-11-00614" ref-type="bibr">51</xref>]. The UPR transcriptional program that induces adaptation, survival, transformation, angiogenesis, and resistance to cell death [<xref rid="B52-cancers-11-00614" ref-type="bibr">52</xref>], is regulated by three main sensors localized at the ER membrane: the inositol-requiring enzyme 1α (IRE1α), PKR-like ER kinase (PERK) and the activating transcription factor 6 (ATF6) [<xref rid="B47-cancers-11-00614" ref-type="bibr">47</xref>] (<xref ref-type="fig" rid="cancers-11-00614-f002">Figure 2</xref>). Under basal condition, an ER luminal chaperone protein, GRP78/BiP (glucose-regulated protein 78/binding immunoglobulin protein), binds to these molecules from the ER lumen to suppress their activation [<xref rid="B53-cancers-11-00614" ref-type="bibr">53</xref>]. During ER stress, misfolded proteins in ER bind BiP preventing its inhibitory binding to IRE1α, PERK, and ATF-6, thus leading to their activation [<xref rid="B54-cancers-11-00614" ref-type="bibr">54</xref>]. IRE1α and PERK undergo oligomerization and trans-autophosphorylation [<xref rid="B55-cancers-11-00614" ref-type="bibr">55</xref>] while ATF6 moves from the ER to the Golgi apparatus where undergoes cleavage in the soluble active form that migrates to the nucleus to activate transcription [<xref rid="B56-cancers-11-00614" ref-type="bibr">56</xref>]. The IRE1α trans-autophosphorylation induces a conformational change with endoribonuclease activation leading to expression of the transcription factor XBP1(S) by a non-conventional XBP1 mRNA splicing [<xref rid="B57-cancers-11-00614" ref-type="bibr">57</xref>]. XBP1(S) increases the expression of ER chaperones and ER mass, stimulates lipid biogenesis, and degrades unfolded proteins to enhance the secretory function of ER to suppress ER stress-mediated cell death [<xref rid="B47-cancers-11-00614" ref-type="bibr">47</xref>,<xref rid="B58-cancers-11-00614" ref-type="bibr">58</xref>]. The unbalance of the components of the UPR system may contribute to several pathologies including cancer [<xref rid="B59-cancers-11-00614" ref-type="bibr">59</xref>]. In this regard, the activation of IRE1/XBP1 pathway is involved in the progression of different tumors including glioblastoma, triple-negative breast cancer and multiple myeloma [<xref rid="B60-cancers-11-00614" ref-type="bibr">60</xref>] and may contribute to metastatic progression and chemoresistance [<xref rid="B61-cancers-11-00614" ref-type="bibr">61</xref>] Interestingly, depletion or knockdown of p53 has been shown to increase IRE1α/XBPI pathway and BiP expression, in the presence or absence of ER stress, as p53 drives IRE1α protein to degradation through proteasome, while ATF6 and PERK/eIF2a pathways are suppressed [<xref rid="B62-cancers-11-00614" ref-type="bibr">62</xref>]. BiP overexpression has been shown to suppress PERK and ATF6 activation, rendering cells resistant to ER stress [<xref rid="B56-cancers-11-00614" ref-type="bibr">56</xref>,<xref rid="B63-cancers-11-00614" ref-type="bibr">63</xref>], suggesting an aberrant UPR activation under p53 depletion. In line with this evidence, p53 null cells are resistant to ER stress-induced cell death. Therefore, pharmacological inhibition of IRE1α in p53-null cancer cells abolishes such resistance and significantly reduces tumor growth in an in vivo mouse model [<xref rid="B62-cancers-11-00614" ref-type="bibr">62</xref>]. Intriguingly, IRE1α is overexpressed in cancer cells lines expressing mutp53, compared to cells expressing wild-type p53, linking mutp53 to the adaptation of tumor cells to ER stress and highlighting an important proof-of-concept for targeting UPR, particularly the IRE1/XBP1 pathway, in tumors harboring mutant p53 [<xref rid="B62-cancers-11-00614" ref-type="bibr">62</xref>].</p><p>Interestingly, HSP and UPR are inter-connected responses [<xref rid="B64-cancers-11-00614" ref-type="bibr">64</xref>]. Indeed HSP90, which is involved in mutp53 stabilization in tumor cells, may modulate the transcriptional arm of UPR through its association with the cytoplasmic domain of IRE1 and PERK [<xref rid="B65-cancers-11-00614" ref-type="bibr">65</xref>], as described for other HSP90 client type I transmembrane kinases [<xref rid="B66-cancers-11-00614" ref-type="bibr">66</xref>,<xref rid="B67-cancers-11-00614" ref-type="bibr">67</xref>,<xref rid="B68-cancers-11-00614" ref-type="bibr">68</xref>,<xref rid="B69-cancers-11-00614" ref-type="bibr">69</xref>]. HSP90 inhibition with geldanamicyn (that, as said above, promotes mutp53 degradation) induces the ER stress response with reduction of IRE1 protein and increase of BiP expression [<xref rid="B65-cancers-11-00614" ref-type="bibr">65</xref>]. As mutp53 may activate HSF1 to promote HSP induction [<xref rid="B30-cancers-11-00614" ref-type="bibr">30</xref>], the above findings highlight a link between mup53, HSF1/HSP, and UPR, molecules cooperating in the adaption of cancer cells to proteotoxic stress to allow their survival (<xref ref-type="fig" rid="cancers-11-00614-f002">Figure 2</xref>). More recently, by comparative gene expression profiling of p53-mutated and p53-depleted cancer cells, ectonucleoside triphosphate diphosphohydrolase 5 (ENTPD5) has been identified as a new mutp53 target gene. ENTPD5 promotes the folding of N-glycosylated membrane proteins in the calnexin/calreticulin cycle of the ER, ensuring enhanced expression of membrane receptors. Mutp53 is recruited by Sp1 to the ENTPD5 core promoter to induce its expression. ENTPD5 overexpression is another pro-tumorigenic effect of mutp53, and therefore it might represent another promising target for the treatment of tumors harboring p53 GOF mutations [<xref rid="B70-cancers-11-00614" ref-type="bibr">70</xref>]. These findings suggest that a better understanding of the interplay between mutp53, HSF1/HSP, and UPR response may unveil new possible druggable targets to reduce cancer cell adaptation to stresses and thus tumor progression and chemoresistance [<xref rid="B16-cancers-11-00614" ref-type="bibr">16</xref>].</p></sec><sec id="sec4-cancers-11-00614"><title>4. Mutant p53, Nuclear Factor Erythroid 2-Related Factor 2 (NRF2), Hypoxia-Inducible Factor-1 (HIF-1) and Estrogen Receptor α (ERα) Oncogenic Signaling</title><p>Cancer cells adapt and survival to various forms of oxidative, electrophilic, thermal and inflammatory stress by activating not only the HSF/HSP response and UPR but also the nuclear factor erythroid 2-related factor 2 (NRF2) encoded by the <italic>NFE2L2</italic> gene, considered the major regulator of the antioxidant response [<xref rid="B71-cancers-11-00614" ref-type="bibr">71</xref>]. Both HSF1 and NRF2 trigger a transcriptional program for the maintenance of cellular structure, redox, and intermediate metabolism, as they share transcriptional targets such as p62, ATF3, HSP70, and heme-oxygenase 1 (HO-1) [<xref rid="B72-cancers-11-00614" ref-type="bibr">72</xref>]. Although transient activation of HSF1 and NRF2 is undoubtedly broadly cytoprotective, their persistent activation may promote tumor progression and chemoresistance. During oxidative and electrophilic stress, canonical NRF2 activation is achieved by release from its negative regulator KEAP1 (Kelch-like ECH-associated protein 1). Then, stabilized NRF2 moves to the nucleus where heterodimerizes with small Maf proteins or ATF4 to bind to anti-oxidant responsive elements (ARE) in the DNA promoter of target genes, including phase I (i.e, aldoketoreductases), phase II and phase III (drug transporters and drug efflux pumps) detoxifying enzymes (<xref ref-type="fig" rid="cancers-11-00614-f003">Figure 3</xref>a). The phase II detoxifying enzymes include catalase, superoxide dismutase (SOD), HO-1, NAD(P)H quinone oxidoreductase 1 (NQO1), and glutathione (GSH), that help to restore cellular redox homeostasis [<xref rid="B73-cancers-11-00614" ref-type="bibr">73</xref>]. NRF2 may also repress genes that promote apoptosis [<xref rid="B71-cancers-11-00614" ref-type="bibr">71</xref>] and, for that reason, it is considered a “double face” molecule having both tumor suppressive and tumor-promoting effects, the latter being described as the “dark side of NRF2” [<xref rid="B74-cancers-11-00614" ref-type="bibr">74</xref>,<xref rid="B75-cancers-11-00614" ref-type="bibr">75</xref>,<xref rid="B76-cancers-11-00614" ref-type="bibr">76</xref>]. Because of the protective role of NRF2 transcriptional program, controlled activation of this pathway, as well as of the oxidative stress, has been recognized as a means for chemoprevention [<xref rid="B77-cancers-11-00614" ref-type="bibr">77</xref>]. Constitutive activation of NRF2, mainly due to inactivating mutations on the <italic>KEAP1</italic> gene or gain-of-function mutations on the <italic>NFE2L2</italic> gene, that occur in several different kinds of tumors (e.g., lung, melanoma, hepatocellular carcinoma), may act as a driver of cancer progression, metastasis, and resistance to therapies [<xref rid="B71-cancers-11-00614" ref-type="bibr">71</xref>]. Therefore, targeting NRF2 is considered a helpful strategy to halt tumor growth [<xref rid="B78-cancers-11-00614" ref-type="bibr">78</xref>]. Among the NRF2 targets involved in chemotherapeutic resistance, there is catalase, whose overexpression protects cancer cells from apoptosis induced by DNA-damaging agents [<xref rid="B79-cancers-11-00614" ref-type="bibr">79</xref>,<xref rid="B80-cancers-11-00614" ref-type="bibr">80</xref>] and NQO1, whose inhibition potentiates the cytotoxicity of anticancer treatments [<xref rid="B81-cancers-11-00614" ref-type="bibr">81</xref>,<xref rid="B82-cancers-11-00614" ref-type="bibr">82</xref>]. The NRF2 pathway can intersect with the autophagy pathway, a catabolic process also activated during various conditions of cellular stress, including nutrient deprivation or DNA damage. Autophagy may help to eliminate unfolded proteins or damaged organelles, promoting cell survival in the face of bioenergetic stress even if, in some instances, it may induce cell death [<xref rid="B83-cancers-11-00614" ref-type="bibr">83</xref>]. In particular, the bridging molecule between NRF2 and autophagy is p62 (also called sequestosome 1 -SQSTM1), an autophagy adaptor protein transcribed by both HSF1 and NRF2. P62 is mainly degraded through autophagy and is thus considered a marker of efficient autophagic flux [<xref rid="B84-cancers-11-00614" ref-type="bibr">84</xref>,<xref rid="B85-cancers-11-00614" ref-type="bibr">85</xref>]. Among several functions, p62 induces KEAP1 degradation through autophagy, thereby triggering noncanonical NRF2 stabilization and activation [<xref rid="B86-cancers-11-00614" ref-type="bibr">86</xref>] (<xref ref-type="fig" rid="cancers-11-00614-f003">Figure 3</xref>a). NRF2 activation can thus be a consequence of autophagy reduction and may, as said above, promote tumor progression and chemoresistance. Another noncanonical activation of NRF2 can be mediated by the p53 target p21<sup>Cip1/WAF1</sup> that directly interacts with NRF2 interrupting the KEAP1/NRF2 complex, leading to NRF2 stabilization and upregulation of the NRF2 signaling pathway, under both basal and induced stressful conditions [<xref rid="B87-cancers-11-00614" ref-type="bibr">87</xref>] (<xref ref-type="fig" rid="cancers-11-00614-f003">Figure 3</xref>a). In addition, the ER stress-induced PERK activation may phosphorylate and activate NRF2 [<xref rid="B88-cancers-11-00614" ref-type="bibr">88</xref>] linking ER stress/UPR to the oxidative stress signaling, both involved in the expression of pro-survival genes [<xref rid="B89-cancers-11-00614" ref-type="bibr">89</xref>] (<xref ref-type="fig" rid="cancers-11-00614-f002">Figure 2</xref>).</p><p>Recent findings showed that mutp53 may interact with NRF2 and differentially modulate NRF2 transcriptional activity. This selected activation of the NRF2 transcriptional pathway allows cancer cells to manage high levels of intracellular ROS, promoting a pro-survival antioxidant response [<xref rid="B90-cancers-11-00614" ref-type="bibr">90</xref>,<xref rid="B91-cancers-11-00614" ref-type="bibr">91</xref>]. Thus, the mutp53-NRF2 interaction upregulates thioredoxin (TXN) that is associated with poor prognosis in breast cancer, as its silencing decreases survival and migration of breast cancer cells. Conversely, the mutp53-NRF2 interaction prevents NRF2 binding to other targets, such as NQO1 and HO-1, reported to induce cytotoxic effects in cancer cells, as demonstrated by their silencing that increases breast cancer cell survival and migration (<xref ref-type="fig" rid="cancers-11-00614-f003">Figure 3</xref>b) [<xref rid="B90-cancers-11-00614" ref-type="bibr">90</xref>,<xref rid="B91-cancers-11-00614" ref-type="bibr">91</xref>]. The proof-of-principle of the pro-oncogenic function of mutp53-NRF2 interaction comes from in vivo studies of carcinogenesis and invasion in a mouse model of pancreas-specific mutant K-ras and p53 double mutant, where deletion of NRF2 decreases the formation of pancreatic carcinogenesis and invasion [<xref rid="B92-cancers-11-00614" ref-type="bibr">92</xref>]. In accordance, a combination therapeutic strategy using the specific TXN inhibitor, Auranofin, and APR-246 drug targeting mutp53, synergistically reduces breast cancer cell growth [<xref rid="B91-cancers-11-00614" ref-type="bibr">91</xref>]. The oncogenic interaction between mutp53 and NRF2 has been also shown in an interesting study from the same authors demonstrating that five different GOF mutants, in the context of their respective triple negative breast cancer (TNBC) cell lines, cooperate with NRF2 to induce transcription of 20S/26S proteasome/immunoproteasome gene, as a new GOF program of mutp53 [<xref rid="B93-cancers-11-00614" ref-type="bibr">93</xref>]. This unusual overexpressed signature enhances the degradation of tumor suppressor proteins and confers resistance to proteasome inhibitor therapy. Therefore, combined inhibition of mutp53 with APR-246/PRIMA1-Met and of the proteasome with carfilzomib may effectively overcome this resistance mechanism [<xref rid="B93-cancers-11-00614" ref-type="bibr">93</xref>]. </p><p>To make the link between NRF2 and mutp53 even more complex, it has been recently shown that mutp53 may cooperate with hypoxia-inducible factor 1 (HIF-1). HIF-1 is a heterodimeric transcription factor that consists of the HIF-1β subunit, constitutively expressed in cells, and the HIF-1α subunit whose stability is stimulated by low intracellular oxygen or genetic alterations [<xref rid="B94-cancers-11-00614" ref-type="bibr">94</xref>]. HIF-1 is considered the main effector of the cellular response to hypoxia inducing the transcription of target genes involved in many aspects of cancer progression, including angiogenesis, metabolic adaptation, chemoresistance, apoptosis evasion, invasion and metastasis, therefore, its targeting is considered a useful anticancer strategy [<xref rid="B95-cancers-11-00614" ref-type="bibr">95</xref>,<xref rid="B96-cancers-11-00614" ref-type="bibr">96</xref>]. Mutp53 physically interacts with HIF-1α subunit and shuttles it to the DNA genomic elements impinging on HIF-1 transcriptional activity, thus transcriptionally regulating a gene expression signature involved in tumor progression of non-small cell lung cancer, in vitro and in vivo [<xref rid="B97-cancers-11-00614" ref-type="bibr">97</xref>]. Intriguingly, both HIF-1 and NRF2 are activated in response to hypoxia, likely due to the formation of hypoxia-induced ROS, and both cooperate to promote metastasis and play complementary roles in chemoresistance [<xref rid="B98-cancers-11-00614" ref-type="bibr">98</xref>]. Knockdown of NRF2 or its pharmacologic inhibition by drugs such as brusatol [<xref rid="B99-cancers-11-00614" ref-type="bibr">99</xref>,<xref rid="B100-cancers-11-00614" ref-type="bibr">100</xref>,<xref rid="B101-cancers-11-00614" ref-type="bibr">101</xref>] downregulates HIF-1α promoting its proteasomal degradation, highlighting the therapeutic potential of NRF2 targeting to counteract the hypoxia-induced chemoresistance. However, the most successful strategy to overcome chemoresistance seems to be simultaneous targeting of both pathways, i.e., by triptolide, a molecule derived from Chinese herbal extract [<xref rid="B102-cancers-11-00614" ref-type="bibr">102</xref>]. </p><p>In this context, it is worth to discuss that one of the main tumor promoter roles of NRF2 is its ability to induce cancer cell proliferation and aggressiveness by affecting cancer cell metabolism. Thus, NRF2 redirects glucose and glutamine into anabolic pathways, in particular under the sustained activation of PI3K-Akt signaling [<xref rid="B103-cancers-11-00614" ref-type="bibr">103</xref>]. In addition, NRF2 controls the expression of the key serine/glycine biosynthesis enzyme genes PHGDH, PSAT1 and SHMT2 via ATF4 to support glutathione and nucleotide production. This signature confers poor prognosis in human non-small cell lung cancer cells [<xref rid="B104-cancers-11-00614" ref-type="bibr">104</xref>]. Metabolic reprogramming is a hallmark of cancer cells and plays a role in tumor progression [<xref rid="B105-cancers-11-00614" ref-type="bibr">105</xref>]. In this regard, mutp53 activates glycolysis in cancer cells to promote cancer cell growth, another GOF for mutp53 [<xref rid="B106-cancers-11-00614" ref-type="bibr">106</xref>], suggesting that unveiling the link between mutp53 and NRF2 oncogenic signaling may reveal additional druggable targets to manipulate the metabolic reprogramming and arrest tumor growth.</p><p>To further link these pathways together, a reciprocal interplay has been shown between HIF-1 and Estrogen receptor-α (ERα). Thus, HIF-1α is a direct transcriptional target of ERα [<xref rid="B107-cancers-11-00614" ref-type="bibr">107</xref>]. A majority of breast cancers are driven by estrogen via ERα, a nuclear transcription factor that is critical for mammary epithelial cell division and breast cancer progression thus, inhibiting Estrogen receptor action by reducing the estrogen levels may be beneficial for early-stage patients and those with advanced disease [<xref rid="B108-cancers-11-00614" ref-type="bibr">108</xref>]. These two pathways may act in cooperation to promote breast cancer progression, as assessed by clinical studies showing that HIF-1α and hypoxia gene signature were correlated with poorer survival in response to hormone therapy [<xref rid="B107-cancers-11-00614" ref-type="bibr">107</xref>]. These results complement findings showing that, in response to UPR or ER stress, XBP1 might interact with HIF-1α to confer antiestrogen resistance in triple negative breast cancer [<xref rid="B109-cancers-11-00614" ref-type="bibr">109</xref>]. Intriguingly, some studies showed that estrogen receptors are able to act in <italic>cis</italic> with p53 at canonical, as well as noncanonical p53 target sequences to enhance transactivation and this synergy applies to cancer-associated p53 mutants, greatly expanding the transcriptional master network regulated by p53 in terms of genes affected and levels of expression [<xref rid="B110-cancers-11-00614" ref-type="bibr">110</xref>]. These findings further link mutp53 with HIF-1 through ERα. Intriguingly, knockdown of ERα has been shown to induce autophagy and inhibit antiestrogen-mediated UPR activation, promoting ROS-induced breast cancer cell death [<xref rid="B111-cancers-11-00614" ref-type="bibr">111</xref>]. It would be interesting to evaluate, whether, in this context mutp53 undergoes autophagy-mediated degradation, to link the pathways together for therapeutic purpose. Thus, these findings suggest that the relationship between mutp53, ERα/HIF-1 under conditions of chronic stress, may be a druggable pathway to increase the efficacy of endocrine therapy in breast cancers.</p><p>Altogether, these findings underline the strict relationship between mutp53, HSF1, NRF2 and HIF-1/ERα signaling pathways that reinforce each other, increasing their oncogenic potential. Given the interplay among them, it is conceivable that blocking one pathway may influence the other pathways and that synchronously blocking them may have greater success in anticancer therapy.</p></sec><sec id="sec5-cancers-11-00614"><title>5. Mutant p53 and Autophagy: Linking the Pathways Together</title><p>In the last years, direct mup53 protein-targeting drug strategies have been developed at various preclinical levels for mutp53 degradation and/or wtp53 reactivation. Pleiomorphic degradation is the most advanced strategy that shows impressive survival effects in mutp53 knock-in mouse models [<xref rid="B11-cancers-11-00614" ref-type="bibr">11</xref>]. We have shown that mutp53 degradation can occur through autophagy activation. This effect was obtained by natural compounds, such as Zn(II)-curcumin and capsaicin, that, by acting on protein folding, reactivate wtp53 that induces its target gene <italic>DRAM</italic> (damage-regulated autophagy modulator) promoting autophagy-induced degradation of mutp53 (R175H and R273H mutants) proteins and restoring cancer chemosensitivity [<xref rid="B112-cancers-11-00614" ref-type="bibr">112</xref>,<xref rid="B113-cancers-11-00614" ref-type="bibr">113</xref>,<xref rid="B114-cancers-11-00614" ref-type="bibr">114</xref>,<xref rid="B115-cancers-11-00614" ref-type="bibr">115</xref>,<xref rid="B116-cancers-11-00614" ref-type="bibr">116</xref>]. Intriguingly, these natural molecules may instigate ER stress and reduce HSP90 expression, all effects favoring mutp53 degradation [<xref rid="B117-cancers-11-00614" ref-type="bibr">117</xref>]. Other natural compounds have been reported to induce mutp53H273 protein degradation through autophagy, including the dietary spice turmeric, and its bioactive component curcumin [<xref rid="B118-cancers-11-00614" ref-type="bibr">118</xref>]. Gambogic acid, a potent apoptotic molecule, may stimulate the degradation of mutp53 through autophagy and consequently increase the response to chemotherapies [<xref rid="B119-cancers-11-00614" ref-type="bibr">119</xref>], although it may also induce protein degradation through proteasome ubiquitination by CHIP [<xref rid="B120-cancers-11-00614" ref-type="bibr">120</xref>]. Similarly, cruciferous-vegetable-derived phenethyl isothiocyanate (PEICT) renders p53H175 sensitive to degradation by both proteasome and autophagy [<xref rid="B121-cancers-11-00614" ref-type="bibr">121</xref>]. We found that apigenin activates wtp53 [<xref rid="B122-cancers-11-00614" ref-type="bibr">122</xref>] and, intriguingly, it also induces mutp53 degradation through autophagy, involving ROS generation and NRF2 activation [<xref rid="B117-cancers-11-00614" ref-type="bibr">117</xref>]. Another important strategy to induce mutp53 degradation via autophagy, both in vitro and in vivo, is glucose restriction (<xref ref-type="fig" rid="cancers-11-00614-f004">Figure 4</xref>a) [<xref rid="B123-cancers-11-00614" ref-type="bibr">123</xref>] and long-term nutrient deprivation that has been reported to induce mutp53 degradation by selective chaperone-mediated autophagy (CMA) [<xref rid="B124-cancers-11-00614" ref-type="bibr">124</xref>]. Finally, inhibition of MKK3, a dual specificity protein kinase that belongs to the MAP kinase kinase family, reduces mutp53 protein levels through ER stress-induced autophagy [<xref rid="B125-cancers-11-00614" ref-type="bibr">125</xref>].</p><p>Interestingly, a mutual interplay between autophagy and mutp53 occurs, as on one hand autophagy degrades mutp53 rendering the cancer cells free from this oncogene and, on the other hand, mutp53 inhibits autophagy counteracting its own elimination, and promoting chemoresistance [<xref rid="B126-cancers-11-00614" ref-type="bibr">126</xref>] (<xref ref-type="fig" rid="cancers-11-00614-f004">Figure 4</xref>a). Thus, the repression of autophagy is functional to the pro-survival and anti-apoptotic GOF of p53 mutants (<xref ref-type="fig" rid="cancers-11-00614-f004">Figure 4</xref>b) [<xref rid="B127-cancers-11-00614" ref-type="bibr">127</xref>]. The inhibition of autophagy by mutp53 is achieved by several mechanisms including inhibition of beclin 1 and ATG12 or reduction of AMPK and activation of mammalian target of rapamycin (mTOR)/PKM2 signaling [<xref rid="B127-cancers-11-00614" ref-type="bibr">127</xref>,<xref rid="B128-cancers-11-00614" ref-type="bibr">128</xref>]. mTOR, a highly conserved serine/threonine kinase, a downstream effector of PI3K/Akt or Ras/MAPK pathways, is a key regulator of the autophagic pathway [<xref rid="B129-cancers-11-00614" ref-type="bibr">129</xref>,<xref rid="B130-cancers-11-00614" ref-type="bibr">130</xref>]. It comprises two different complexes, namely mTOR complex 1 (mTORC1) and mTOR complex 2 (mTOR2), the former being the main regulator of autophagy that can be directly targeted by rapamycin or its analog everolimus. mTORC1 inhibition, which can also occur under nutrient starvation, stimulates autophagy whereas its activation, i.e., in nutrient-rich conditions, reduces this process [<xref rid="B131-cancers-11-00614" ref-type="bibr">131</xref>,<xref rid="B132-cancers-11-00614" ref-type="bibr">132</xref>,<xref rid="B133-cancers-11-00614" ref-type="bibr">133</xref>]. To date, pharmacological induction of autophagy, i.e., through mTOR inhibition or AMPK activation, has been shown to have some potential in cancer prevention and therapy [<xref rid="B134-cancers-11-00614" ref-type="bibr">134</xref>]. Interestingly, the mutp53-induced stimulation of the mTOR pathway, that inhibits autophagy, has been shown to sensitize cancer cells to mTOR inhibitor everolimus [<xref rid="B127-cancers-11-00614" ref-type="bibr">127</xref>]. Intriguingly, the same authors showed that mutp53 may modify autophagy gene transcription by its interaction with p50 NF-kB subunit, opening new avenues in the developing of new drugs that inhibit this oncogenic mechanism and restore autophagy [<xref rid="B127-cancers-11-00614" ref-type="bibr">127</xref>]. Of note, mutp53 promotes glycolysis by enhancing mTORC1-mediated phosphorylation of glycolytic enzyme PKM2, sustaining tumor progression [<xref rid="B128-cancers-11-00614" ref-type="bibr">128</xref>]. </p><p>Given the interplay between mutp53 and NRF2/HIF-1, between ERα and HIF-1, between mutp53 and autophagy, and between NRF2/HIF and autophagy, it is conceivable to hypothesize that mutp53 stabilization could promote NRF2 and ERα/HIF-1 activation also by reducing autophagy. In the case of NRF2, because it is stabilized by p62 that accumulates following autophagy inhibition by mutp53 and, in the case of HIF-1, because its lysosomal degradation may be reduced by mutp53. On the other hand, the oncogenic potential of these partners in crime may be dismantled by induction of autophagy to degrade mutp53 and disrupt the connected complexes like falling dominoes. Of note, differently from the other pro-survival pathways that are activated by mutp53, autophagy seems to be negatively regulated by this oncogenic protein. This may represent a self-protective mechanism, as autophagy contributes to mutp53 degradation. For this effect, for the autophagy capacity to degrade other oncogenic proteins other than mutp53, such as HIF-1 and c-myc [<xref rid="B135-cancers-11-00614" ref-type="bibr">135</xref>] and for its role in promoting the immunogenic cell death [<xref rid="B134-cancers-11-00614" ref-type="bibr">134</xref>,<xref rid="B136-cancers-11-00614" ref-type="bibr">136</xref>], autophagy might turn out to be a process that possibly fights cancer, instead of promoting it, as it has been for a long time considered [<xref rid="B137-cancers-11-00614" ref-type="bibr">137</xref>]. </p></sec><sec sec-type="conclusions" id="sec6-cancers-11-00614"><title>6. Conclusions</title><p>Many different types of cancer show a high incidence of <italic>TP53</italic> mutations and some of them may acquire oncogenic functions that underline the aggressive phenotype of breast cancer, pancreatic cancer, and non-small cell lung cancer, therefore providing numerous exciting therapeutic possibilities [<xref rid="B138-cancers-11-00614" ref-type="bibr">138</xref>]. Given its pivotal role in oncogenesis, mutp53 protein-targeting drug strategies, aimed at inducing its degradation and/or restoring wtp53 function, are currently being developed at various preclinical levels [<xref rid="B11-cancers-11-00614" ref-type="bibr">11</xref>,<xref rid="B139-cancers-11-00614" ref-type="bibr">139</xref>]. However, mutp53 may interact with transcription factors involved in the cell response to stress, including HSF1, NRF2, and HIF-1, that reinforce each other, increasing their oncogenic potential, making the targeted therapies even more challenging. Therefore, it is conceivable that blocking one pathway may influence the other pathways and that synchronously blocking them may have more profound consequences than anticipated.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors wish to thank all members of the laboratories for critical discussion.</p></ack><notes><title>Author Contributions</title><p>G.D. and M.C. conceived and discussed the topic and wrote the manuscript.</p></notes><notes><title>Funding</title><p>The research in the laboratory of GD is supported by grants from the Italian Association for Cancer Research (IG 2013 11377, IG 2015 Id.16742) and Fondi Ateneo University “G. d’Annunzio”; in the laboratory of MC is supported by grants from ASI (Agenzia Spaziale Italiana) (2014-033-R.O.), Pasteur Insitute-Italia Fondazione Cenci-Bolognetti, and University of Rome “Sapienza” Ricerche Universitarie (N° C26A15CX3M).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><glossary><title>Abbreviations</title><p>ARE: anti-oxidant responsive elements; ENTPD5, ectonucleoside triphosphate diphosphohydrolase 5; ER, endopasmic reticulum; ERα, estrogen receptor-α; GOF, gain-of-function; GRP78/BiP, glucose-regulated protein 78/binding immunoglobulin protein; GSH, glutathione; HIF-1; HO-1, heme-oxygenase 1; HSF1, heat shock factor 1; HSP, heat shock protein; IRE1α, inositol-requiring enzyme 1α; mTOR, mammalian target of rapamycin; mTORC1/2, mTOR complex 1/2; mutant p53, mutp53; MVP, mevalonate pathway; NQO1, NAD(P)H:quinone oxidoreductase 1; NRF2, nuclear factor erythroid 2-related factor 2; PERK, PKR-like ER kinase; ROS, reactive oxygen species; SOD, superoxide dismutase; TXN, thioredoxin; UPR, unfolded protein response; wtp53, wild-type p53.</p></glossary><ref-list><title>References</title><ref id="B1-cancers-11-00614"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vousden</surname><given-names>K.H.</given-names></name></person-group><article-title>Live or let die: The cell’s response to p53</article-title><source>Nat. Rev. Cancer</source><year>2002</year><volume>2</volume><fpage>594</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1038/nrc864</pub-id><pub-id pub-id-type="pmid">12154352</pub-id></element-citation></ref><ref id="B2-cancers-11-00614"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reinhardt</surname><given-names>H.C.</given-names></name><name><surname>Schumacher</surname><given-names>B.</given-names></name></person-group><article-title>The p53 network: Cellular and systemic DNA damage responses in ageing and cancer</article-title><source>Trends Genet.</source><year>2012</year><volume>28</volume><fpage>128</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.tig.2011.12.002</pub-id><pub-id pub-id-type="pmid">22265392</pub-id></element-citation></ref><ref id="B3-cancers-11-00614"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bykov</surname><given-names>V.J.N.</given-names></name><name><surname>Eriksson</surname><given-names>S.E.</given-names></name><name><surname>Bianchi</surname><given-names>J.</given-names></name><name><surname>Wiman</surname><given-names>K.G.</given-names></name></person-group><article-title>Targeting mutant p53 for efficient cancer therapy</article-title><source>Nat. Rev.</source><year>2018</year><volume>18</volume><fpage>89</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1038/nrc.2017.109</pub-id><pub-id pub-id-type="pmid">29242642</pub-id></element-citation></ref><ref id="B4-cancers-11-00614"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Housman</surname><given-names>G.</given-names></name><name><surname>Byler</surname><given-names>S.</given-names></name><name><surname>Heerboth</surname><given-names>S.</given-names></name><name><surname>Lapinska</surname><given-names>K.</given-names></name><name><surname>Longacre</surname><given-names>M.</given-names></name><name><surname>Snyder</surname><given-names>N.</given-names></name><name><surname>Sarkar</surname><given-names>S.</given-names></name></person-group><article-title>Drug resistance in cancer: An overview</article-title><source>Cancers</source><year>2014</year><volume>6</volume><fpage>1769</fpage><lpage>1792</lpage><pub-id pub-id-type="doi">10.3390/cancers6031769</pub-id><pub-id pub-id-type="pmid">25198391</pub-id></element-citation></ref><ref id="B5-cancers-11-00614"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zahreddine</surname><given-names>H.</given-names></name><name><surname>Borden</surname><given-names>K.L.</given-names></name></person-group><article-title>Mechanisms and insights into drug resistance in cancer</article-title><source>Front. Pharmacol.</source><year>2013</year><volume>4</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.3389/fphar.2013.00028</pub-id><pub-id pub-id-type="pmid">23346057</pub-id></element-citation></ref><ref id="B6-cancers-11-00614"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kandoth</surname><given-names>C.</given-names></name><name><surname>McLellan</surname><given-names>M.D.</given-names></name><name><surname>Vandin</surname><given-names>F.</given-names></name><name><surname>Ye</surname><given-names>K.</given-names></name><name><surname>Niu</surname><given-names>B.</given-names></name><name><surname>Lu</surname><given-names>C.</given-names></name><name><surname>Xie</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>McMichael</surname><given-names>J.F.</given-names></name><name><surname>Wyczalkowski</surname><given-names>M.A.</given-names></name><etal></etal></person-group><article-title>Mutational landscape and significance across 12 major cancer types</article-title><source>Nature</source><year>2013</year><volume>502</volume><fpage>333</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1038/nature12634</pub-id><pub-id pub-id-type="pmid">24132290</pub-id></element-citation></ref><ref id="B7-cancers-11-00614"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>M.P.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Lozano</surname><given-names>G.</given-names></name></person-group><article-title>Mutant p53: Multiple mechanisms define biologic activity in cancer</article-title><source>Front. Oncol.</source><year>2015</year><volume>5</volume><fpage>249</fpage><pub-id pub-id-type="doi">10.3389/fonc.2015.00249</pub-id><pub-id pub-id-type="pmid">26618142</pub-id></element-citation></ref><ref id="B8-cancers-11-00614"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>P.A.</given-names></name><name><surname>Vousden</surname><given-names>K.H.</given-names></name></person-group><article-title>Mutant p53 in cancer: New functions and therapeutic opportunities</article-title><source>Cancer Cell.</source><year>2014</year><volume>25</volume><fpage>304</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2014.01.021</pub-id><pub-id pub-id-type="pmid">24651012</pub-id></element-citation></ref><ref id="B9-cancers-11-00614"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Reumers</surname><given-names>J.</given-names></name><name><surname>Couceiro</surname><given-names>J.R.</given-names></name><name><surname>De Smet</surname><given-names>F.</given-names></name><name><surname>Gallardo</surname><given-names>R.</given-names></name><name><surname>Rudyak</surname><given-names>S.</given-names></name><name><surname>Cornelis</surname><given-names>A.</given-names></name><name><surname>Rozenski</surname><given-names>J.</given-names></name><name><surname>Zwolinska</surname><given-names>A.</given-names></name><name><surname>Marine</surname><given-names>J.C.</given-names></name><etal></etal></person-group><article-title>Gain of function of mutant p53 by coaggregation with multiple tumor suppressors</article-title><source>Nat. Chem. Biol.</source><year>2011</year><volume>7</volume><fpage>285</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1038/nchembio.546</pub-id><pub-id pub-id-type="pmid">21445056</pub-id></element-citation></ref><ref id="B10-cancers-11-00614"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>P.B.</given-names></name><name><surname>Attardi</surname><given-names>L.D.</given-names></name></person-group><article-title>Illuminating p53 function in cancer with genetically engineered mouse models</article-title><source>Semin. Cell. Dev. Biol.</source><year>2014</year><volume>0</volume><fpage>74</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2013.12.014</pub-id></element-citation></ref><ref id="B11-cancers-11-00614"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz-Heddergott</surname><given-names>R.</given-names></name><name><surname>Moll</surname><given-names>U.M.</given-names></name></person-group><article-title>Gain-of-function (GOF) mutant p53 are actionable therapeutic target</article-title><source>Cancers</source><year>2018</year><volume>10</volume><elocation-id>188</elocation-id><pub-id pub-id-type="doi">10.3390/cancers10060188</pub-id></element-citation></ref><ref id="B12-cancers-11-00614"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>M.P.</given-names></name><name><surname>Lozano</surname><given-names>G.</given-names></name></person-group><article-title>Mutant p53 partners in crime</article-title><source>Cell. Death Diff.</source><year>2017</year><volume>25</volume><fpage>161</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1038/cdd.2017.185</pub-id></element-citation></ref><ref id="B13-cancers-11-00614"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cordani</surname><given-names>M.</given-names></name><name><surname>Pacchiana</surname><given-names>R.</given-names></name><name><surname>Butera</surname><given-names>G.</given-names></name><name><surname>D’Orazi</surname><given-names>G.</given-names></name><name><surname>Scarpa</surname><given-names>A.</given-names></name><name><surname>Donadelli</surname><given-names>M.</given-names></name></person-group><article-title>Mutant p53 proteins alter cancer cell secretome and tumor micorenvironmen: Involvement in cancer invasion and metastasis</article-title><source>Cancer Lett.</source><year>2016</year><volume>376</volume><fpage>303</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2016.03.046</pub-id><pub-id pub-id-type="pmid">27045472</pub-id></element-citation></ref><ref id="B14-cancers-11-00614"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurtner</surname><given-names>A.</given-names></name><name><surname>Falcone</surname><given-names>E.</given-names></name><name><surname>Garibaldi</surname><given-names>F.</given-names></name><name><surname>Piaggio</surname><given-names>G.</given-names></name></person-group><article-title>Dysregulation of microRNA biogenesis in cancer: The impact of mutant p53 on Drosha complex activity</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2016</year><volume>35</volume><fpage>45</fpage><pub-id pub-id-type="doi">10.1186/s13046-016-0319-x</pub-id><pub-id pub-id-type="pmid">26971015</pub-id></element-citation></ref><ref id="B15-cancers-11-00614"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantovani</surname><given-names>F.</given-names></name><name><surname>Collavin</surname><given-names>L.</given-names></name><name><surname>Del Sal</surname><given-names>G.</given-names></name></person-group><article-title>Mutant p53 as a guardian of the cancer cells</article-title><source>Cell. Death Differ.</source><year>2019</year><volume>26</volume><fpage>199</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1038/s41418-018-0246-9</pub-id><pub-id pub-id-type="pmid">30538286</pub-id></element-citation></ref><ref id="B16-cancers-11-00614"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riha</surname><given-names>R.</given-names></name><name><surname>Gupta-Saraf</surname><given-names>P.</given-names></name><name><surname>Bhanja</surname><given-names>P.</given-names></name><name><surname>Badkul</surname><given-names>S.</given-names></name><name><surname>Saha</surname><given-names>S.</given-names></name></person-group><article-title>Stressed out–– Therapeutic implications of ER stress related cancer research</article-title><source>Oncomedicine</source><year>2017</year><volume>2</volume><fpage>156</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.7150/oncm.22477</pub-id><pub-id pub-id-type="pmid">29445586</pub-id></element-citation></ref><ref id="B17-cancers-11-00614"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sane</surname><given-names>S.</given-names></name><name><surname>Rezvani</surname><given-names>K.</given-names></name></person-group><article-title>Essential Roles of E3 ubiquitin ligases in p53 regulation</article-title><source>Int. J. Mol. Sci.</source><year>2017</year><volume>18</volume><elocation-id>442</elocation-id><pub-id pub-id-type="doi">10.3390/ijms18020442</pub-id><pub-id pub-id-type="pmid">28218667</pub-id></element-citation></ref><ref id="B18-cancers-11-00614"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>P.A.J.</given-names></name><name><surname>Vousden</surname><given-names>K.H.</given-names></name></person-group><article-title>P53 mutations in cancer</article-title><source>Nat. Cell. Biol.</source><year>2013</year><volume>15</volume><fpage>2</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/ncb2641</pub-id><pub-id pub-id-type="pmid">23263379</pub-id></element-citation></ref><ref id="B19-cancers-11-00614"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joerger</surname><given-names>A.C.</given-names></name><name><surname>Fersht</surname><given-names>A.R.</given-names></name></person-group><article-title>Structure-function-rescue: The diverse nature of common p53 cancer mutants</article-title><source>Oncogene</source><year>2007</year><volume>26</volume><fpage>2226</fpage><lpage>2242</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210291</pub-id><pub-id pub-id-type="pmid">17401432</pub-id></element-citation></ref><ref id="B20-cancers-11-00614"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lukashchuk</surname><given-names>N.</given-names></name><name><surname>Vousden</surname><given-names>K.H.</given-names></name></person-group><article-title>Ubiquitination and degradation of mutant p53</article-title><source>Mol. Cell. Biol.</source><year>2007</year><volume>27</volume><fpage>8284</fpage><lpage>8295</lpage><pub-id pub-id-type="doi">10.1128/MCB.00050-07</pub-id><pub-id pub-id-type="pmid">17908790</pub-id></element-citation></ref><ref id="B21-cancers-11-00614"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Marchencko</surname><given-names>N.D.</given-names></name><name><surname>Moll</surname><given-names>U.M.</given-names></name></person-group><article-title>SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis</article-title><source>Cell. Death. Diff.</source><year>2011</year><volume>18</volume><fpage>1904</fpage><lpage>1913</lpage><pub-id pub-id-type="doi">10.1038/cdd.2011.71</pub-id></element-citation></ref><ref id="B22-cancers-11-00614"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandrova</surname><given-names>E.M.</given-names></name><name><surname>Moll</surname><given-names>U.M.</given-names></name></person-group><article-title>Depleting stabilized GOF mutant p53 proteins by inhibiting molecular folding chaperones: A new promise in cancer therapy</article-title><source>Cell. Death Differ.</source><year>2017</year><volume>24</volume><fpage>3</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1038/cdd.2016.145</pub-id><pub-id pub-id-type="pmid">27935583</pub-id></element-citation></ref><ref id="B23-cancers-11-00614"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Lu</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name></person-group><article-title>Inhibition of MDM2 by HSP90 contributes to mutant p53 stabilization</article-title><source>J. Biol. Chem.</source><year>2001</year><volume>44</volume><fpage>40583</fpage><lpage>40590</lpage><pub-id pub-id-type="doi">10.1074/jbc.M102817200</pub-id></element-citation></ref><ref id="B24-cancers-11-00614"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Marchenko</surname><given-names>N.D.</given-names></name><name><surname>Schultz</surname><given-names>R.</given-names></name><name><surname>Fischer</surname><given-names>V.</given-names></name><name><surname>Velasco-Hernandez</surname><given-names>T.</given-names></name><name><surname>Talos</surname><given-names>F.</given-names></name><name><surname>Moll</surname><given-names>U.M.</given-names></name></person-group><article-title>Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells</article-title><source>Mol. Cancer Res.</source><year>2011</year><volume>9</volume><fpage>577</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-10-0534</pub-id><pub-id pub-id-type="pmid">21478269</pub-id></element-citation></ref><ref id="B25-cancers-11-00614"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trepel</surname><given-names>J.</given-names></name><name><surname>Mollapour</surname><given-names>M.</given-names></name><name><surname>Gaccone</surname><given-names>G.</given-names></name><name><surname>Neckers</surname><given-names>L.</given-names></name></person-group><article-title>Targeting the dynamic HSP90 complex in cancer</article-title><source>Nat. Rev. Cancer</source><year>2010</year><volume>10</volume><fpage>537</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1038/nrc2887</pub-id><pub-id pub-id-type="pmid">20651736</pub-id></element-citation></ref><ref id="B26-cancers-11-00614"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitesell</surname><given-names>L.</given-names></name><name><surname>Sutphin</surname><given-names>P.D.</given-names></name><name><surname>Pulcini</surname><given-names>E.J.</given-names></name><name><surname>Martinez</surname><given-names>J.D.</given-names></name><name><surname>Cook</surname><given-names>P.H.</given-names></name></person-group><article-title>The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent</article-title><source>Mol. Cell. Biol.</source><year>1998</year><volume>18</volume><fpage>1517</fpage><lpage>1524</lpage><pub-id pub-id-type="doi">10.1128/MCB.18.3.1517</pub-id><pub-id pub-id-type="pmid">9488468</pub-id></element-citation></ref><ref id="B27-cancers-11-00614"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Proia</surname><given-names>D.A.</given-names></name><name><surname>Bates</surname><given-names>R.C.</given-names></name></person-group><article-title>Ganetespib and HSP90: Translating preclinical hypotheses into clinical promise</article-title><source>Cancer Res.</source><year>2014</year><volume>74</volume><fpage>1294</fpage><lpage>1300</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-3263</pub-id><pub-id pub-id-type="pmid">24556722</pub-id></element-citation></ref><ref id="B28-cancers-11-00614"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solárová</surname><given-names>Z.</given-names></name><name><surname>Mojžiš</surname><given-names>J.</given-names></name><name><surname>Solár</surname><given-names>P.</given-names></name></person-group><article-title>Hsp90 inhibitors as a sensitizer of cancer cells to different therapies</article-title><source>Int. J. Oncol.</source><year>2015</year><volume>46</volume><fpage>907</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.3892/ijo.2014.2791</pub-id><pub-id pub-id-type="pmid">25501619</pub-id></element-citation></ref><ref id="B29-cancers-11-00614"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krämer</surname><given-names>O.H.</given-names></name><name><surname>Mahboobi</surname><given-names>S.</given-names></name><name><surname>Sellmer</surname><given-names>A.</given-names></name></person-group><article-title>Drugging the HDAC6-HSP90 interplay in malignant cells</article-title><source>Trends Pharmacol. Sci.</source><year>2014</year><volume>35</volume><fpage>501</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2014.08.001</pub-id><pub-id pub-id-type="pmid">25234862</pub-id></element-citation></ref><ref id="B30-cancers-11-00614"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Ozog</surname><given-names>L.</given-names></name><name><surname>Marchenko</surname><given-names>N.</given-names></name></person-group><article-title>A gain-of-function mutant p53-HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress</article-title><source>Cell Death Dis.</source><year>2014</year><volume>5</volume><fpage>e1194</fpage><pub-id pub-id-type="doi">10.1038/cddis.2014.158</pub-id><pub-id pub-id-type="pmid">24763051</pub-id></element-citation></ref><ref id="B31-cancers-11-00614"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Pastor</surname><given-names>R.</given-names></name><name><surname>Burchfiel</surname><given-names>E.T.</given-names></name><name><surname>Thiele</surname><given-names>D.J.</given-names></name></person-group><article-title>Regulation of heath shock transcription factors and their role in physiology and disease</article-title><source>Nat. Rev. Mol. Cell. Biol.</source><year>2018</year><volume>19</volume><fpage>4</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1038/nrm.2017.73</pub-id><pub-id pub-id-type="pmid">28852220</pub-id></element-citation></ref><ref id="B32-cancers-11-00614"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Home</surname><given-names>T.</given-names></name><name><surname>Jensen</surname><given-names>R.A.</given-names></name><name><surname>Rap</surname><given-names>R.</given-names></name></person-group><article-title>Heat shock factor 1 in protein homeostasis and oncogenic signal integration</article-title><source>Cancer Res.</source><year>2015</year><volume>75</volume><fpage>907</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-2905</pub-id><pub-id pub-id-type="pmid">25724679</pub-id></element-citation></ref><ref id="B33-cancers-11-00614"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>C.</given-names></name><name><surname>Seo</surname><given-names>Y.H.</given-names></name></person-group><article-title>Small molecule inhibitors of HSF1-activated pathways as potential next-generation anticancer therapeutics</article-title><source>Molecules</source><year>2018</year><volume>23</volume><elocation-id>2757</elocation-id><pub-id pub-id-type="doi">10.3390/molecules23112757</pub-id><pub-id pub-id-type="pmid">30356024</pub-id></element-citation></ref><ref id="B34-cancers-11-00614"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>C.</given-names></name><name><surname>Santagata</surname><given-names>S.</given-names></name><name><surname>Tang</surname><given-names>Z.</given-names></name><name><surname>Shi</surname><given-names>J.</given-names></name><name><surname>Cao</surname><given-names>J.</given-names></name><name><surname>Kwon</surname><given-names>H.</given-names></name><name><surname>Bronson</surname><given-names>R.T.</given-names></name><name><surname>Whitesell</surname><given-names>L.</given-names></name><name><surname>Lindquist</surname><given-names>S.</given-names></name></person-group><article-title>Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis</article-title><source>J. Clin. Investig.</source><year>2012</year><volume>122</volume><fpage>3742</fpage><lpage>3754</lpage><pub-id pub-id-type="doi">10.1172/JCI62727</pub-id><pub-id pub-id-type="pmid">22945628</pub-id></element-citation></ref><ref id="B35-cancers-11-00614"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>P.A.</given-names></name><name><surname>Caswell</surname><given-names>P.T.</given-names></name><name><surname>Doyle</surname><given-names>B.</given-names></name><name><surname>Iwanicki</surname><given-names>M.P.</given-names></name><name><surname>Tan</surname><given-names>E.H.</given-names></name><name><surname>Karim</surname><given-names>S.</given-names></name><name><surname>Lukashchuk</surname><given-names>N.</given-names></name><name><surname>Gillespie</surname><given-names>D.A.</given-names></name><name><surname>Ludwig</surname><given-names>R.L.</given-names></name><name><surname>Gosselin</surname><given-names>P.</given-names></name><etal></etal></person-group><article-title>Mutant p53 drives invasion by promoting integrin recycling</article-title><source>Cell</source><year>2009</year><volume>139</volume><fpage>1327</fpage><lpage>1341</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.11.026</pub-id><pub-id pub-id-type="pmid">20064378</pub-id></element-citation></ref><ref id="B36-cancers-11-00614"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yarden</surname><given-names>Y.</given-names></name><name><surname>Pines</surname><given-names>G.</given-names></name></person-group><article-title>the ERBB network at last, cancer therapy meets systems biology</article-title><source>Nat. Rev. Cancer</source><year>2012</year><volume>12</volume><fpage>553</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1038/nrc3309</pub-id><pub-id pub-id-type="pmid">22785351</pub-id></element-citation></ref><ref id="B37-cancers-11-00614"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>C.</given-names></name><name><surname>Whitesell</surname><given-names>L.</given-names></name><name><surname>Rogers</surname><given-names>A.B.</given-names></name><name><surname>Lindquist</surname><given-names>S.</given-names></name></person-group><article-title>Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis</article-title><source>Cell</source><year>2007</year><volume>130</volume><fpage>1005</fpage><lpage>1018</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.07.020</pub-id><pub-id pub-id-type="pmid">17889646</pub-id></element-citation></ref><ref id="B38-cancers-11-00614"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parrales</surname><given-names>A.</given-names></name><name><surname>Ranjan</surname><given-names>A.</given-names></name><name><surname>Iyer</surname><given-names>S.V.</given-names></name><name><surname>Padhye</surname><given-names>S.</given-names></name><name><surname>Weir</surname><given-names>S.J.</given-names></name><name><surname>Roy</surname><given-names>A.</given-names></name><name><surname>Iwakuma</surname><given-names>T.</given-names></name></person-group><article-title>DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway</article-title><source>Nat. Cell. Biol.</source><year>2016</year><volume>18</volume><fpage>1233</fpage><lpage>1243</lpage><pub-id pub-id-type="doi">10.1038/ncb3427</pub-id><pub-id pub-id-type="pmid">27775703</pub-id></element-citation></ref><ref id="B39-cancers-11-00614"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiech</surname><given-names>M.</given-names></name><name><surname>Olszewski</surname><given-names>M.B.</given-names></name><name><surname>Tracz-Gaszewska</surname><given-names>Z.</given-names></name><name><surname>Wawrzynow</surname><given-names>B.</given-names></name><name><surname>Zylicz</surname><given-names>M.</given-names></name><name><surname>Zylicz</surname><given-names>A.</given-names></name></person-group><article-title>Molecular mechanism of mutant p53 stabilization: The role of HSP70 and MDM2</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e51426</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0051426</pub-id><pub-id pub-id-type="pmid">23251530</pub-id></element-citation></ref><ref id="B40-cancers-11-00614"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freed-Pastor</surname><given-names>W.A.</given-names></name><name><surname>Mizuno</surname><given-names>H.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Langerød</surname><given-names>A.</given-names></name><name><surname>Moon</surname><given-names>S.H.</given-names></name><name><surname>Rodriguez-Barrueco</surname><given-names>R.</given-names></name><name><surname>Barsotti</surname><given-names>A.</given-names></name><name><surname>Chicas</surname><given-names>A.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Polotskaia</surname><given-names>A.</given-names></name><etal></etal></person-group><article-title>Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway</article-title><source>Cell</source><year>2012</year><volume>148</volume><fpage>244</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.12.017</pub-id><pub-id pub-id-type="pmid">22265415</pub-id></element-citation></ref><ref id="B41-cancers-11-00614"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullen</surname><given-names>P.J.</given-names></name><name><surname>Yu</surname><given-names>R.</given-names></name><name><surname>Longo</surname><given-names>J.</given-names></name><name><surname>Archer</surname><given-names>M.C.</given-names></name><name><surname>Penn</surname><given-names>L.Z.</given-names></name></person-group><article-title>The interplay between cell signaling and the mevalonate pathway in cancer</article-title><source>Nat. Rev. Cancer</source><year>2016</year><volume>16</volume><fpage>718</fpage><lpage>731</lpage><pub-id pub-id-type="doi">10.1038/nrc.2016.76</pub-id><pub-id pub-id-type="pmid">27562463</pub-id></element-citation></ref><ref id="B42-cancers-11-00614"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorrentino</surname><given-names>G.</given-names></name><name><surname>Ruggeri</surname><given-names>N.</given-names></name><name><surname>Specchia</surname><given-names>V.</given-names></name><name><surname>Cordenonsi</surname><given-names>M.</given-names></name><name><surname>Mano</surname><given-names>M.</given-names></name><name><surname>Dupont</surname><given-names>S.</given-names></name><name><surname>Manfrin</surname><given-names>A.</given-names></name><name><surname>Ingallina</surname><given-names>E.</given-names></name><name><surname>Sommaggio</surname><given-names>R.</given-names></name><name><surname>Piazza</surname><given-names>S.</given-names></name><etal></etal></person-group><article-title>Metabolic control of YAP and TAZ by yje mevalonate pathway</article-title><source>Nat. Cell. Biol.</source><year>2014</year><volume>16</volume><fpage>357</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1038/ncb2936</pub-id><pub-id pub-id-type="pmid">24658687</pub-id></element-citation></ref><ref id="B43-cancers-11-00614"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ingallina</surname><given-names>E.</given-names></name><name><surname>Sorrentino</surname><given-names>G.</given-names></name><name><surname>Bertolio</surname><given-names>R.</given-names></name><name><surname>Lisek</surname><given-names>K.</given-names></name><name><surname>Zannini</surname><given-names>A.</given-names></name><name><surname>Azzolin</surname><given-names>L.</given-names></name><name><surname>Severino</surname><given-names>L.U.</given-names></name><name><surname>Scaini</surname><given-names>D.</given-names></name><name><surname>Mano</surname><given-names>M.</given-names></name><name><surname>Mantovani</surname><given-names>F.</given-names></name><etal></etal></person-group><article-title>Mechanical cues control mutant p53 stability through a mevalonate-RhoA axis</article-title><source>Nat. Cell. Biol.</source><year>2018</year><volume>20</volume><fpage>28</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1038/s41556-017-0009-8</pub-id><pub-id pub-id-type="pmid">29255172</pub-id></element-citation></ref><ref id="B44-cancers-11-00614"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>S.H.</given-names></name><name><surname>Huang</surname><given-names>C.H.</given-names></name><name><surname>Houlihan</surname><given-names>S.L.</given-names></name><name><surname>Regunath</surname><given-names>K.</given-names></name><name><surname>Freed-Pastor</surname><given-names>W.A.</given-names></name><name><surname>Morris</surname><given-names>J.P.</given-names><suffix>IV</suffix></name><name><surname>Tschaharganeh</surname><given-names>D.F.</given-names></name><name><surname>Kastenhuber</surname><given-names>E.R.</given-names></name><name><surname>Barsotti</surname><given-names>A.M.</given-names></name><name><surname>Culp-Hill</surname><given-names>R.</given-names></name><etal></etal></person-group><article-title>p53 represses the mevalonate pathway to mediate tumor suppression</article-title><source>Cell</source><year>2019</year><volume>176</volume><fpage>564</fpage><lpage>580.e19</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.11.011</pub-id><pub-id pub-id-type="pmid">30580964</pub-id></element-citation></ref><ref id="B45-cancers-11-00614"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandrova</surname><given-names>E.M.</given-names></name><name><surname>Marchenko</surname><given-names>N.D.</given-names></name></person-group><article-title>Mutant p53-heat shock response oncogenic cooperation: A new mechanism of cancer cell survival</article-title><source>Front. Endocrinol.</source><year>2015</year><volume>6</volume><fpage>53</fpage><pub-id pub-id-type="doi">10.3389/fendo.2015.00053</pub-id><pub-id pub-id-type="pmid">25954247</pub-id></element-citation></ref><ref id="B46-cancers-11-00614"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walter</surname><given-names>P.</given-names></name><name><surname>Gilmore</surname><given-names>R.</given-names></name><name><surname>Blobel</surname><given-names>G.</given-names></name></person-group><article-title>Protein translocation across the endoplasmic reticulum</article-title><source>Cell</source><year>1984</year><volume>38</volume><fpage>5</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(84)90520-8</pub-id><pub-id pub-id-type="pmid">6088076</pub-id></element-citation></ref><ref id="B47-cancers-11-00614"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hetz</surname><given-names>C.</given-names></name></person-group><article-title>The unfolded protein response: Controlling cell fate decision under ER stress and beyond</article-title><source>Nat. Rev. Mol. Cell. Biol.</source><year>2012</year><volume>13</volume><fpage>89</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1038/nrm3270</pub-id><pub-id pub-id-type="pmid">22251901</pub-id></element-citation></ref><ref id="B48-cancers-11-00614"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walter</surname><given-names>P.</given-names></name><name><surname>Ron</surname><given-names>D.</given-names></name></person-group><article-title>The unfolded protein response: From stress pathway to homeostatic regulation</article-title><source>Science</source><year>2011</year><volume>334</volume><fpage>1081</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.1126/science.1209038</pub-id><pub-id pub-id-type="pmid">22116877</pub-id></element-citation></ref><ref id="B49-cancers-11-00614"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donnelly</surname><given-names>N.</given-names></name><name><surname>Storchov</surname><given-names>Z.</given-names></name></person-group><article-title>Aneuploidy and proteotoxic stress in cancer</article-title><source>Mol. Cell. Oncol.</source><year>2015</year><volume>2</volume><fpage>e976491</fpage><pub-id pub-id-type="doi">10.4161/23723556.2014.976491</pub-id><pub-id pub-id-type="pmid">27308438</pub-id></element-citation></ref><ref id="B50-cancers-11-00614"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deegan</surname><given-names>S.</given-names></name><name><surname>Saveljeva</surname><given-names>S.</given-names></name><name><surname>Gorman</surname><given-names>A.M.</given-names></name><name><surname>Samali</surname><given-names>A.</given-names></name></person-group><article-title>Stress-induced self-cannibalism: On the regulation of autophagy by endoplasmic reticulum stress</article-title><source>Cell. Mol. Life Sci.</source><year>2013</year><volume>70</volume><fpage>2425</fpage><lpage>2541</lpage><pub-id pub-id-type="doi">10.1007/s00018-012-1173-4</pub-id><pub-id pub-id-type="pmid">23052213</pub-id></element-citation></ref><ref id="B51-cancers-11-00614"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Nice</surname><given-names>E.C.</given-names></name><name><surname>Huang</surname><given-names>C.</given-names></name></person-group><article-title>Stress management by autophagy: Implications for chemoresistance</article-title><source>Int. J. Cancer</source><year>2016</year><volume>139</volume><fpage>23</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1002/ijc.29990</pub-id><pub-id pub-id-type="pmid">26757106</pub-id></element-citation></ref><ref id="B52-cancers-11-00614"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avril</surname><given-names>T.</given-names></name><name><surname>Vauleon</surname><given-names>E.</given-names></name><name><surname>Chevet</surname><given-names>E.</given-names></name></person-group><article-title>Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers</article-title><source>Oncogenesis</source><year>2017</year><volume>6</volume><fpage>e373</fpage><pub-id pub-id-type="doi">10.1038/oncsis.2017.72</pub-id><pub-id pub-id-type="pmid">28846078</pub-id></element-citation></ref><ref id="B53-cancers-11-00614"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chevet</surname><given-names>E.</given-names></name><name><surname>Hetz</surname><given-names>C.</given-names></name><name><surname>Samali</surname><given-names>A.</given-names></name></person-group><article-title>Endoplasmic reticulum stress-activated cell reprogramming in oncogenesis</article-title><source>Cancer Discov.</source><year>2015</year><volume>5</volume><fpage>586</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-14-1490</pub-id><pub-id pub-id-type="pmid">25977222</pub-id></element-citation></ref><ref id="B54-cancers-11-00614"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yadav</surname><given-names>R.K.</given-names></name><name><surname>Chae</surname><given-names>S.W.</given-names></name><name><surname>Kim</surname><given-names>H.R.</given-names></name><name><surname>Char</surname><given-names>J.</given-names></name></person-group><article-title>Endoplasmic reticulum stress and cancer</article-title><source>J. Cancer Prev.</source><year>2014</year><volume>19</volume><fpage>75</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.15430/JCP.2014.19.2.75</pub-id><pub-id pub-id-type="pmid">25337575</pub-id></element-citation></ref><ref id="B55-cancers-11-00614"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertolotti</surname><given-names>A.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Hendershot</surname><given-names>L.M.</given-names></name><name><surname>Harding</surname><given-names>H.P.</given-names></name><name><surname>Ron</surname><given-names>D.</given-names></name></person-group><article-title>Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response</article-title><source>Nat. Cell. Biol.</source><year>2000</year><volume>2</volume><fpage>326</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1038/35014014</pub-id><pub-id pub-id-type="pmid">10854322</pub-id></element-citation></ref><ref id="B56-cancers-11-00614"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Hendershot</surname><given-names>L.</given-names></name><name><surname>Prywes</surname><given-names>R.</given-names></name></person-group><article-title>ER stress regulation of ATF6 localization by dissociation of BiP/GRP78 binding and unmasking of Golgi localization signals</article-title><source>Dev. Cell</source><year>2002</year><volume>3</volume><fpage>99</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/S1534-5807(02)00203-4</pub-id><pub-id pub-id-type="pmid">12110171</pub-id></element-citation></ref><ref id="B57-cancers-11-00614"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>H.</given-names></name><name><surname>Matsui</surname><given-names>T.</given-names></name><name><surname>Yamamoto</surname><given-names>A.</given-names></name><name><surname>Okada</surname><given-names>T.</given-names></name><name><surname>Mori</surname><given-names>K.</given-names></name></person-group><article-title>XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor</article-title><source>Cell</source><year>2001</year><volume>107</volume><fpage>881</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(01)00611-0</pub-id><pub-id pub-id-type="pmid">11779464</pub-id></element-citation></ref><ref id="B58-cancers-11-00614"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acosta-Alvear</surname><given-names>D.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Blais</surname><given-names>A.</given-names></name><name><surname>Tsikitis</surname><given-names>M.</given-names></name><name><surname>Lents</surname><given-names>N.H.</given-names></name><name><surname>Arias</surname><given-names>C.</given-names></name><name><surname>Lennon</surname><given-names>C.J.</given-names></name><name><surname>Kluger</surname><given-names>Y.</given-names></name><name><surname>Dynlacht</surname><given-names>B.D.</given-names></name></person-group><article-title>XBP1 controls diverse cell type- and condition-specific transcriptional regulatory networks</article-title><source>Mol. Cell.</source><year>2007</year><volume>27</volume><fpage>53</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2007.06.011</pub-id><pub-id pub-id-type="pmid">17612490</pub-id></element-citation></ref><ref id="B59-cancers-11-00614"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senft</surname><given-names>D.</given-names></name><name><surname>Ronai</surname><given-names>Z.A.</given-names></name></person-group><article-title>UPR, autophagy, and mitochondria crosstalk underlies the ER stress response</article-title><source>Trends Biochem. Sci.</source><year>2015</year><volume>3</volume><fpage>141</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2015.01.002</pub-id></element-citation></ref><ref id="B60-cancers-11-00614"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urra</surname><given-names>H.</given-names></name><name><surname>Dufey</surname><given-names>E.</given-names></name><name><surname>Avril</surname><given-names>T.</given-names></name><name><surname>Chevet</surname><given-names>E.</given-names></name><name><surname>Hetx</surname><given-names>C.</given-names></name></person-group><article-title>Endoplasmic reticulum stress and the hallmarks of cancer</article-title><source>Trends Cancer</source><year>2016</year><volume>2</volume><fpage>252</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2016.03.007</pub-id><pub-id pub-id-type="pmid">28741511</pub-id></element-citation></ref><ref id="B61-cancers-11-00614"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shajahan</surname><given-names>A.N.</given-names></name><name><surname>Riggings</surname><given-names>R.B.</given-names></name><name><surname>Clarke</surname><given-names>R.</given-names></name></person-group><article-title>The role of X-box binding protein-1 in tumorigenicity</article-title><source>Drug News Perspect.</source><year>2009</year><volume>22</volume><fpage>241</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1358/dnp.2009.22.5.1378631</pub-id><pub-id pub-id-type="pmid">19609461</pub-id></element-citation></ref><ref id="B62-cancers-11-00614"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Namba</surname><given-names>T.</given-names></name><name><surname>Chu</surname><given-names>K.</given-names></name><name><surname>Kodama</surname><given-names>R.</given-names></name><name><surname>Byun</surname><given-names>S.</given-names></name><name><surname>Wan Yoon</surname><given-names>K.</given-names></name><name><surname>Hiraki</surname><given-names>M.</given-names></name><name><surname>Mandinova</surname><given-names>A.</given-names></name><name><surname>Lee</surname><given-names>S.W.</given-names></name></person-group><article-title>Loss of p53 enhances the function of the endoplasmic reticulum through activation of the IRE1α/XBP1 pathway</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>19990</fpage><lpage>20001</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.4598</pub-id><pub-id pub-id-type="pmid">26254280</pub-id></element-citation></ref><ref id="B63-cancers-11-00614"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>B.</given-names></name><name><surname>Lee</surname><given-names>A.S.</given-names></name></person-group><article-title>The critical role of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies</article-title><source>Oncogene</source><year>2013</year><volume>32</volume><fpage>805</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.1038/onc.2012.130</pub-id><pub-id pub-id-type="pmid">22508478</pub-id></element-citation></ref><ref id="B64-cancers-11-00614"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>C.</given-names></name><name><surname>Dai</surname><given-names>S.</given-names></name><name><surname>Cao</surname><given-names>J.</given-names></name></person-group><article-title>Proteotoxic stress of cancer: Implication of the heat-shock response in oncogenesis</article-title><source>Cell. Physiol.</source><year>2012</year><volume>227</volume><fpage>2982</fpage><lpage>2987</lpage><pub-id pub-id-type="doi">10.1002/jcp.24017</pub-id></element-citation></ref><ref id="B65-cancers-11-00614"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcu</surname><given-names>M.G.</given-names></name><name><surname>Doyle</surname><given-names>M.</given-names></name><name><surname>Bertolotti</surname><given-names>A.</given-names></name><name><surname>Ron</surname><given-names>D.</given-names></name><name><surname>Hendershot</surname><given-names>L.</given-names></name><name><surname>Neckers</surname><given-names>L.</given-names></name></person-group><article-title>Heat shock protein 90 modulates the unfolded protein response by stabilizing IRE1 alpha</article-title><source>Mol. Cell. Biol.</source><year>2002</year><volume>22</volume><fpage>8506</fpage><lpage>8513</lpage><pub-id pub-id-type="doi">10.1128/MCB.22.24.8506-8513.2002</pub-id><pub-id pub-id-type="pmid">12446770</pub-id></element-citation></ref><ref id="B66-cancers-11-00614"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schultze</surname><given-names>T.W.</given-names></name><name><surname>Blagosklonny</surname><given-names>M.V.</given-names></name><name><surname>Ingui</surname><given-names>C.</given-names></name><name><surname>Neckers</surname><given-names>L.</given-names></name></person-group><article-title>Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association</article-title><source>J. Biol. Chem.</source><year>1995</year><volume>270</volume><fpage>24585</fpage><lpage>24588</lpage><pub-id pub-id-type="doi">10.1074/jbc.270.41.24585</pub-id><pub-id pub-id-type="pmid">7592678</pub-id></element-citation></ref><ref id="B67-cancers-11-00614"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>S.</given-names></name><name><surname>Fujita</surname><given-names>N.</given-names></name><name><surname>Tsuruo</surname><given-names>T.</given-names></name></person-group><article-title>Modulation of Akt kinase activity by binding to Hsp90</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2000</year><volume>97</volume><fpage>10832</fpage><lpage>10837</lpage><pub-id pub-id-type="doi">10.1073/pnas.170276797</pub-id><pub-id pub-id-type="pmid">10995457</pub-id></element-citation></ref><ref id="B68-cancers-11-00614"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donze</surname><given-names>O.</given-names></name><name><surname>Abbas-Terki</surname><given-names>T.</given-names></name><name><surname>Picard</surname><given-names>D.</given-names></name></person-group><article-title>The Hsp90 chaperone complex is both a facilitator and a repressor of the dsRNA-dependent kinase <italic>PKR</italic></article-title><source>EMBO J.</source><year>2001</year><volume>20</volume><fpage>3771</fpage><lpage>3780</lpage><pub-id pub-id-type="doi">10.1093/emboj/20.14.3771</pub-id><pub-id pub-id-type="pmid">11447118</pub-id></element-citation></ref><ref id="B69-cancers-11-00614"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Mimmaugh</surname><given-names>E.</given-names></name><name><surname>Rosser</surname><given-names>M.F.</given-names></name><name><surname>Nicchitta</surname><given-names>C.</given-names></name><name><surname>Marcu</surname><given-names>M.</given-names></name><name><surname>Yarden</surname><given-names>Y.</given-names></name><name><surname>Neckers</surname><given-names>L.</given-names></name></person-group><article-title>Sensitivity of mature Erbb2 to geldanamicyn is conferred by its kinase domain and is mediated by the chaperone protein Hsp90</article-title><source>J. Biol. Chem.</source><year>2001</year><volume>276</volume><fpage>3702</fpage><lpage>3708</lpage><pub-id pub-id-type="doi">10.1074/jbc.M006864200</pub-id><pub-id pub-id-type="pmid">11071886</pub-id></element-citation></ref><ref id="B70-cancers-11-00614"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogiatzi</surname><given-names>F.</given-names></name><name><surname>Brandt</surname><given-names>D.T.</given-names></name><name><surname>Schneikert</surname><given-names>J.</given-names></name><name><surname>Fuchs</surname><given-names>J.</given-names></name><name><surname>Grikscheit</surname><given-names>K.</given-names></name><name><surname>Wanzel</surname><given-names>M.</given-names></name><name><surname>Pavlakis</surname><given-names>E.</given-names></name><name><surname>Charles</surname><given-names>J.P.</given-names></name><name><surname>Timofeev</surname><given-names>O.</given-names></name><name><surname>Nist</surname><given-names>A.</given-names></name><etal></etal></person-group><article-title>Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2016</year><volume>113</volume><fpage>E8433</fpage><lpage>E8442</lpage><pub-id pub-id-type="doi">10.1073/pnas.1612711114</pub-id><pub-id pub-id-type="pmid">27956623</pub-id></element-citation></ref><ref id="B71-cancers-11-00614"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rojo de la Vega</surname><given-names>M.</given-names></name><name><surname>Chapman</surname><given-names>E.</given-names></name><name><surname>Zhang</surname><given-names>D.D.</given-names></name></person-group><article-title>NRF2 and kallmarks of cancer</article-title><source>Cancer Cell</source><year>2018</year><volume>34</volume><fpage>21</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2018.03.022</pub-id><pub-id pub-id-type="pmid">29731393</pub-id></element-citation></ref><ref id="B72-cancers-11-00614"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dayalan Naidu</surname><given-names>S.</given-names></name><name><surname>Kostov</surname><given-names>R.V.</given-names></name><name><surname>Dinkova-Kostova</surname><given-names>A.T.</given-names></name></person-group><article-title>Transcription factors Hsf1 and Nrf2 engage in crosstalk for cytoprotection</article-title><source>Trends Pharmacol. Sci.</source><year>2015</year><volume>36</volume><fpage>6</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2014.10.011</pub-id><pub-id pub-id-type="pmid">25465722</pub-id></element-citation></ref><ref id="B73-cancers-11-00614"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>S.</given-names></name><name><surname>Lu</surname><given-names>H.</given-names></name><name><surname>Bai</surname><given-names>Y.</given-names></name></person-group><article-title>Nrf2 in cancers: A double-edged sword</article-title><source>Cancer Med.</source><year>2019</year><pub-id pub-id-type="doi">10.1002/cam4.2101</pub-id></element-citation></ref><ref id="B74-cancers-11-00614"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.J.</given-names></name><name><surname>Sun</surname><given-names>Z.</given-names></name><name><surname>Villeneuve</surname><given-names>N.F.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Zhao</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Yi</surname><given-names>X.</given-names></name><name><surname>Zheng</surname><given-names>W.</given-names></name><name><surname>Wondrak</surname><given-names>G.T.</given-names></name></person-group><article-title>Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2</article-title><source>Carcinogenesis</source><year>2008</year><volume>29</volume><fpage>1235</fpage><lpage>1243</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgn095</pub-id><pub-id pub-id-type="pmid">18413364</pub-id></element-citation></ref><ref id="B75-cancers-11-00614"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>A.</given-names></name><name><surname>Villeneuve</surname><given-names>N.F.</given-names></name><name><surname>Sun</surname><given-names>Z.</given-names></name><name><surname>Wong</surname><given-names>P.K.</given-names></name><name><surname>Zhang</surname><given-names>D.D.</given-names></name></person-group><article-title>Dual roles of Nrf2 in cancers</article-title><source>Pharmacol. Res.</source><year>2008</year><volume>58</volume><fpage>262</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2008.09.003</pub-id><pub-id pub-id-type="pmid">18838122</pub-id></element-citation></ref><ref id="B76-cancers-11-00614"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menegon</surname><given-names>S.</given-names></name><name><surname>Columbano</surname><given-names>A.</given-names></name><name><surname>Giordano</surname><given-names>S.</given-names></name></person-group><article-title>The dual roles of Nrf2 in cancer</article-title><source>Trends Mol. Med.</source><year>2016</year><volume>22</volume><fpage>578</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2016.05.002</pub-id><pub-id pub-id-type="pmid">27263465</pub-id></element-citation></ref><ref id="B77-cancers-11-00614"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Villani</surname><given-names>R.M.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Simpson</surname><given-names>M.J.</given-names></name><name><surname>Roberts</surname><given-names>M.S.</given-names></name><name><surname>Tang</surname><given-names>M.</given-names></name><name><surname>Liang</surname><given-names>X.</given-names></name></person-group><article-title>The role of cellular reactive oxygen species in cancer chemotherapy</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2018</year><volume>37</volume><fpage>266</fpage><pub-id pub-id-type="doi">10.1186/s13046-018-0909-x</pub-id><pub-id pub-id-type="pmid">30382874</pub-id></element-citation></ref><ref id="B78-cancers-11-00614"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>No</surname><given-names>J.H.</given-names></name><name><surname>Kim</surname><given-names>Y.B.</given-names></name><name><surname>Song</surname><given-names>Y.S.</given-names></name></person-group><article-title>Targeting Nrf2 signaling to combat chemoresistance</article-title><source>J. Cancer Prev.</source><year>2014</year><volume>19</volume><fpage>111</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.15430/JCP.2014.19.2.111</pub-id><pub-id pub-id-type="pmid">25337579</pub-id></element-citation></ref><ref id="B79-cancers-11-00614"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glorieux</surname><given-names>V.</given-names></name><name><surname>Calderon</surname><given-names>P.B.</given-names></name></person-group><article-title>Catalase, a remarkable enzyme: Targeting the oldest antioxidant enzyme to find a new cancer treatment approach</article-title><source>Biol. Chem.</source><year>2017</year><volume>398</volume><fpage>1095</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1515/hsz-2017-0131</pub-id><pub-id pub-id-type="pmid">28384098</pub-id></element-citation></ref><ref id="B80-cancers-11-00614"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glorieux</surname><given-names>C.</given-names></name><name><surname>Calderon</surname><given-names>P.B.</given-names></name></person-group><article-title>Catalase down-regulation in cancer cells exposed to arsenic trioxide is involved in their increased sensitivity to a pro-oxidant treatment</article-title><source>Cancer Cell. Int.</source><year>2018</year><volume>18</volume><fpage>24</fpage><pub-id pub-id-type="doi">10.1186/s12935-018-0524-0</pub-id><pub-id pub-id-type="pmid">29467594</pub-id></element-citation></ref><ref id="B81-cancers-11-00614"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeekpudsa</surname><given-names>P.</given-names></name><name><surname>Kukongviriyapan</surname><given-names>V.</given-names></name><name><surname>Senggunprai</surname><given-names>L.</given-names></name><name><surname>Sripa</surname><given-names>B.</given-names></name><name><surname>Prawan</surname><given-names>A.</given-names></name></person-group><article-title>Suppression of NAD(P)H-quinone oxidoreductase 1 enhanced the susceptibility of cholangiocarcinoma cells to chemotherapeutic agents</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2014</year><volume>3</volume><fpage>11</fpage><pub-id pub-id-type="doi">10.1186/1756-9966-33-11</pub-id></element-citation></ref><ref id="B82-cancers-11-00614"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Cui</surname><given-names>X.</given-names></name><name><surname>Lin</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name></person-group><article-title>Clinical implications of high NQO1 expression in breast cancers</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2014</year><volume>33</volume><fpage>14</fpage><pub-id pub-id-type="doi">10.1186/1756-9966-33-14</pub-id><pub-id pub-id-type="pmid">24499631</pub-id></element-citation></ref><ref id="B83-cancers-11-00614"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doherty</surname><given-names>J.</given-names></name><name><surname>Baehrcke</surname><given-names>E.H.</given-names></name></person-group><article-title>Life, death and autophagy</article-title><source>Nat. Cell. Biol.</source><year>2018</year><volume>20</volume><fpage>1110</fpage><lpage>1117</lpage><pub-id pub-id-type="doi">10.1038/s41556-018-0201-5</pub-id><pub-id pub-id-type="pmid">30224761</pub-id></element-citation></ref><ref id="B84-cancers-11-00614"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pankiv</surname><given-names>S.</given-names></name><name><surname>Clausen</surname><given-names>T.H.</given-names></name><name><surname>Lamark</surname><given-names>T.</given-names></name><name><surname>Brech</surname><given-names>A.</given-names></name><name><surname>Bruun</surname><given-names>J.A.</given-names></name><name><surname>Outzen</surname><given-names>H.</given-names></name><name><surname>Overvatn</surname><given-names>A.</given-names></name><name><surname>Bjorkoy</surname><given-names>G.</given-names></name><name><surname>Johansen</surname><given-names>T.</given-names></name></person-group><article-title>p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy</article-title><source>J. Biol. Chem.</source><year>2007</year><volume>282</volume><fpage>24131</fpage><lpage>24145</lpage><pub-id pub-id-type="doi">10.1074/jbc.M702824200</pub-id><pub-id pub-id-type="pmid">17580304</pub-id></element-citation></ref><ref id="B85-cancers-11-00614"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klionsky</surname><given-names>D.J.</given-names></name><name><surname>Abdelmohsen</surname><given-names>K.</given-names></name><name><surname>Abe</surname><given-names>A.</given-names></name><name><surname>Abedin</surname><given-names>M.J.</given-names></name><name><surname>Abeliovich</surname><given-names>H.</given-names></name><name><surname>Acevedo Arozena</surname><given-names>A.</given-names></name><name><surname>Adachi</surname><given-names>H.</given-names></name><name><surname>Adams</surname><given-names>C.M.</given-names></name><name><surname>Adams</surname><given-names>P.D.</given-names></name><name><surname>Adeli</surname><given-names>K.</given-names></name><etal></etal></person-group><article-title>Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)</article-title><source>Autophagy</source><year>2016</year><volume>12</volume><fpage>1</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1080/15548627.2015.1100356</pub-id><pub-id pub-id-type="pmid">26799652</pub-id></element-citation></ref><ref id="B86-cancers-11-00614"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>T.</given-names></name><name><surname>Harder</surname><given-names>B.</given-names></name><name><surname>Rojo de la Vega</surname><given-names>M.</given-names></name><name><surname>Wong</surname><given-names>P.K.</given-names></name><name><surname>Chapman</surname><given-names>E.</given-names></name><name><surname>Zhand</surname><given-names>D.D.</given-names></name></person-group><article-title>p62 links autophagy and Nrf2 signaling</article-title><source>Free Rad. Biol. Med.</source><year>2015</year><volume>88</volume><fpage>199</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2015.06.014</pub-id><pub-id pub-id-type="pmid">26117325</pub-id></element-citation></ref><ref id="B87-cancers-11-00614"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Sun</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>X.J.</given-names></name><name><surname>Jiang</surname><given-names>T.</given-names></name><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Fang</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>D.D.</given-names></name></person-group><article-title>Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response</article-title><source>Mol. Cell</source><year>2009</year><volume>34</volume><fpage>663</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2009.04.029</pub-id><pub-id pub-id-type="pmid">19560419</pub-id></element-citation></ref><ref id="B88-cancers-11-00614"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cullinan</surname><given-names>S.B.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Hannink</surname><given-names>M.</given-names></name><name><surname>Arvisais</surname><given-names>E.</given-names></name><name><surname>Kaufman</surname><given-names>R.J.</given-names></name><name><surname>Diehl</surname><given-names>J.A.</given-names></name></person-group><article-title>Nrf2 Is a direct PERK substrate and effector of PERK-dependent cell survival</article-title><source>Mol. Cell. Biol.</source><year>2003</year><volume>23</volume><fpage>7198</fpage><lpage>7209</lpage><pub-id pub-id-type="doi">10.1128/MCB.23.20.7198-7209.2003</pub-id><pub-id pub-id-type="pmid">14517290</pub-id></element-citation></ref><ref id="B89-cancers-11-00614"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harding</surname><given-names>H.P.</given-names></name><name><surname>Zhangm</surname><given-names>Y.</given-names></name><name><surname>Bertolottim</surname><given-names>A.</given-names></name><name><surname>Zeng</surname><given-names>H.</given-names></name><name><surname>Ron</surname><given-names>D.</given-names></name></person-group><article-title>Perk is essential for translational regulation and cell survival during the unfolded protein response</article-title><source>Mol. Cell</source><year>2000</year><volume>5</volume><fpage>897</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(00)80330-5</pub-id><pub-id pub-id-type="pmid">10882126</pub-id></element-citation></ref><ref id="B90-cancers-11-00614"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalo</surname><given-names>E.</given-names></name><name><surname>Kogan-Sakin</surname><given-names>I.</given-names></name><name><surname>Solomon</surname><given-names>H.</given-names></name><name><surname>Bar-Nathan</surname><given-names>E.</given-names></name><name><surname>Shay</surname><given-names>M.</given-names></name><name><surname>Shetzer</surname><given-names>Y.</given-names></name><name><surname>Dekel</surname><given-names>E.</given-names></name><name><surname>Goldfinger</surname><given-names>N.</given-names></name><name><surname>Buganim</surname><given-names>Y.</given-names></name><name><surname>Stambolsky</surname><given-names>P.</given-names></name><etal></etal></person-group><article-title>Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species</article-title><source>J. Cell Sci.</source><year>2012</year><volume>125</volume><fpage>5578</fpage><lpage>5586</lpage><pub-id pub-id-type="doi">10.1242/jcs.106815</pub-id><pub-id pub-id-type="pmid">22899716</pub-id></element-citation></ref><ref id="B91-cancers-11-00614"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lisek</surname><given-names>K.</given-names></name><name><surname>Campaner</surname><given-names>E.</given-names></name><name><surname>Ciani</surname><given-names>Y.</given-names></name><name><surname>Walerych</surname><given-names>D.</given-names></name><name><surname>Del Sal</surname><given-names>G.</given-names></name></person-group><article-title>Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells</article-title><source>Oncotarget</source><year>2018</year><volume>9</volume><fpage>20508</fpage><lpage>20523</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.24974</pub-id><pub-id pub-id-type="pmid">29755668</pub-id></element-citation></ref><ref id="B92-cancers-11-00614"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamada</surname><given-names>S.</given-names></name><name><surname>Taguchi</surname><given-names>K.</given-names></name><name><surname>Masamume</surname><given-names>A.</given-names></name><name><surname>Yamamoto</surname><given-names>M.</given-names></name><name><surname>Shimosegawa</surname><given-names>T.</given-names></name></person-group><article-title>Nrf2 promotes mutant R-<italic>ras/p53</italic> driven pancreatic carcinogenesis</article-title><source>Carcinogenesis</source><year>2017</year><volume>38</volume><fpage>661</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgx043</pub-id><pub-id pub-id-type="pmid">29240881</pub-id></element-citation></ref><ref id="B93-cancers-11-00614"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walerych</surname><given-names>D.</given-names></name><name><surname>Lisek</surname><given-names>K.</given-names></name><name><surname>Sommaggio</surname><given-names>R.</given-names></name><name><surname>Piazza</surname><given-names>S.</given-names></name><name><surname>Ciani</surname><given-names>Y.</given-names></name><name><surname>Dalla</surname><given-names>E.</given-names></name><name><surname>Rajkowska</surname><given-names>K.</given-names></name><name><surname>Gaweda-Walerych</surname><given-names>K.</given-names></name><name><surname>Ingallina</surname><given-names>E.</given-names></name><name><surname>Tonelli</surname><given-names>C.</given-names></name><etal></etal></person-group><article-title>Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer</article-title><source>Nat. Cell. Biol.</source><year>2016</year><volume>18</volume><fpage>897</fpage><lpage>909</lpage><pub-id pub-id-type="doi">10.1038/ncb3380</pub-id><pub-id pub-id-type="pmid">27347849</pub-id></element-citation></ref><ref id="B94-cancers-11-00614"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>G.L.</given-names></name><name><surname>Jiang</surname><given-names>H.</given-names></name><name><surname>Rue</surname><given-names>E.A.</given-names></name><name><surname>Semenza</surname><given-names>G.L.</given-names></name></person-group><article-title>Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1995</year><volume>92</volume><fpage>5510</fpage><lpage>5514</lpage><pub-id pub-id-type="doi">10.1073/pnas.92.12.5510</pub-id><pub-id pub-id-type="pmid">7539918</pub-id></element-citation></ref><ref id="B95-cancers-11-00614"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soni</surname><given-names>S.</given-names></name><name><surname>Padwad</surname><given-names>Y.S.</given-names></name></person-group><article-title>HIF-1 in cancer therapy: Two decade long story of a transcription factor</article-title><source>Acta Oncol.</source><year>2017</year><volume>56</volume><fpage>503</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1080/0284186X.2017.1301680</pub-id><pub-id pub-id-type="pmid">28358664</pub-id></element-citation></ref><ref id="B96-cancers-11-00614"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Tang</surname><given-names>B.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name></person-group><article-title>Development of inhibitors targeting Hypoxia-inducible Factor 1 and 2 for cancer therapy</article-title><source>Yonsei Med. J.</source><year>2017</year><volume>58</volume><fpage>489</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.3349/ymj.2017.58.3.489</pub-id><pub-id pub-id-type="pmid">28332352</pub-id></element-citation></ref><ref id="B97-cancers-11-00614"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amelio</surname><given-names>I.</given-names></name><name><surname>Mancini</surname><given-names>M.</given-names></name><name><surname>Petrova</surname><given-names>V.</given-names></name><name><surname>Cairns</surname><given-names>R.A.</given-names></name><name><surname>Vikhreva</surname><given-names>P.</given-names></name><name><surname>Nicolai</surname><given-names>S.</given-names></name><name><surname>Marini</surname><given-names>A.</given-names></name><name><surname>Antonov</surname><given-names>A.A.</given-names></name><name><surname>Le Quesne</surname><given-names>J.</given-names></name><name><surname>Baena Acevedo</surname><given-names>J.D.</given-names></name><etal></etal></person-group><article-title>P53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2018</year><volume>115</volume><fpage>E10869</fpage><lpage>E10878</lpage><pub-id pub-id-type="doi">10.1073/pnas.1808314115</pub-id><pub-id pub-id-type="pmid">30381462</pub-id></element-citation></ref><ref id="B98-cancers-11-00614"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toth</surname><given-names>R.K.</given-names></name><name><surname>Warfel</surname><given-names>N.A.</given-names></name></person-group><article-title>Strange Bedfellows: Nuclear Factor, Erythroid 2-Like 2 (Nrf2) and Hypoxia-Inducible Factor 1 (HIF-1) in Tumor Hypoxia</article-title><source>Antioxidants</source><year>2017</year><volume>6</volume><elocation-id>27</elocation-id><pub-id pub-id-type="doi">10.3390/antiox6020027</pub-id></element-citation></ref><ref id="B99-cancers-11-00614"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>D.</given-names></name><name><surname>Villeneuve</surname><given-names>N.F.</given-names></name><name><surname>Jiang</surname><given-names>T.</given-names></name><name><surname>Wu</surname><given-names>T.</given-names></name><name><surname>Lau</surname><given-names>A.</given-names></name><name><surname>Toppin</surname><given-names>H.A.</given-names></name></person-group><article-title>Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2011</year><volume>108</volume><fpage>1433</fpage><lpage>1438</lpage><pub-id pub-id-type="doi">10.1073/pnas.1014275108</pub-id><pub-id pub-id-type="pmid">21205897</pub-id></element-citation></ref><ref id="B100-cancers-11-00614"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>Y.</given-names></name><name><surname>Ye</surname><given-names>W.</given-names></name><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Lou</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>D.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>B.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name></person-group><article-title>Brusatol inhibits growth and induces apoptosis in pancreatic cancer cells via JNK/p38 MAPK/NF-κb/Stat3/Bcl-2 signaling pathway</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2017</year><volume>10</volume><fpage>820</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2017.04.133</pub-id><pub-id pub-id-type="pmid">28455228</pub-id></element-citation></ref><ref id="B101-cancers-11-00614"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>Y.</given-names></name><name><surname>Ye</surname><given-names>W.</given-names></name><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Yu</surname><given-names>D.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Deng</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Lou</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Shi</surname><given-names>K.</given-names></name></person-group><article-title>Brusatol enhances the chemotherapy efficacy of gemcitabine in pancreatic cancer via the Nrf2 signalling pathway</article-title><source>Oxid. Med. Cell. Long.</source><year>2018</year><pub-id pub-id-type="doi">10.1155/2018/2360427</pub-id><pub-id pub-id-type="pmid">29849873</pub-id></element-citation></ref><ref id="B102-cancers-11-00614"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Guo</surname><given-names>X.</given-names></name><name><surname>Shi</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Xu</surname><given-names>B.</given-names></name></person-group><article-title>Triptolide, a Chinese herbal extract, enhances drug sensitivity of resistant myeloid leukemia cell lines through downregulation of HIF-1α and Nrf2</article-title><source>Pharmacogenom</source><year>2013</year><volume>14</volume><fpage>1305</fpage><lpage>1317</lpage><pub-id pub-id-type="doi">10.2217/pgs.13.122</pub-id><pub-id pub-id-type="pmid">23930677</pub-id></element-citation></ref><ref id="B103-cancers-11-00614"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitsuishi</surname><given-names>Y.</given-names></name><name><surname>Taguchi</surname><given-names>K.</given-names></name><name><surname>Kawatani</surname><given-names>Y.</given-names></name><name><surname>Shibata</surname><given-names>T.</given-names></name><name><surname>Nukiwa</surname><given-names>T.</given-names></name><name><surname>Aburatani</surname><given-names>H.</given-names></name><name><surname>Yamamoto</surname><given-names>M.</given-names></name><name><surname>Motohash</surname><given-names>H.</given-names></name></person-group><article-title>Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming</article-title><source>Cancer Cell.</source><year>2012</year><volume>22</volume><fpage>66</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2012.05.016</pub-id><pub-id pub-id-type="pmid">22789539</pub-id></element-citation></ref><ref id="B104-cancers-11-00614"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeNicola</surname><given-names>G.M.</given-names></name><name><surname>Chen</surname><given-names>P.H.</given-names></name><name><surname>Mullarky</surname><given-names>E.</given-names></name><name><surname>Sudderth</surname><given-names>J.A.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Wu</surname><given-names>D.</given-names></name><name><surname>Tang</surname><given-names>H.</given-names></name><name><surname>Xie</surname><given-names>Y.</given-names></name><name><surname>Asara</surname><given-names>J.M.</given-names></name><name><surname>Huffman</surname><given-names>K.E.</given-names></name><etal></etal></person-group><article-title>NRF2 regulates serine biosynthesis in non-small cell lung cancer</article-title><source>Nat. Genet.</source><year>2015</year><volume>47</volume><fpage>1475</fpage><lpage>1481</lpage><pub-id pub-id-type="doi">10.1038/ng.3421</pub-id><pub-id pub-id-type="pmid">26482881</pub-id></element-citation></ref><ref id="B105-cancers-11-00614"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolpaw</surname><given-names>A.J.</given-names></name><name><surname>Dang</surname><given-names>C.V.</given-names></name></person-group><article-title>Exploiting metabolic vulnerabilities of cancer with precision and accuracy</article-title><source>Trends Cell. Biol.</source><year>2018</year><fpage>201</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2017.11.006</pub-id><pub-id pub-id-type="pmid">29229182</pub-id></element-citation></ref><ref id="B106-cancers-11-00614"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Hu</surname><given-names>W.</given-names></name><name><surname>Feng</surname><given-names>Z.</given-names></name></person-group><article-title>Tumor suppressor p53 and metabolism</article-title><source>J. Mol. Cell. Biol.</source><year>2019</year><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/jmcb/mjy070</pub-id><pub-id pub-id-type="pmid">30239845</pub-id></element-citation></ref><ref id="B107-cancers-11-00614"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>AlTahan</surname><given-names>A.</given-names></name><name><surname>Jones</surname><given-names>D.T.</given-names></name><name><surname>Buffa</surname><given-names>F.M.</given-names></name><name><surname>Bridges</surname><given-names>E.</given-names></name><name><surname>Interiano</surname><given-names>R.B.</given-names></name><name><surname>Quc</surname><given-names>C.</given-names></name><name><surname>Vogt</surname><given-names>N.</given-names></name><name><surname>Lia</surname><given-names>J.-L.</given-names></name><name><surname>Baban</surname><given-names>D.</given-names></name><etal></etal></person-group><article-title>Estrogen receptor-α directly regulates the hypoxia inducible factor 1 pathway associated with antiestrogen response in breast cancer</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2015</year><volume>112</volume><fpage>15172</fpage><lpage>15177</lpage><pub-id pub-id-type="doi">10.1073/pnas.1422015112</pub-id><pub-id pub-id-type="pmid">26598706</pub-id></element-citation></ref><ref id="B108-cancers-11-00614"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shanle</surname><given-names>E.K.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name></person-group><article-title>Selectively targeting estrogen receptors for cancer treatment</article-title><source>Adv. Drug Deliv. Rev.</source><year>2010</year><volume>62</volume><fpage>1265</fpage><lpage>1276</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2010.08.001</pub-id><pub-id pub-id-type="pmid">20708050</pub-id></element-citation></ref><ref id="B109-cancers-11-00614"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Iliopoulos</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Tang</surname><given-names>Q.</given-names></name><name><surname>Greenblatt</surname><given-names>M.B.</given-names></name><name><surname>Hatziapostolou</surname><given-names>M.</given-names></name><name><surname>Lim</surname><given-names>E.</given-names></name><name><surname>Tam</surname><given-names>W.L.</given-names></name><name><surname>Ni</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><etal></etal></person-group><article-title>XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway</article-title><source>Nature</source><year>2014</year><volume>508</volume><fpage>103</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1038/nature13119</pub-id><pub-id pub-id-type="pmid">24670641</pub-id></element-citation></ref><ref id="B110-cancers-11-00614"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menendez</surname><given-names>D.</given-names></name><name><surname>Inga</surname><given-names>A.</given-names></name><name><surname>Resnick</surname><given-names>M.A.</given-names></name></person-group><article-title>Estrogen receptor acting in cis enhances WT and mutant p53 transactivation at canonical and noncanonical p53 target sequences</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>1500</fpage><lpage>1505</lpage><pub-id pub-id-type="doi">10.1073/pnas.0909129107</pub-id><pub-id pub-id-type="pmid">20080630</pub-id></element-citation></ref><ref id="B111-cancers-11-00614"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>K.L.</given-names></name><name><surname>Clarke</surname><given-names>P.A.G.</given-names></name><name><surname>Parmar</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>R.</given-names></name><name><surname>Schwartz-Roberts</surname><given-names>J.L.</given-names></name><name><surname>Abu-Asab</surname><given-names>M.</given-names></name><name><surname>Warri</surname><given-names>A.</given-names></name><name><surname>Baumann</surname><given-names>W.T.</given-names></name><name><surname>Clarke</surname><given-names>R.</given-names></name></person-group><article-title>Knockdown of estrogen receptor-α induces autophagy and inhibits antiestrogen-mediated unfolded protein response activation, promoting ROS-induced breast cancer cell death</article-title><source>FASEB J.</source><year>2014</year><volume>28</volume><fpage>3891</fpage><lpage>3905</lpage><pub-id pub-id-type="doi">10.1096/fj.13-247353</pub-id><pub-id pub-id-type="pmid">24858277</pub-id></element-citation></ref><ref id="B112-cancers-11-00614"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garufi</surname><given-names>A.</given-names></name><name><surname>Trisciuoglio</surname><given-names>D.</given-names></name><name><surname>Porru</surname><given-names>M.</given-names></name><name><surname>Leonetti</surname><given-names>C.</given-names></name><name><surname>Stoppacciaro</surname><given-names>A.</given-names></name><name><surname>D’Orazi</surname><given-names>V.</given-names></name><name><surname>Avantaggiati</surname><given-names>M.</given-names></name><name><surname>Crispini</surname><given-names>A.</given-names></name><name><surname>Pucci</surname><given-names>D.</given-names></name><name><surname>D’Orazi</surname><given-names>G.</given-names></name></person-group><article-title>A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R174H and R273H) p53 in cancer cells</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2013</year><volume>32</volume><fpage>72</fpage><pub-id pub-id-type="doi">10.1186/1756-9966-32-72</pub-id><pub-id pub-id-type="pmid">24220325</pub-id></element-citation></ref><ref id="B113-cancers-11-00614"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garufi</surname><given-names>A.</given-names></name><name><surname>Pucci</surname><given-names>D.</given-names></name><name><surname>D’Orazi</surname><given-names>V.</given-names></name><name><surname>Cirone</surname><given-names>M.</given-names></name><name><surname>Bossi</surname><given-names>G.</given-names></name><name><surname>Avantaggiati</surname><given-names>M.L.</given-names></name><name><surname>D’Orazi</surname><given-names>G.</given-names></name></person-group><article-title>Degradation of mutant p53H175 protein by Zn(II) through autophagy</article-title><source>Cell. Death Dis.</source><year>2014</year><volume>5</volume><fpage>e1271</fpage><pub-id pub-id-type="doi">10.1038/cddis.2014.217</pub-id><pub-id pub-id-type="pmid">24874727</pub-id></element-citation></ref><ref id="B114-cancers-11-00614"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garufi</surname><given-names>A.</given-names></name><name><surname>D’Orazi</surname><given-names>V.</given-names></name><name><surname>Crispini</surname><given-names>A.</given-names></name><name><surname>D’Orazi</surname><given-names>G.</given-names></name></person-group><article-title>Zn(II)-curc targets p53 in thyroid cancer cells</article-title><source>Int. J. Oncol.</source><year>2015</year><volume>47</volume><fpage>1241</fpage><lpage>1248</lpage><pub-id pub-id-type="doi">10.3892/ijo.2015.3125</pub-id><pub-id pub-id-type="pmid">26314369</pub-id></element-citation></ref><ref id="B115-cancers-11-00614"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garufi</surname><given-names>A.</given-names></name><name><surname>Pistritto</surname><given-names>G.</given-names></name><name><surname>Cirone</surname><given-names>M.</given-names></name><name><surname>D’Orazi</surname><given-names>G.</given-names></name></person-group><article-title>Reactivation of mutant p53 by capsaicin, the major constituent of peppers</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2016</year><volume>351</volume><fpage>136</fpage><pub-id pub-id-type="doi">10.1186/s13046-016-0417-9</pub-id></element-citation></ref><ref id="B116-cancers-11-00614"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garufi</surname><given-names>A.</given-names></name><name><surname>Pistritto</surname><given-names>G.</given-names></name><name><surname>Baldari</surname><given-names>S.</given-names></name><name><surname>Toietta</surname><given-names>G.</given-names></name><name><surname>Cirone</surname><given-names>M.</given-names></name><name><surname>D’Orazi</surname><given-names>G.</given-names></name></person-group><article-title>p53-Dependent PUMA to DRAM antagonistic interplay as a key molecular switch in cell-fate decision in normal/high glucose conditions</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2017</year><volume>36</volume><fpage>126</fpage><pub-id pub-id-type="doi">10.1186/s13046-017-0596-z</pub-id><pub-id pub-id-type="pmid">28893313</pub-id></element-citation></ref><ref id="B117-cancers-11-00614"><label>117.</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>D’Orazi</surname><given-names>G.</given-names></name><name><surname>Cirone</surname><given-names>M.</given-names></name><aff>University ‘G. d’Annunzio’, Chieti, Italy</aff></person-group><comment>Unpublished work</comment><year>2019</year></element-citation></ref><ref id="B118-cancers-11-00614"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thongrakard</surname><given-names>V.</given-names></name><name><surname>Titone</surname><given-names>R.</given-names></name><name><surname>Follo</surname><given-names>C.</given-names></name><name><surname>Morani</surname><given-names>F.</given-names></name><name><surname>Suksamrarn</surname><given-names>A.</given-names></name><name><surname>Tencomanao</surname><given-names>T.</given-names></name><name><surname>Isidoro</surname><given-names>C.</given-names></name></person-group><article-title>Turmeric toxicity in A431 epidermoid cancer cells associates with autophagy degradation of anti-apoptotic and anti-autophagic p53 mutant</article-title><source>Phytother. Res.</source><year>2014</year><volume>28</volume><fpage>1761</fpage><lpage>1769</lpage><pub-id pub-id-type="doi">10.1002/ptr.5196</pub-id><pub-id pub-id-type="pmid">25044209</pub-id></element-citation></ref><ref id="B119-cancers-11-00614"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foggetti</surname><given-names>G.</given-names></name><name><surname>Ottaggio</surname><given-names>L.</given-names></name><name><surname>Russo</surname><given-names>D.</given-names></name><name><surname>Monti</surname><given-names>P.</given-names></name><name><surname>Degan</surname><given-names>P.</given-names></name><name><surname>Fronza</surname><given-names>G.</given-names></name></person-group><article-title>Gambogic acid counteracts mutant p53 stability by inducing autophagy</article-title><source>Biochim. Biophys. Acta Mol. Cell. Res.</source><year>2017</year><volume>1864</volume><fpage>382</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2016.11.023</pub-id><pub-id pub-id-type="pmid">27899303</pub-id></element-citation></ref><ref id="B120-cancers-11-00614"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>Q.</given-names></name><name><surname>Qi</surname><given-names>Q.</given-names></name><name><surname>Gu</surname><given-names>H.Y.</given-names></name><name><surname>Rong</surname><given-names>J.J.</given-names></name><name><surname>Mu</surname><given-names>R.</given-names></name></person-group><article-title>Gambogic acid-induced degradation of mutant p53 is mediated by proteasome and related to CHIP</article-title><source>J. Cell. Biochem.</source><year>2011</year><volume>112</volume><fpage>509</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1002/jcb.22941</pub-id><pub-id pub-id-type="pmid">21268072</pub-id></element-citation></ref><ref id="B121-cancers-11-00614"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname><given-names>M.</given-names></name><name><surname>Saxena</surname><given-names>R.</given-names></name><name><surname>Sinclair</surname><given-names>E.</given-names></name><name><surname>Fu</surname><given-names>Y.</given-names></name><name><surname>Jacobs</surname><given-names>A.</given-names></name><name><surname>Dyba</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Berry</surname><given-names>D.</given-names></name><name><surname>Kallakury</surname><given-names>B.</given-names></name><name><surname>Mueller</surname><given-names>S.C.</given-names></name><etal></etal></person-group><article-title>Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth</article-title><source>Cell. Death Diff.</source><year>2016</year><volume>23</volume><fpage>1615</fpage><lpage>1627</lpage><pub-id pub-id-type="doi">10.1038/cdd.2016.48</pub-id></element-citation></ref><ref id="B122-cancers-11-00614"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Granato</surname><given-names>M.</given-names></name><name><surname>Gilardini Montani</surname><given-names>M.S.</given-names></name><name><surname>D’Orazi</surname><given-names>G.</given-names></name><name><surname>Faggioni</surname><given-names>A.</given-names></name><name><surname>Cirone</surname><given-names>M.</given-names></name></person-group><article-title>Apigenin, by activating p53 and inhibiting STAT3, modulates the balance between pro-apoptotic and pro-survival pathways to induce PEL cell death</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2017</year><volume>36</volume><fpage>167</fpage><pub-id pub-id-type="doi">10.1186/s13046-017-0632-z</pub-id><pub-id pub-id-type="pmid">29179721</pub-id></element-citation></ref><ref id="B123-cancers-11-00614"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>O.C.</given-names></name><name><surname>Choudhury</surname><given-names>S.</given-names></name><name><surname>Kolukula</surname><given-names>V.</given-names></name><name><surname>Vietsch</surname><given-names>E.E.</given-names></name><name><surname>Catania</surname><given-names>J.</given-names></name><name><surname>Preet</surname><given-names>A.</given-names></name><name><surname>Reynoso</surname><given-names>K.</given-names></name><name><surname>Bargonetti</surname><given-names>J.</given-names></name><name><surname>Wellstein</surname><given-names>A.</given-names></name><name><surname>Albanese</surname><given-names>C.</given-names></name><name><surname>Avantaggiati</surname><given-names>M.L.</given-names></name></person-group><article-title>Dietary downregulation of mutant p53 levels via glucose restriction: Mechanisms and implications for tumor therapy</article-title><source>Cell. Cycle</source><year>2012</year><volume>11</volume><fpage>4436</fpage><lpage>4446</lpage><pub-id pub-id-type="doi">10.4161/cc.22778</pub-id><pub-id pub-id-type="pmid">23151455</pub-id></element-citation></ref><ref id="B124-cancers-11-00614"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vakifahmetoglu-Norberg</surname><given-names>H.</given-names></name><name><surname>Kim</surname><given-names>M.</given-names></name><name><surname>Xia</surname><given-names>H.G.</given-names></name><name><surname>Iwanicki</surname><given-names>M.P.</given-names></name><name><surname>Ofengeim</surname><given-names>D.</given-names></name><name><surname>Coloff</surname><given-names>J.L.</given-names></name><name><surname>Pan</surname><given-names>L.</given-names></name><name><surname>Ince</surname><given-names>T.A.</given-names></name><name><surname>Kroemer</surname><given-names>G.</given-names></name><name><surname>Brugge</surname><given-names>J.S.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name></person-group><article-title>Chaperone-mediated autophagy degrades mutant p53</article-title><source>Genes Dev.</source><year>2013</year><volume>27</volume><fpage>1718</fpage><lpage>1730</lpage><pub-id pub-id-type="doi">10.1101/gad.220897.113</pub-id><pub-id pub-id-type="pmid">23913924</pub-id></element-citation></ref><ref id="B125-cancers-11-00614"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldari</surname><given-names>S.</given-names></name><name><surname>Ubertini</surname><given-names>V.</given-names></name><name><surname>Garufi</surname><given-names>A.</given-names></name><name><surname>D’Orazi</surname><given-names>G.</given-names></name><name><surname>Bossi</surname><given-names>G.</given-names></name></person-group><article-title>Targeting MKK3 as a novel anticancer strategy: Molecular mechanisms and therapeutical implications</article-title><source>Cell. Death Dis.</source><year>2015</year><volume>6</volume><fpage>e1621</fpage><pub-id pub-id-type="doi">10.1038/cddis.2014.591</pub-id><pub-id pub-id-type="pmid">25633290</pub-id></element-citation></ref><ref id="B126-cancers-11-00614"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cordani</surname><given-names>M.</given-names></name><name><surname>Butera</surname><given-names>G.</given-names></name><name><surname>Pacchiana</surname><given-names>R.</given-names></name><name><surname>Donadelli</surname><given-names>M.</given-names></name></person-group><article-title>Molecular interplay between mutant p53 proteins and autophagy in cancer cells</article-title><source>Biochim. Biophys. Acta Rev. Cancer</source><year>2017</year><volume>1867</volume><fpage>19</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.bbcan.2016.11.003</pub-id><pub-id pub-id-type="pmid">27871965</pub-id></element-citation></ref><ref id="B127-cancers-11-00614"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cordani</surname><given-names>M.</given-names></name><name><surname>Oppici</surname><given-names>E.</given-names></name><name><surname>Dando</surname><given-names>I.</given-names></name><name><surname>Buttirini</surname><given-names>E.</given-names></name><name><surname>Dalla Pozza</surname><given-names>E.</given-names></name><name><surname>Nadal-Serrano</surname><given-names>M.</given-names></name><name><surname>Oliver</surname><given-names>J.</given-names></name><name><surname>Roca</surname><given-names>P.</given-names></name><name><surname>Mariotto</surname><given-names>S.</given-names></name><name><surname>Cellini</surname><given-names>B.</given-names></name><etal></etal></person-group><article-title>Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition</article-title><source>Mol. Oncol.</source><year>2016</year><volume>10</volume><fpage>1008</fpage><lpage>1029</lpage><pub-id pub-id-type="doi">10.1016/j.molonc.2016.04.001</pub-id><pub-id pub-id-type="pmid">27118659</pub-id></element-citation></ref><ref id="B128-cancers-11-00614"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dando</surname><given-names>I.</given-names></name><name><surname>Cordani</surname><given-names>M.</given-names></name><name><surname>Donadelli</surname><given-names>M.</given-names></name></person-group><article-title>Mutant p53 and mTOR/PKM2 regulation in cancer cells</article-title><source>IUBMB Life</source><year>2016</year><volume>68</volume><fpage>722</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1002/iub.1534</pub-id><pub-id pub-id-type="pmid">27385486</pub-id></element-citation></ref><ref id="B129-cancers-11-00614"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wullschleger</surname><given-names>S.</given-names></name><name><surname>Loewith</surname><given-names>R.</given-names></name><name><surname>Hall</surname><given-names>M.N.</given-names></name></person-group><article-title>TOR signaling in growth and metabolism</article-title><source>Cell</source><year>2006</year><volume>124</volume><fpage>471</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.01.016</pub-id><pub-id pub-id-type="pmid">16469695</pub-id></element-citation></ref><ref id="B130-cancers-11-00614"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paquette</surname><given-names>M.</given-names></name><name><surname>El-Houjeiri</surname><given-names>L.</given-names></name><name><surname>Pause</surname><given-names>A.</given-names></name></person-group><article-title>mTOR pathways in cancer and autophagy</article-title><source>Cancers</source><year>2018</year><volume>10</volume><elocation-id>18</elocation-id><pub-id pub-id-type="doi">10.3390/cancers10010018</pub-id><pub-id pub-id-type="pmid">29329237</pub-id></element-citation></ref><ref id="B131-cancers-11-00614"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>G.G.</given-names></name><name><surname>Buel</surname><given-names>G.R.</given-names></name><name><surname>Blenis</surname><given-names>J.</given-names></name></person-group><article-title>Nutrient Regulation of the mTOR Complex 1 Signaling Pathway</article-title><source>Mol. Cell</source><year>2013</year><volume>35</volume><fpage>463</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1007/s10059-013-0138-2</pub-id></element-citation></ref><ref id="B132-cancers-11-00614"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jewell</surname><given-names>J.L.</given-names></name><name><surname>Guan</surname><given-names>K.L.</given-names></name></person-group><article-title>Nutrient signaling to mTOR and cell growth</article-title><source>Trends Biochem. Sci.</source><year>2013</year><volume>38</volume><fpage>233</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2013.01.004</pub-id><pub-id pub-id-type="pmid">23465396</pub-id></element-citation></ref><ref id="B133-cancers-11-00614"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catena</surname><given-names>V.</given-names></name><name><surname>Fanciulli</surname><given-names>M.</given-names></name></person-group><article-title>Deptor: Not only a mTOR inhibitor</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2017</year><volume>36</volume><fpage>12</fpage><pub-id pub-id-type="doi">10.1186/s13046-016-0484-y</pub-id><pub-id pub-id-type="pmid">28086984</pub-id></element-citation></ref><ref id="B134-cancers-11-00614"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietrocola</surname><given-names>F.</given-names></name><name><surname>Bravo-San Pedro</surname><given-names>J.M.</given-names></name><name><surname>Galluzzi</surname><given-names>L.</given-names></name><name><surname>Kroemer</surname><given-names>G.</given-names></name></person-group><article-title>Autophagy in natural and therapy-driven anticancer immunosurveillance</article-title><source>Autophagy</source><year>2017</year><volume>13</volume><fpage>2163</fpage><lpage>2170</lpage><pub-id pub-id-type="doi">10.1080/15548627.2017.1310356</pub-id><pub-id pub-id-type="pmid">28598229</pub-id></element-citation></ref><ref id="B135-cancers-11-00614"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Granato</surname><given-names>M.</given-names></name><name><surname>Rizzello</surname><given-names>C.</given-names></name><name><surname>Romeo</surname><given-names>M.A.</given-names></name><name><surname>Yadav</surname><given-names>S.</given-names></name><name><surname>Santarelli</surname><given-names>R.</given-names></name><name><surname>D’Orazi</surname><given-names>G.</given-names></name><name><surname>Faggioni</surname><given-names>A.</given-names></name><name><surname>Cirone</surname><given-names>M.</given-names></name></person-group><article-title>Concomitant reduction of c-Myc expression and PI3K/AKT/mTOR signaling by quercetin induces a strong cytotoxic effect against Burkitt’s lymphoma</article-title><source>Int. J. Biochem. Cell Biol.</source><year>2016</year><volume>79</volume><fpage>393</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2016.09.006</pub-id><pub-id pub-id-type="pmid">27620077</pub-id></element-citation></ref><ref id="B136-cancers-11-00614"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masuelli</surname><given-names>L.</given-names></name><name><surname>Granato</surname><given-names>M.</given-names></name><name><surname>Benvenuto</surname><given-names>M.</given-names></name><name><surname>Mattera</surname><given-names>R.</given-names></name><name><surname>Bernardini</surname><given-names>R.</given-names></name><name><surname>Mattei</surname><given-names>M.</given-names></name><name><surname>d’Amati</surname><given-names>G.</given-names></name><name><surname>D’Orazi</surname><given-names>G.</given-names></name><name><surname>Faggioni</surname><given-names>A.</given-names></name><name><surname>Bei</surname><given-names>R.</given-names></name><name><surname>Cirone</surname><given-names>M.</given-names></name></person-group><article-title>Chloroquine supplementation increases the cytotoxic effect of curcumin against Her2/neu overepressing breast cancer cells in vitro and in vivo in nude mice while counteracts it in immune competent mice</article-title><source>OncoImmunology</source><year>2017</year><volume>6</volume><fpage>e1356151</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2017.1356151</pub-id><pub-id pub-id-type="pmid">29147611</pub-id></element-citation></ref><ref id="B137-cancers-11-00614"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>E.</given-names></name></person-group><article-title>The role for autophagy in cancer</article-title><source>J. Clin. Investig.</source><year>2015</year><volume>125</volume><fpage>42</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1172/JCI73941</pub-id><pub-id pub-id-type="pmid">25654549</pub-id></element-citation></ref><ref id="B138-cancers-11-00614"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurpinar</surname><given-names>E.</given-names></name><name><surname>Vousden</surname><given-names>K.H.</given-names></name></person-group><article-title>Hitting cancers’ weak spots: Vulnerabilities imposed by p53 mutation</article-title><source>Trends Cell Biol.</source><year>2015</year><volume>25</volume><fpage>486</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2015.04.001</pub-id><pub-id pub-id-type="pmid">25960041</pub-id></element-citation></ref><ref id="B139-cancers-11-00614"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blandino</surname><given-names>G.</given-names></name><name><surname>Di Agostino</surname><given-names>S.</given-names></name></person-group><article-title>New therapeutic strategies to treat human cancers expressing mutant p53 proteins</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2018</year><volume>37</volume><fpage>30</fpage><pub-id pub-id-type="doi">10.1186/s13046-018-0705-7</pub-id><pub-id pub-id-type="pmid">29448954</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="cancers-11-00614-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Mutant p53 and heat shock proteins (HSP) machinery. (<bold>a</bold>) Mutp53 protein binds the cellular chaperone HSP90 that protects it from MDM2-dependent degradation. Activation of HSP90 includes deacetylation by HDAC6. Mutp53 stabilization is achieved also by the interaction with chaperone HSP40 and HSP70, that protect mutp53 from CHIP-mediated degradation and cooperate with HSP90 in stabilizing mutp53. The mutp53 hyperstability is necessary for mutp53 oncogenic functions (GOF). Inhibitors of HSP90 and HDAC6 are indicated and allow mutp53 degradation. (<bold>b</bold>) HSP90 transcription is mediated by HSF1. Mutp53 interacts with activated p-Ser326 HSF1 stimulating its transcriptional activity toward HSP90. Then, HSP90 stabilizes mutp53 itself by inhibiting MDM2. Mutp53 drives enhanced recycling of EGFR to the cancer cell surface activating the MAPK and PI3K signaling cascade leading to HSF1 phosphoactivation.</p></caption><graphic xlink:href="cancers-11-00614-g001"></graphic></fig><fig id="cancers-11-00614-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Molecular mechanisms of ER stress unfolded protein response (UPR) pathways. Following internal or external stimuli that induce ER stress, BiP detaches from the three main sensors of UPR, localized at the ER membrane, and active them: inositol-requiring enzyme 1α (IRE1α), PKR-like ER kinase (PERK), and activating transcription factor 6 (ATF6). IRE1α activation induces XBP1(S) transcription factor, PERK phosphorylates and activates NRF2 and eIF2α, ATF6 is translocated to and is processed at the Golgi apparatus to create a highly active transcription factor. All three transcription factors upregulate chaperones and specific targets genes involved in protein folding, antioxidant response, autophagy, and apoptosis, to restore ER homeostasis or to induce cell death pathways. HSP90, which is involved in mutp53 stabilization, may modulate UPR through its association with the cytoplasmic domain of IRE1 and PERK. Mutp53 may activate HSF1 to promote HSP90 induction, highlighting a link between mup53, HSF1/HSP, and UPR.</p></caption><graphic xlink:href="cancers-11-00614-g002"></graphic></fig><fig id="cancers-11-00614-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Mutant p53 and the NRF2 signaling. (<bold>a</bold>) NRF2 undergoes protein degradation following interaction with KEAP1 that can be released by oxidative stress and reactive oxygen species (ROS) generation or by p62- and p21-induced noncanonical KEAP1 degradation. (<bold>b</bold>) Mutp53 may interact with NRF2 and bind the antioxidant response elements (ARE) of target genes and differentially modulate NRF2 transcriptional activity, increasing thioredoxin (TXN) and reducing NAD(P)H:quinone oxidoreductase 1 (NQO1) and heme oxygenase 1 (HO-1) expression.</p></caption><graphic xlink:href="cancers-11-00614-g003"></graphic></fig><fig id="cancers-11-00614-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Interplay between mutp53 and autophagy and the effect of mutp53 stability/degradation. (<bold>a</bold>) Mutual interplay between autophagy and mutp53: autophagy degrades mutp53 and mutp53 inhibits autophagy counteracting its own elimination. (<bold>b</bold>) Schematic representation of mutp53 GOF depending on mutp53 expression: the reduction of mutp53 expression (green triangle) reduces GOF while increased mutp53 expression (red triangle) increases GOF.</p></caption><graphic xlink:href="cancers-11-00614-g004"></graphic></fig></floats-group></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000886 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000886 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |